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1 Introduction 
1.1 Mammary gland development and cellular organization 
Mammary gland is a very specific organ which distinguishes mammals from all other animals due to 
unique anatomical structure that enables production and secretion of the milk for the nourishment of 
the offspring. Adult human breast consists of the parenchyma, which originates from the ectoderm and 
the stroma, which develops from mesodermal elements (Figure 1). The parenchyma is a system of 
branching ducts and acini, while the stroma mainly consists of adipose tissue (Forsyth, 1991; Javed and 
Lteif, 2013; Medina, 1996). The mammary gland reaches its final development late after birth, during 
pregnancy (Inman et al., 2015; Macias and Hinck, 2012) which facilitates studying its developmental 
process. Most of the knowledge about embryonal development of the mammary gland arises from 
studies in rodents. 
   
The stadium of the embryonal development comprises of two phases: (1) formation of the primary 
mammary bud and (2) development of a rudimentary mammary gland (Hughes, 1950; Inman et al., 
2015). Once the mammary sprout reaches the fat pad, its further sprouting is initiated to form a 
rudimentary ductal tree. The ductal tree consists of epithelial and myoepithelial cells forming 15-20 
secondary branches, each containing a lactiferous duct which finally leads to a nipple and enables 
collection and directing of the milk stream. At the time of birth, the nipple is formed from epidermal 
cells overlying the bud, while the rudimentary ductal tree protrudes into the surrounding fat pad.  (Hens 
and Wysolmerski, 2005; Hogg et al., 1983; Macias and Hinck, 2012; Sakakura et al., 1976). 
In the period from birth until the age of two, not many changes occur, mostly maturation of the ducts 
and sprouting of the vasculature. From the third year until puberty, the mammary gland remains 
quiescent and its development continues with the beginning of sex hormone secretion (Anbazhagan et 
al., 1991; Naccarato et al., 2000). Under their influence, extensive proliferation occurs which results in 
filling the fat pad and formation of mammary lobes. The mammary lobe comprises of the mammary 
Figure 1: Anatomy of the human mammary 
gland. Each lactiferous duct in the mammary 
gland starts from the nipple and branches into 
ducts that end with the acini (in a non-
lactating breast) or alveoli (in a lactating 
breast). Therefore the alveoli in a lactating 
breast occupy more space than in a non-
lactating one, on the cost of adipose stromal 
tissue. Picture modified from 
https://theanatomybody.com/mammary-
gland-anatomy/ 
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ducts which end with the terminal end buds (TEB) (Hinck and Silberstein, 2005; Macias and Hinck, 
2012; Paine and Lewis, 2017). Cap cells of the TEBs differentiate into myoepithelial cells, forming the 
outer layer, and the inner layer consist of the luminal cells (Williams and Daniel, 1983). During puberty, 
before pregnancy, the ends of the mammary tree are blind-ended ducts, called acini (Howard and 
Gusterson, 2000). These acini protrude in the fat pad, and consist of predominantly adipocytes, but also 
endothelial cells (which form a vascular net), fibroblasts and immune cells (Macias and Hinck, 2012; 
Sheffield, 1988). At the time of puberty, estrogen secretion starts and together with the pituitary growth 
hormone and insulin-like growth factor-1 (IGF-1)  initiates further events in the mammary gland 
development (Kleinberg and Ruan, 2008). Those processes involve formation of the breast bud with 
elevation of the nipple and enlargement of the diameter of the areola around the nipple (Marshall and 
Tanner, 1969). Constant increase in the size of the mammary gland during puberty is a result of changes 
in both, parenchymal and stromal tissue (Howard and Gusterson, 2000), with first preparation of the 
surrounding fibrous and fatty tissue which then enables further elongation and sprouting of the 
parenchymal mammary ducts (Howard and Gusterson, 2000; Russo and Russo, 2004) 
Intensive growth and changing during puberty results in formation of the final structure of a double 
layered ducto-alveolar net in mammary parenchyma. The outer layer of cells consists of myoepithelial 
cells, responsible for the contraction and the guidance of milk that is produced by alveolar cells from 
inner layer. The alveolar cells form the inner layer together with luminal cells, lining the lumen of ducts 
and alveoli (Tiede and Kang, 2011; Watson and Khaled, 2008). During each menstrual cycle, upon a 
complex effect of hormones, the number and size of the alveoli increase, while significant increase is 
only seen when pregnancy occurs (Monaghan et al., 1990; Russo and Russo, 2004). All these processes 
are dictated mainly by the female sex hormones secreted by the ovaries, such as estrogen (inducing 
ductal elongation) and progesterone (responsible for side branching) (Brisken et al., 1998). Mammary 
ducts are branching to smaller ducts and further to very small ductuli ending with acini. All the acini 
arising from one terminal duct together with the surrounding stroma form the functional unit of the 
breast called the terminal duct lobular unit (TDLU) (Howard and Gusterson, 2000; Javed and Lteif, 
2013). Again, most information about mammary growth during pregnancy and involution came from 
studies in mice. During pregnancy numerous changes occur in the mammary gland under the influence 
of progesterone and prolactin. Intensive branching of secondary and tertiary ducts is followed by 
alveolar development, when epithelial cells forming alveolar buds start proliferating and differentiating 
into milk-secreting lobules. The growth of mammary ducts and alveoli continues on a cost of stromal 
adipose tissue, which is reduced and disappears. Simultaneously the vascular net is branching and by 
late pregnancy every functional alveolus is surrounded by a capillary network (Baillo et al., 2011). A 
functionally mature gland is then fully developed and prepared for milk production and secretion. 
The involution process starts with the weaning. At the weaning phase the produced milk is retained in 
the mammary epithelium, the branched mammary tree is removed and milk-producing epithelial cells 
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are disappearing. This process starts with a reversible phase of alveolar cells detachment, their 
accumulation in the lumen and apoptosis inducing engorgement of the alveoli. After this phase, the 
alveoli start to collapse, and milk supply is lost. As of that moment involution becomes an irreversible 
process. In this phase, tissue remodeling is most prominent while activation of matrix 
metalloproteinases (MMP) induces degradation of extracellular matrix (ECM) and an intensive 
apoptotic wave in mammary epithelial cells. As a result, the mammary gland is anatomically very 
similar to the original mammary gland before pregnancy, but interestingly the pattern of gene expression 
differs (Balogh et al., 2006; D'Cruz et al., 2002). The mammary development processes with all 
described phases is depicted in the Figure 2. 
 
Figure 2: The stages of postnatal mammary gland development. At birth, the mammary epithelium is rudimentary, consisting 
of only a few small ducts. At the onset of puberty, expansive growth that fills the fat pad with the epithelial mammary tree 
happens. This growth is influenced by the growth hormones (GH), estrogen, and insulin-like growth factor-1 (IGF1). When 
pregnancy begins, sprouting and further branching of the existing branches continues and alveologenesis occurs under the 
influence of progesterone and prolactin. Prolactin stimulation continues during the stage of lactogenesis, culminating in milk 
production that continues until involution, the process of mammary gland remodeling back to its original adult state before 
pregnancy. Picture modified from (Macias and Hinck, 2012). 
1.2 Stem cell hierarchy during mammary gland development  
All the changes that the mammary gland undergoes during maturation and during the described cyclic 
differentiation process, are based on the function of undifferentiated stem cells (Stingl et al., 2006). In 
a first step division and differentiation of the mammary stem cells give rise to self-renewed stem cells 
and mammary progenitor cells. These progenitor cells continue to divide and further differentiate into 
matured mammary cells, while self-renewed stem cells persist and wait for another activation signal to 
divide again. Hence, in the parenchyma of the mammary gland, among undifferentiated stem and 
differentiated mature cells also progenitors reside, which are in between these two populations in regard 
of their differentiation status. 
Early gland development is based on the expansion of the bipotent fetal mammary stem cells (fMaSCs) 
(Spike et al., 2012). Repeated cycles of expansion and involution of mammary glands during menstrual 
cycles and pregnancies clearly indicate the existence of the adult counterparts to fMaSC that are able to 
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expand and give the progeny of different lineages. These cells named adult mammary stem cells 
(aMaSCs) are much less abundant than fMaSC, with 1/50 and 1/14 cells in corresponding tissues 
respectively (Spike et al., 2012). These cells are slow cycling cells waiting for internal and external 
signals to activate them, renew and give the progeny instructions to develop all the changes in the adult 
gland (Guo, 2014; Pasic et al., 2011; Zeng and Nusse, 2010). A hierarchy of mammary cells is 
maintained in the adult mammary gland which, beside stem cells comprise of progenitors and 
differentiated mammary cells. 
Thus, the mammary gland is a hierarchically structured organ (Stingl et al., 2006). The proof of 
pluripotency of adult mammary stem cells (MaSC) was provided in the work of Shakelton and 
colleagues who succeeded to reconstitute the whole mouse mammary gland upon transplantation of a 
single cell (Shackleton et al., 2006). Transplantation of pieces of a human mammary gland resulted in 
engraftment and mammary gland reconstitution in immunodeficient mice (Kuperwasser et al., 2004). 
All different processes during mammary gland development are strictly controlled by growth factors 
and hormones and disruption of that signaling composition can lead to increased growth of the 
mammary gland and breast cancer (Martin, 2003).  In line with the evidence that changes in the 
mammary gland are driven by growth and division of mammary stem cells, a corresponding 
subpopulation of mammary cancer stem cells (MaCSC) are believed to initiate breast cancer (Luo et 
al., 2015; Morrison et al., 2008). 
In line with the stem cell theory that proposes that all cells in the mammary gland originate from a small 
proportion of stem cells, cancer stem cell theory proposes that among all cancer cell pool only a few of 
them act as so-called cancer stem cells (CSC), which reproduce themselves and sustain the cancer, 
much like normal stem cells renew and sustain organs and tissues (Yoo and Hatfield, 2008). New data, 
showing that the majority of malignant cells, rather than only CSCs can sustain tumors questions the 
stem cell theory, emphasizing it must be reevaluated. (Yoo and Hatfield, 2008). In accordance with 
previously stated, albeit still under controversy, nowadays both stem and progenitor cells are candidate 
cells-of-origin in tumorigenesis (Chen et al., 2017). Besides the theories that aberrations in less 
differentiated (stem and progenitors) cells cause cancer, some clues indicate that also differentiated 
cells, which sustain neoplastic transformation can acquire properties of less differentiated stem or 
progenitors and become the founders of malignancies (Bjerkvig et al., 2005). Cancer cells that leave the 
primary site and home to distant organs can i) undergo cell death; ii) proliferate and give rise to 
metastasis or iii) lodge and stay quiescent for a certain period (Aguirre-Ghiso, 2007; Goss and 
Chambers, 2010; Reymond et al., 2013). Such outcome we exactly see in our stem cell model where 
majority of cells undergo anoikis, few of them start immediate proliferation and give rise to 
mammospheres and rest stay quiescent but retain the potential to be reactivated. Some data show that 
all the cells that extravasate to distant organs first undergo the same state of dormancy (Paez et al., 
2012) or proliferation (Wang et al., 2015a). The nature of the cells that acquire the ability to disseminate 
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from the primary tumor is still under investigation. It is also unknown which population in the hierarchy 
of mammary epithelial cells is capable to leave the primary site and lodge to distant organs. 
Cellular heterogeneity and hierarchical organization present in the mammary gland are also found 
within mammary tumors (Bliss et al., 2018; Hassiotou et al., 2013). In line with MaSCs, MaCSCs are 
less differentiated cells in the cell hierarchy of mammary tumors, able to give rise to more differentiated 
progeny, like non-cancer stem cells (non-CSCs). Although they are not numerous, CSCs exert a very 
important and potent function in breast tumors. CSCs possess the features of both cancer cells and stem 
cells, hence they have the ability to seed tumors when transplanted into an animal host (Clarke et al., 
2006). They also possess the capacity for self-renewal and the ability to differentiate into diverse 
specialized cell types. A pool of undifferentiated multipotent stem cells is maintained through the self-
renewal process (Yu et al., 2012). Analysis of the gene expression profiles of different cell populations 
isolated from the mammary gland based on the expression of surface markers revealed similarities to 
specific subtypes of breast cancer, with CSCs being closest to claudin-low breast cancer, progenitors to 
basal-like breast cancer, and luminal A and luminal B showing most similarities to differentiated 
mammary cells (Figure 3) (da Silveira et al., 2017). The frequency of detected tumors of a certain type 
increases in the direction from less to more differentiated cells, but the aggressiveness of the tumors is 
inversely correlated (Figure 3) (da Silveira et al., 2017).  
 
Figure 3: Connection between stem cell hierarchy and breast cancer subtypes. The mammary stem cell (MaSC) may give rise 
to a "committed progenitor”, which further differentiates into luminal and myoepithelial cells. MaSC profile corresponds to 
most aggressive claudin-low (triple-negative) breast cancer. Less aggressive basal-like breast cancers have profiles most 
similar to progenitor cells, while luminal breast cancers result from more differentiated cells. BC – breast cancer. Picture 
adapted from (da Silveira et al., 2017). 
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1.3 Breast cancer 
Breast cancer is the most frequent type of cancer among women, with 2.09 million new cases and 
627000 deaths in 2018 worldwide. In 2012 the number of newly diagnosed cases was 1.7 million and 
these numbers are constantly increasing (WHO, 2018). Breast cancer includes numerous cancer types, 
which are most frequently systematized using TNM (Tumor, Node, Metastasis) staging. Classification 
of the tumors depends on the size of the primary tumor (T), the number of the nearby lymph nodes 
positive for the presence of tumor cells (N), and presence of distant metastasis (M) (Roland et al., 2016). 
Besides TNM staging, the histological grade of the tumors is determined. Although histological grade 
does not correlate to the overall survival of the patients, it can generate important information related 
to the clinical behavior of breast cancers (Rakha et al., 2010). The result of the histological grading of 
the tumor is grade 1 to 3 and is determined as a result of the three variables: 1) the frequency of mitotic 
cells; 2) formation of the tubular gland structures, and 3) how closely tumor cells resemble normal 
breast cells (nuclear grade) (Elston and Ellis, 1991). Grade 1 tumors comprise of the small tubules and 
cords (for ductal cancer or lobular cancer, respectively) with slowly growing, well differentiated cells. 
These tumors give the best prognosis for the patient. Grade 2 tumors are moderately differentiated and 
based on all parameters lie in between tumors of grades 1 and 3. The worst prognosis have the patients 
with tumor grade 3, that is characterized with poorly differentiated cells that lack normal organization 
and grow rapidly, resulting in a faster spread than in tumors of lower grades (Rakha et al., 2010). In the 
last decades, a new approach was developed for breast cancer classification, based on the systemic 
investigation of expression patterns of thousands of genes using cDNA microarrays (Sorlie et al., 2001) 
in collectives of breast cancer samples, classified to following groups using immunohistological 
staining, with non-transformed mammary tissue as healthy controls. Hierarchical clustering separated 
the analyzed cohorts into two main branches, basal-like/estrogen receptor (ER)- and luminal/ER+ 
groups. ER- branch comprised of basal-like, Her2-like and normal breast-like mammary tumors, while 
ER+ cells comprised of several types of luminal-like tumors. Both, overall and relapse-free survival 
analysis showed a highly significant difference between ER- and ER+ groups, with the basal-like and 
Her2+ subtypes being associated with the shortest survival times (Sorlie et al., 2001; Sotiriou et al., 
2003). So far, irrespective of the subtype, for the majority of the breast cancers the first line therapy is 
surgery followed by chemotherapy and radiation therapy, that kill the cancer cells that eventually were 
not seen and removed during surgery (Dhankhar et al., 2010). In some cases neoadjuvant therapy is 
given before the surgery to shrink tumor bulk and increase the feasibility of the conservation surgery 
treatments (Abbas et al., 2011; Reyal et al., 2018). 
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1.4 Metastasis 
Despite the advances in diagnosis and treatment of the primary tumors (PT), no significant 
improvements were made during last decades in the field of metastatic disease. More than 90% of cancer 
related deaths are due to metastases which are resistant to conventional therapies (Fidler, 2003; Redig 
and McAllister, 2013; Weigelt et al., 2005). Although metastases are detected in only 6% of newly 
diagnosed patients, around 30% of women with breast cancer ultimately develop metastases, with bone 
being the most frequent metastatic organ (O'Shaughnessy, 2005; Redig and McAllister, 2013). This 
number did not significantly change in the last decades pointing towards the fact that this process still 
remains the least understood aspect of cancer biology. 
Existing knowledge shows that the metastatic cascade is a highly demanding multistep process where 
failure in any step will result in a failure of metastasis establishment. Therefore, only a small fraction 
of cancer cells acquire the ability to migrate and home to distant organs, making this a very inefficient 
process (Chambers et al., 2002; Valastyan and Weinberg, 2011; Weiss, 1990). The metastatic cascade 
starts with local invasion of cells originating from the primary tumor into the surrounding host tissue 
(1), when tumor cells migrate through the extracellular matrix (ECM) and stromal cells they reach 
lymphatic and/or blood vessels and crawl through the endothelial cells to intravasate into the circulation 
(2) where they face to survive in “unfriendly” conditions (shear stress, immunoevasion, flow) (3) until 
they reach a distant organ where they get stuck in the small blood vessels (4) and then extravasate to 
the distant organ (5), into the unknown hostile environment where they need to survive (6) and start 
proliferation in order to colonize the target organ and successfully establish a foothold for the metastasis 
(7) (Figure 4) (Bill and Christofori, 2015; Scully et al., 2012; Valastyan and Weinberg, 2011).  
During metastatic invasion tumor cell plasticity is challenged. Therefore, cancer cells constantly 
undergo changes enabling them to survive and exert their function. The concept of epithelial-
mesenchymal transition (EMT) preceding migration, followed by mesenchymal-epithelial transition 
(MET) at the distant site, a process conditional for proliferation and colonization is widely accepted in 
the scientific community (Bill and Christofori, 2015; Hartwell et al., 2006; Jung et al., 2008; Mani et 
al., 2007). 
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Figure 4: Metastatic cascade with involvement of EMT and MET. Tumor cells undergo EMT to acquire the potential to start 
local tissue invasion (1) and migration towards blood vessels. Upon intravasation into blood vessels (2) cells must survive (3) 
and arrive at target organs (4), where they are arrested in small capillary vessels mostly due to size and then they (5) extravasate. 
In the distant organs tumor cells must survive in a new type of environment. Therefore they need to adapt by reversing the 
phenotype in MET process (6), regains proliferating phenotype to establish micro- and macrometastases (7). Picture modified 
from (Bill and Christofori, 2015). 
As previously mentioned, breast cancer metastasizes predominantly to bones, liver, lung and brain (Jin 
et al., 2018; Wang et al., 2017). This organotropism is not only seen in breast cancer (Lu and Kang, 
2007), but also in other cancer entities such as colorectal, prostate, lung and prostate cancers (Jin et al., 
2012; Milovanovic et al., 2017; Reichert et al., 2018; Thobe et al., 2011). Based on the knowledge 
acquired from the autopsies of 735 women with breast cancer, Stephen Paget proposed the “seed and 
soil” hypothesis claiming that tumor cells (the “seed”) grew preferentially in the microenvironment of 
selected organs (the “soil”), and metastases can grow only when appropriate seed is planted in the 
corresponding soil (Paget, 1989). The basis for “seed and soil” mechanism is chemical attraction 
between cancer cells and factors expressed in metastatic organ. Several factors were identified to play 
a role, including osteopontin, osteonectin, chemokine ligand 21 (CCL21, 6Ckine) and stromal-derived 
factor-1 (SDF-1, CXCL12) expressed in bones (Ibrahim et al., 2000; Jacob et al., 1999; Luker and 
Luker, 2006; Muller et al., 2001). These chemokines are ligands for the receptors expressed on the 
breast cancer cells, such as C-C chemokine receptor type 4 (CXCR4, binds CXCL12) or C-C chemokine 
receptor type 7 (CXCR7, binds CCL21) (Luker and Luker, 2006; Mattern et al., 1996; Muller et al., 
2001; Qian et al., 2018). An opposing theory was proposed by Ewing, who claimed that organ tropism 
is a consequence of the mechanical arrest of cancer cells in small capillaries (Chu and Allan, 2012). 
Nowadays it is commonly understood that these two theories are not mutually exclusive and both factors 
contribute to the organ specificity of metastases (Chu and Allan, 2012; Weiss, 1992). 
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1.5 Disseminated cancer cells 
During migration through the circulatory system (lymph or blood) cancer cells are referred to as 
circulating cancer cells (CCC) while upon extravasation and lodging to distant organs they are termed 
disseminated cancer cells (DCC). DCCs in mesenchymal organs such as the bone marrow or lymph 
nodes are detected upon using cytokeratin (CK8, CK18, and CK19, expressed only in epithelial cells) 
staining as a marker for DCCs.  30% of breast cancer patients are found positive for DCCs in the bone 
marrow (Braun et al., 2005). DCC presence in the bone marrow aspirates of patients with cancer both, 
breast and prostate, is a risk factor for developing metastases (Janni et al., 2011; Mathiesen et al., 2012; 
Wiedswang et al., 2003). Furthermore, DCC persistence in the BM of patients diagnosed with breast 
cancer correlates to the decreased disease-free survival (DFS) and overall survival (OS) during the first 
5 years following cancer diagnosis. (Janni et al., 2011). DCCs isolated using anti-CK staining can be 
used only for genomic studies, while these cells must be permeabilized prior to detection procedure and 
therefore the whole transcriptome is lost. Genomic analyses result in information which are insufficient 
in the battle against cancer as it is known that not only genetic changes, but also dysregulated gene 
expression contribute to the neoplastic transformation (Ferrone and Marincola, 1995; Timp and 
Feinberg, 2013). Therefore, epithelial cell adhesion/activating molecule (EpCAM, CD326), expressed 
on the surface of the cells, was introduced as a marker that enables isolation of living tumor cells. 
EpCAM is overexpressed in many different human carcinomas (Baeuerle and Gires, 2007; Kimura et 
al., 2007; Massoner et al., 2014; Osta et al., 2004; Spizzo et al., 2004; Stoecklein et al., 2006; Went et 
al., 2006) and it was the first human tumor-associated antigen identified with monoclonal antibodies 
(Herlyn et al., 1979). Cell isolation using anti-EpCAM staining enables simultaneous isolation of both 
genome and transcriptome of the same cell (Klein et al., 2002) and therefore a much broader spectrum 
of analyses. 
For a long time it was accepted that cancer cell dissemination occurs in later stages of tumor 
development (Koscielny et al., 1984), but the evidence from previous years strongly challenges that 
theory, pointing to dissemination as a process that occurs early during tumor development (Klein, 
2009). Studies performed on mouse models in melanoma (Eyles et al., 2010) and breast cancer 
(Hosseini et al., 2016b; Husemann et al., 2008) strongly support the hypothesis on early dissemination 
of cancer cells and parallel progression of primary tumors and metastases. The proposed model of 
parallel progression (Klein, 2009) suggests that cancer cells disseminate early, as supported by evidence 
from melanoma, where it was shown that lymphatic dissemination occurs shortly after dermal invasion 
of the primary lesion at a median thickness of ~0.5 mm, a phase when the primary tumor is undetectable 
by standard screening techniques (Werner-Klein et al., 2018). In the early phases of tumor development, 
cancer cells harbor fewer genetic aberrations compared to primary tumor cells at the time of diagnosis, 
which in the context of early dissemination is explained by two possible scenarios: (1) DCCs harbor 
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fewer aberrations than cells from PT, indicating that DCCs progress and evolve slower or (2) DCCs 
harbor the same number or more aberrations than cells from the PT, indicating that DCCs progress and 
evolve faster than PT cells and therefore metastases arise quickly. Analyses of the DCCs from BM 
aspirates of breast cancer patients show that DCCs are less aberrant than PT cells and even share very 
few aberrations with them (Schmidt-Kittler et al., 2003), additionally supporting the first scenario and 
the theory of parallel evolution of tumor cells at the primary site and the metastatic organs. Although 
dissemination is an undeniable process in tumor biology, the relevance of early DCCs in establishment 
of metastases was questioned. Using the rodent models Eyles (melanoma) and Hosseini (breast cancer) 
with colleagues showed that metastases in both, melanoma and breast cancer evolve from early DCCs 
(Eyles et al., 2010; Hosseini et al., 2016b). 
1.6 Dormancy of disseminated cancer cells 
Initial steps of the metastatic cascade, such as invasion and dissemination are very efficient processes 
(Chambers et al., 2002) but compared to that, metastasis formation  rate is very inefficient. This 
indicates that the critical step for metastasis formation is colonization of the metastatic organ. Upon 
extravasation to distant organs DCCs can die, resume the growth immediately or enter a state of 
dormancy (Aguirre-Ghiso, 2007; Chambers et al., 2002; Ranganathan et al., 2006). The relevance of 
the state of dormancy of DCCs was intensively studied in the last decades. 
Eyles and colleagues showed that single cells spread very early during oncogenesis of melanoma, 3 
weeks after the clinical onset of the primary tumor, but detectable metastases became apparent much 
later in life, up to 1.5 years (Eyles et al., 2010), suggesting that these early DCCs remained dormant for 
a long period. In line with that BM-DCCs in Balb-NeuT mice do not proliferate but can be reactivated 
upon transplantation into lethally irradiated siblings, showing that they retain the potential to proliferate, 
but reside in a dormant state (Hosseini et al., 2016b; Husemann et al., 2008). This is not only the case 
in rodent animal models. Existence of dormant DCCs in humans was shown in the case of a patient that 
was treated for melanoma and died 16 years later due to brain death without any signs of secondary 
disease or detectable metastases. This patient was used as a kidney donor and 2 years after 
transplantation both recipients died from metastases of malignant melanoma, although they were never 
diagnosed with melanoma. Thus, even though the donor had no signs of clinical disease, melanoma 
cells survived and were transferred with the graft to the recipients. Since such patients are under 
immunosuppression therapy to avoid graft rejection, the condition of impaired immunosurveillance was 
favorable for the vigorous growth of metastases (MacKie et al., 2003). Such cases support the concept 
of dormancy in disseminated cells. Long latency periods observed between the treatment of primary 
tumors and metastatic recurrence in patients are also used as a proof for the existence of clinical tumor 
dormancy (Klein, 2011). 
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The fate of DCCs upon extravasation depends on both intrinsic and extrinsic signals (Bloom and Zaman, 
2014). Prolonged period of dormancy is induced and maintained by different mechanisms, including 
tumor-microenvironmental factors (such as cytokines, immunosurveillance, angiogenesis), metastasis 
suppressor gene activity and anti-cancer therapy (Osisami and Keller, 2013). We can discriminate two 
main types of tumor dormancy: (1) dormancy of single cancer cell, when cells reside in a proliferation 
arrested state (G0/G1 arrest) that is reversible and they can re-enter the cell cycle (reactivate 
proliferation) and (2) tumor mass dormancy, a phenomenon when cells do not undergo cell cycle arrest, 
but the rate of cell proliferation correlates to the rate of apoptosis, resulting  in maintainability of the 
size of metastases (Kareva, 2016). This second type, tumor mass dormancy, is often a result of systemic 
cooperation among tumor cells and the immune system (Koebel et al., 2007; Quesnel, 2008; Vesely et 
al., 2011). On the contrary, different mechanisms are suspected to regulate the dormant state of a single 
cancer cell. For example microenvironmental stress (Adam et al., 2009a; Aguirre-Ghiso et al., 2003), 
cytokines and other factors secreted by stromal cells (Kobayashi et al., 2011; Lim et al., 2011; Shiozawa 
et al., 2010). Further, the inability of DCCs to form cytoskeletal rearrangements and interact with 
environmental cells (Barkan et al., 2008), but also factors like anti-tumor therapy (Chaterjee and van 
Golen, 2011; Schewe and Aguirre-Ghiso, 2008) can result in single DCC dormancy. The existence of 
different types of tumor dormancy makes the concept of metastatic dormancy even more complex, since 
all of the above mentioned mechanisms can be employed in maintaining the dormancy of DCCs at 
distant sites, but there is also the contribution of the foreign environment. 
1.7 Interleukin-6 signaling in physiological and pathological 
settings  
Interleukin 6 (IL-6) is a proinflammatory cytokine that is known to be secreted by several different 
types of cells. In humans it is encoded by the IL6 gene, located on chromosome 7. It belongs to a family 
of cytokines consisting of IL-6, IL-11, oncostatin M (OSM), leukemia inhibitory factor (LIF), ciliary 
neurotrophic factor (CNTF), cardiotrophin 1 (CT-1), cardiotrophin-like cytokine (CLC) and IL-27. Its 
main function is to mediate immune response, when secreted by T cells and macrophages, and to direct 
B cell differentiation. It is also known to be secreted by osteoblasts, and has a role in stimulating 
osteoclast maturation (Dienz et al., 2009; Eto et al., 2011; Udagawa et al., 1995; Yang et al., 2016). 
Nowadays it is known that IL-6 has many different functions and plays a role in numerous inflammation 
related diseases (Schaper and Rose-John, 2015; Tanaka and Kishimoto, 2014; Tanaka et al., 2014).  
IL-6 acts by binding to the glycoprotein 130 (gp130) and can signal via two distinct pathways. The 
classical IL-6 signaling is mediated by direct binding of IL-6 to the heterodimeric receptor consisting 
of the IL-6 receptor α-chain, CD126 (gp80, IL-6Rα, IL-6Ra) and the ubiquitously expressed signal 
transducing receptor subunit glycoprotein 130 (gp130, IL-6Rβ) (Scheller et al., 2011) (Figure 5). Due 
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to the restricted expression of IL-6R to mainly hepatocytes and immune cells (Scheller et al., 2011), 
classical IL-6 signaling is limited to only few cell types. However, a soluble form of IL-6R (sIL-6R) 
can be produced by alternative splicing or limited proteolysis of the membrane-bound receptor. The 
complex of sIL-6R/IL-6 can bind to the ubiquitously expressed gp130 receptor subunit on recipient 
cells and thereby stimulate cells which do not express IL-6R (Rose-John and Heinrich, 1994). This type 
of stimulation, not mediated by a membrane receptor is referred to as trans-signaling. The binding of 
IL-6/IL-6R or IL-6/sIL-6R to the gp130 signaling subunit induces the homodimerization of gp130 
which further triggers an intracellular signaling cascade activating several pathways including Ras/Raf, 
mitogen-activated protein kinase (MAPK), PI3K/Akt and Janus-activated kinase/signal transducers and 
activators of transcription (JAK/STAT) (Kishimoto, 2005; Murray, 2007; Streetz et al., 2003; Wegiel 
et al., 2008). 
 
Figure 5: IL-6 signaling mechanism: IL-6 binds to the heterodimer receptor on the cell membrane, consisting of gp80 (carrying 
binding site for IL-6) and gp130 (IL-6Rβ), which then homodimerizes and activates JAK/STAT, MAPK/ERK and PI3K/Akt 
signaling cascades (classical signaling). In the trans-signaling pathway, sIL-6R, a soluble variant of IL-6Rα present in the 
intercellular space, binds IL-6. The complex IL-6/sIL-6R then binds to ubiquitously expressed gp130 and activates cells that 
do not express IL6R. Image taken from (Luo and Zheng, 2016). 
In recent years the role of IL-6 was studied in different cancers. It was shown that IL-6 levels were 
increased in the sera of the patients with breast cancer, and this increase correlated with tumor stage 
and decreased patient survival (Bachelot et al., 2003; Kozlowski et al., 2003). Additionally, IL-6 plays 
a role in the biology of cancer stem cells in the mammary gland and breast tumors (Marotta et al., 2011; 
Sansone et al., 2007). IL-6 and the activation of an inflammatory feedback-loop have been shown to 
dynamically regulate the equilibrium between cancer cells with stem-like properties and non-stem 
cancer cells (Marotta et al., 2011) (Sansone et al., 2007). Studies on different cancer entities pointed to 
a role of IL-6 signaling in development of primary tumor, but also indicated they facilitate the formation 
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of metastasis, by supporting migration and invasion of cancer cells (Browning et al., 2018; He et al., 
2018; Lee et al., 2019; Tang et al., 2018). 
However, the effect of IL-6 signaling on non-transformed mammary tissue, as well as on putative 
metastasis founder cells (DCCs) has not been fully elucidated. To further investigate the role of this 
cytokine on mammary cells in physiological conditions, we used the non-transformed human breast 
cancer cell line, MCF10A and patient derived human mammary epithelial cells (HMECs). Additionally, 
we examined the IL-6 signaling in DCCs isolated from the bone marrow of the patients with mammary 
carcinomas. 
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2 Material and Methods 
2.1 Methods 
2.1.1 Patient material 
Human non-cancerous mammary tissue was obtained from female patients undergoing reduction 
mammoplasty surgeries at Caritas-Krankenhaus St. Josef, Regensburg in collaboration with Dr. Norbert 
Heine after informed, written consent of patients was obtained (ethics vote number 07/043, ethics 
committee of the University Regensburg). After verification of the non-cancerous origin of the tissue 
by a pathologist at the Institute of Pathology, University hospital Regensburg, mammary glands were 
dissociated and primary human mammary epithelial cells (HMECs) isolated. The tissues showing the 
signs of breast cancer were excluded from the study and not used for this work. Due to hormone changes 
during menopause and proposed hormonal influence in mammary stem and progenitor cells, tissue were 
selected based on an arbitrary age limit (45 years). 
Disseminated cancer cells were obtained from bone marrow aspirates of breast cancer patients with and 
without distant metastases. Human mesenchymal stem cells were obtained from bone marrow aspirates 
of breast cancer patients or healthy donors. Written informed consent of patients was obtained and the 
ethics committee of the University of Regensburg (ethics vote number 07/79) approved bone marrow 
sampling and analysis of isolated cells. 
2.1.1.1 Digestion of the human mammary tissue and isolation of single epithelial cells 
Mammary tissue was minced and dissociated in Ham’s F12/Dulbecco’s modified Eagle’s medium 
[F12:DMEM; 1:1 (v:v)] supplemented with 10 mM HEPES, 2% bovine serum albumin (BSA; Fraction 
V), 5 μg/ml insulin, 0,5 μg/ml hydrocortisone, 10 ng/ml cholera toxin, 300 U/ml collagenase and 100 
U/ml hyaluronidase in the sterile incubator at 37°C, 5% CO2 and 7% O2 for minimum of 18 h. On the 
next day, the digested cell suspension was centrifuged at 210 g for 2 minutes at room temperature. 
Supernatant from the first centrifugation step contained single mammary epithelial and stromal cells 
(fibroblasts), while in the pellet were the organoids (undigested tissue pieces of the tissue). Supernatant 
containing epithelial cells and fibroblasts was further centrifuged 4 minutes at 350xg to separate 
epithelial cell from fibroblasts. Supernatant containing fibroblasts was discarded and pellet (containing 
epithelial cells) was re-suspended in the basal medium, washed, and filtered through 100 m and 40 
m cell strainers consecutively. Mammary epithelial cells were propagated in mammosphere medium 
in ultra-low attachment plates. For the propagation cells were seeded in density of 200.000 cells/ml, 
15 
 
and for the experiments where we assessed the numbers of the mammospheres cells were seeded in 
density of 50.000 cells/ml in 35 mm plates with 3 ml medium per plate. 
For the disaggregation of the mammospheres they were collected after 7 days and centrifuged 1 minute 
at 100xg. Supernatant containing single cells transferred to another 50 ml falcon tube and centrifuged 
5 minutes 500xg to collect quiescent single cells (QSC). Mammospheres were subjected to the 
mechanical/enzymatic digestion using 0,05% trypsin, 0,53 mM EDTA-4Na and 10 minutes of constant 
pipetting using Gilson 1 ml pipette. Trypsinization was inhibited by adding Trypsin neutralizing 
solution (TNS) and cells were washed and re-plated for growing second generation of mammospheres. 
In the first generation of mammospheres can be found some stromal cells, but they succumb anoikis 
and the second mammosphere generation is “pure” and contains only mammary epithelial cells. The 
obtained secondary mammosphere were used for the most of the downstream assays elaborated in this 
work. 
2.1.2 Animals 
2.1.2.1 Maintenance 
NOD.Cg-Prkdcscid IL2rgtmWjl/Sz (also termed NSG) or Balb/c mice were purchased from the Jackson 
Laboratory USA and maintained under specific-pathogen free conditions, with acidified water and food 
ad libitum in the research animal facilities of the University of Regensburg, Germany. Transgenic 
mouse model (Balb-NeuT) was obtained from Dr. Guido Forni. Maintenance in the animal facility was 
performed according to the European Union guidelines. All animal experiments followed EU and 
national institutional regulations (Government of Upper Palatinate, 55.2-2532.1-27/14). At the age of 4 
weeks Balb-NeuT mice were analyzed for the presence of transgene. Female hemizygotes 
(neuT+/neuT-) were further cultivated and regularly inspected (twice a week) for the presence of 
mammary tumors, which were thereafter measured in two perpendicular diameters. Transgene negative 
(neuT-/neuT-) homozygotes served as wild-type Balb/c controls. 
2.1.2.2 Mice dissection  
Mice were sacrificed by cervical dislocation. The organs of interest (mammary glands, tumors and 
lungs) were divided in two parts each and one part was snap frozen while the other was embedded in 
paraffin. Bone marrow was prepared as described in the following section. 
2.1.2.3 Paraffin embedding of tissue samples  
The dissected tissue samples were fixed in a 4% paraformaldehyde (PFA) solution for minimum 12 
hours. Following fixation, the samples were washed 3 times in 1x PBS, dehydrated by series of washing 
steps in alcohol (70%, 85% and 100% ethanol, each step 1 hour) and washed twice for 30 min in 100% 
xylene. This step serves not only the removal of alcohol from the tissue, but also facilitates the 
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penetration of the paraffin during the subsequent embedding. After three incubation steps with paraffin 
(parablast embedding media), tissues were embedded. Paraffin embedded tissues are stored at room 
temperature. These samples have been used for IHC staining. 
2.1.2.4 Isolation of the epithelial cells from mouse mammary gland 
The mice were killed by cervical dislocation. Mammary glands were collected either from Balb/c or 
Balb-NeuT mice in a 50 ml tube with PBS. The tissue was minced with surgical blades to small pieces 
and digested in basal medium (DMEM/F12, 100 nM HEPES buffer, 10 mg/ml insulin, 0.5% BSA and 
0.5x penicillin/streptomycin) with 0,1 mg/ml DNAse I 200 U/ml collagenase and 200 U/ml 
hyaluronidase. The tissue was digested for 1-1,5 hours at 37° C in the incubator and mixed after 20 
minutes of incubation, then after 1 hour and every 10 minutes later until the organoids are disaggregated. 
The cell suspension originating from the digested tissue was filtered through 40 m cell strainer and 
centrifuged 10 minutes at 300xg to isolate mammary epithelial cells. 
2.1.2.5 Mammosphere transplantation 
Before the transplantation of the GFP-labeled mammospheres (50 spheres per mouse, mammosphere 
generation described in paragraph 2.1.3.4) mice were anaesthetized using Midazolam 5mg/kg, Fentanyl 
0,05mg/kg, Medetomidin 0,5mg/kg i.p. The skin around the mammary gland was shaved and small V-
cut made around fourth left mammary gland and small pocket was made between the 4th mammary 
gland and skin. Mammospheres were mixed with matrigel (final concentration of Matrigel 40%) and 
injected into the pocket between the mammary gland and skin of the 4-6 weeks old wt (neuT-) and NSG 
mice. The skin was closed by a suture using polygelatin string and anesthesia was antagonized with 
Flumazenil 0,5mg/kg, Atipamezol 2,5mg/kg, Naloxon 1,2mg/kg s.c. The wound was disinfected with 
Braunol and Hansaplast spray. Mammosphere recipients were sacrificed 4 or 8 weeks after 
transplantation. Curative surgery or sacrifice of mice was done when the diameter of tumors was 
between 5-10 mm. 
2.1.2.6 Bone marrow processing for staining and single cell isolation 
Tibias and femurs were collected from NSG, Balb/c or Balb-NeuT mice and held in PBS. The soft tissue 
surrounding the bones was removed. Epiphyses were removed using scissors and the bone marrow was 
flushed out with 1x PBS into a 50 ml tube using a 26G needle. Afterwards, the cells were pooled and 
centrifuged at 200x g for 10 min. The supernatant was discarded and the pellet was resuspended in 9 
ml of 1x PBS. Cell suspension was slowly and carefully overlaid onto 6 ml of 65% percoll in a 15 ml 
tube to form a layer and centrifuged for 20 min at 1000x g to remove erythrocytes and granulocytes. 
Interphase was carefully collected using a 5 ml pipette and transferred into a new 50 ml tube. The tube 
was filled up with 1x PBS and centrifuged for 10 min at 500x g for washing the cells. The cells were 
resuspended in 5 ml of 1x PBS and counted. For the preparation of slides for staining, 500.000 cells 
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were placed on each adhesion slide. For the isolation of EpCAM+ cells, bone marrow was first subjected 
to CD45 depletion (section 2.1.2.8).  
2.1.2.7 Bone marrow transplantation 
Balb/c (9 weeks old) and NSG (6 weeks old) mice were irradiated previous to BM transplantation. 
Balb/c mice were irradiated twice, two days before transplantation and on a transplantation day 5-6 
hours before BM transplantation, with 5 Gy. NSG mice were irradiated on transplantation day 5-6 hours 
before BM transplantation with 2 Gy. Bone marrow was isolated from 8-10 weeks old Balb-NeuT 
donors as described and naïve bone marrow cell suspension (without removing erythrocytes and 
granulocytes on 65% Percoll) was injected i.v. to previously irradiated mice (7-10x106 BM 
cells/mouse). 
For the transplantation of the CD45-depleted BM, after isolation BM suspension was subjected to two 
rounds of CD45 depletion and the efficiency of the elimination of CD45+ cells was examined by FACS. 
To each of previously irradiated Balb/c mice (as described above) were injected 6,5x106 CD45-depleted 
BM cells. On the following day one Balb/c mouse was sacrificed and 2-5 x106 BM cells were injected 
i.v. 
2.1.2.8 CD45 depletion 
Bone marrow of Balb/c and Balb-NeuT mice was isolated and CD45+ cells were depleted after the 
instructions of the vendor. Briefly, Cells were resuspended in MACS buffer (90 µl per 107 cells) and 
anti-mouse CD45 beads were added (10 µl per each 107 cells). After 15 minutes incubation at 4ºC cells 
were washed with 2 ml of 1x PBS and centrifuged 10 min at 300xg. Supernatant was removed and cells 
resuspended in MACS buffer (500 µl per 108 cells). Column was rinsed once with 2 ml buffer and 
afterwards cells were added to the column. CD45+ cells are kept on the column and CD45- fraction 
collected in the tube. Column was washed twice, with 2 ml and 1 ml of MACS buffer respectively, 
CD45- cells (flow-through) were counted, centrifuged and resuspended in 1x PBS so that we get the 
needed density. 
2.1.2.9 Progesterone treatment 
For the progesterone treatment pellets of 5 mg with 21 days releasing time were implanted as proscribed 
by vendor. Briefly, small neck was made on the lateral side of the neck of the recipient mice (Balb/c 
and Balb-NeuT) and the pocket was formed 2 cm behind the cut using forceps. Pellets were placed into 
the pockets using forceps and the cut was sutured. No alcohol disinfectant was used as it can activate 
releasing of the pellet content before it is placed in the body of the recipient. After 4 or 8 weeks recipient 
mice were sacrificed. 
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2.1.2.10 Bone marrow staining for DTC detection 
At least 106 cells per mouse were stained to detect positive cells and 0,5x106 cells per mouse to control 
the Isotype positivity (Isotype control). Blocking solution (5% rabbit serum in 1x TBS) was added to 
the slides to rehydrate the cells and to block unspecific binding of antibodies to the cells. After 20 min 
the blocking solution was discarded and primary antibody against CK 8 and 18 was added and incubated 
for 60 min. The primary antibody was discarded and slides were washed 3 times for 3 min in 1x TBS. 
Then slides were incubated with the secondary antibody for 25 min, and washed 3 times for 3 min in 
1x TBS followed by incubation with ABC complex for 25 min. Finally, the development system of the 
BCIP/NBT for alkaline phosphatase enzymatic substrate was added for 10 min. The slides were washed 
3 times for 3 min and screened for CK8/18 positive cells. The positive cells were typically violet-to-
black in color. TUBO, a tumor cell line derived from a primary mammary tumor of Balb-NeuT mice 
and expresses CK8/18, was used as a positive control.  
2.1.2.11 Haematoxylin and eosin staining  
Paraffin embedded tissue was cut into 5 µm sections onto poly-L-lysine-coated slide. Sections were 
dewaxed in Xylol for 10 min twice and rehydrated first in 100% ethanol for 3 min and then in 80% 
ethanol for 3 min. The sections were washed in PBS for 1 min thrice and incubated with hematoxylin 
for 45 sec. The slides were rinsed in tap water for a short duration and washed in tap water for 30 min 
in a glass cuvette. Eosin (0.1%) was added to the tissue sections and after 2 min they were washed with 
ddH2O for 1 min. The stained sections were dehydrated in 70% ethanol for 2 min, 100% ethanol for 2 
min and finally in xylol for 15 min. Mounting gel was added to the tissue sections and a cover slip was 
placed carefully on the gel avoiding bubbles and were left to dry overnight. 
2.1.2.12 Immunohistochemistry  
For Her2 immunohistochemistry of tissues, 5 µm sections of paraffin blocks were collected onto poly-
L-lysine-coated slides. Samples were dewaxed by two 5-min washes in xylene and rehydrated with 
graded alcohol by 5-min washes and a final wash in water. A standard Tris-EDTA buffer and pressure 
cooking was the antigen retrieval procedure and then sections were blocked in 0.3% H2O2 in TBS and 
10% normal goat serum. Sections were incubated for 1 hour with primary antibody and after washing 
secondary antibody was added based on manufacturers suggested dilution. After washing with PBS, 
sections were stained using the ABC detection system (Vector laboratory) according to the 
manufacturer’s instruction. Visualization was performed with chromogen reagent (Dako) according to 
manufacture instructions. 
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2.1.3 Cell culture experiments 
2.1.3.1 Storage and propagation of the cell lines 
The identity of all used cell lines was controlled by ATCC recommended DNA fingerprinting and they 
were negative for mycoplasma contamination as confirmed by regular routine tests. Cell lines were 
preserved in liquid nitrogen in medium containing 50% FCS, 40% complete growth medium for 
propagation and 10% DMSO. Cell lines were propagated until 70-80% confluence and re-plated 
afterwards. Cell lines were de-attached using Trypsin/EDTA and re-plated in an appropriate cell 
density. 
The non-tumorigenic mammary epithelial cell line MCF 10A (ATCC, 50) was cultured in Ham’s 
Dulbecco’s modified Eagle’s/F12 (DMEM/F12) medium supplemented with 5% horse serum, 1% 
penicillin/streptomycin, 20 ng/ml EGF, 0.5μg/ml hydrocortisone, 10 μg/ml insulin and 0.1 µg/ml 
cholera toxin. MCF 10A-GFP cells were generated by transducing MCF 10A cells with 
pRRL.sin.cPPT.hCMV-GFP.WPRE. hTERT-HME1-derived cell line HME-EGFR (generously 
provided by Alberto Bardelli, Italy) was maintained in DMEM/F-12 medium  supplemented with 10% 
fetal calf serum, 20 ng/ml EGF, 0.5 µg/ml hydrocortisone, 10 µg/ml insulin and 1% 
penicillin/streptomycin. Murine embryonic fibroblasts C3H10T1/2 (a generous gift from M. Wicha, 
University of Michigan, USA) cells were grown in DMEM medium supplemented with 5% fetal calf 
serum, 2mM glutamine, 1% penicillin/streptomycin. T4-2 and HUVEC cells were a kind gift from Dr. 
Cyrus Ghajar (Laboratory for the Study of Metastatic Microenvironments, Fred Hutchinson Cancer 
Research Center, Seattle, WA, USA). T4-2 cells were propagated in collagen-coated cell culture dishes 
in DMEM/F12 supplemented with 250 ng/ml Insulin, 10 µg/ml apo-Transferrin, 2,6 ng/ml sodium-
selenite, 10-10 M β-estradiol, 1,4x10-6 M Hydrocortisone and 5 µg/ml Prolactin. HUVECs were 
propagated in complete EGM-2 medium (EGM-2 Kit, Lonza) and used maximum until passage 11. All 
cell lines were kept at 37°C and 5% CO2 in a fully humidified incubator. 
2.1.3.2 Preparation of collagen coated plates 
PureCol collagen is approximately 97% Type I collagen with the remainder being comprised of Type 
III collagen and it is used for the coating of the dishes for culture of the cell lines that need additional 
support from the matrix similar to their physiological environment. PureCol (stock concentration 3 
mg/ml) was diluted in ice cold 1x PBS to working concentration of 67 g/ml. This solution was added 
to the cell culture flask at least a day before cell seeding. Per one 75 cm2 flask was added 10 ml of the 
collagen solution and it was incubated overnight at 4ºC. These dishes can be stored at 4ºC for 14 days. 
Before seeding cells the liquid was removed (carefully not to disturb the bottom layer of collagen) and 
gently washed with prewarmed growth medium. 
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2.1.3.3 Preparation of poly-HEMA (ultra-low attachment) plates 
The mammary stem and progenitor cells are able to survive anchorage independent conditions while 
more differentiated progenies are undergoing anoikis. Cells are not able to anchorage to the dish bottom 
if the dishes are covered by poly-HEMA, an organic substance soluble in ethanol. For preparation of 
the coating solution, 2,4 g of poly-hydroxy-ethyl-methyl-acrylate (Poly-HEMA) was added to 20 ml of 
95% ethanol and put on a heating magnetic plate warmed to 65° C and mixed using magnetic stirrer to 
dissolve for minimum ~8 hours. To the above dissolved poly-HEMA, 80 ml of 95% ethanol was added 
and mixed to get the final concentration of 12 mg/ml. The prepared solution could be stored indefinitely 
at 4° C. Poly-HEMA solution was applied to the culture dishes and left to dry overnight in a sterile hood 
with lids slightly opened. On the next day, a fine layer of poly-HEMA covers the culture dish. The poly-
HEMA-coated plates can be stored indefinitely until use at 4° C. Prior to cell seeding poly-HEMA 
coated plates were sterilized by the UV light for 30-60 minutes and the traces of ethanol were removed 
by washing with PBS. 
2.1.3.4 In vitro propagation of mammary cells under anchorage independent condition (sphere 
assay) 
Mammary cell lines were propagated in 2D conditions until they reached the 70% confluence. 
Propagated cells were de-attached and washed in PBS at least two times. The washing steps were 
introduced to remove traces of serum used in the 2D cell line propagation culture strategy. Cell lines 
were propagated in ultra-low attachment plates in cell culture incubator at 37 °C, 5% CO2 and 7% O2 
at a seeding density of 10 000 cells/ml in 35 mm plates with 3 ml medium per plate. All cell lines as 
well as the primary epithelial cells isolated from human and mouse mammary glands were propagated 
in the same mammosphere medium, comprising of a serum-free mammary epithelial growth medium 
(MEBM) supplemented with 0.5x penicillin/streptomycin, 1x B27, 10 ng/ml EGF and 10 ng/ml bFGF 
and 4 μg/ml heparin. To assess uniformity of seeding, cells were resuspended in master mix, containing 
1 ml spare volume and distributed to the ultra-low attachment plates for the cultivation. Mammosphere 
forming ability was assessed 7 days post-plating. During this period, medium was not changed and 
disturbance of the cultures was avoided. 
HIL-6 (a kind gift from Dr. Stefan Rose-John Christian-Albrechts-University, Kiel, Germany) was 
dissolved in DMSO and used at final concentration of 20 ng/ml. Gro-, Rankl and Wnt4 were dissolved 
and used according to the manufacturer’s instructions in final concentrations of 5 ng/ml, 50 ng/ml and 
5 ng/ml respectively. Collagen I was dissolved according to the manufacturer’s instructions and used 
in final concentration of 50 g/ml. ALK5i, p38i and RTKi were dissolved and used according to the 
manufacturer’s instructions in final concentrations of 10 M, 2 M and 2 M respectively. 
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2.1.4 Microvascular niche 
2.1.4.1 Production of the lentiviral (GFP) and retroviral particles (RFP) 
For the production of lentiviral particles we used 293T cells and for the production of retroviral particles 
Phoenix Ampho (PA) cells. Both 293T and PA cells were propagated in DMEM medium supplemented 
with 10% FCS and 2 mM Glutamine. Antibiotics decrease virus production and their usage was avoided. 
PA cell line is a variant of 293T cell line that has been stably transfected to express viral packaging 
proteins, so they do not require addition of viral plasmids, but only the plasmid of interest. Transfection 
efficiency is strongly affected by cell culturing method, passage number, cell confluence, pH, 
temperature and many other factors. Therefore this procedure is very requiring and must be carefully 
conducted. Reaching confluence significantly decreases virus production capability and the cells must 
be passaged upon reaching 70% confluence. 
For virus production 4 x 106 cells were seeded in a 10 cm petri dish in the evening before transfection. 
Transfection medium (DMEM with 10% FCS) containing 25 μM chloroquine was added to the cells 45 
min before the start of transfection. Chloroquine blocks endosome/lysosome function which 
subsequently decreases degradation of plasmids and increases transfection rate. 30 to 60 minutes after 
chloroquine addition transfection mixture was added dropwise to chloroquine containing medium. 
Transfection mixture for 293T cells comprise of pMD2G (envelope plasmid), psPAX2 (packaging 
plasmid), lentiviral plasmid (target DNA, carrying a gene of interest) and 0,25 M CaCl2 in HeBS buffer 
(pH of buffer must be 7,05 at room temperature). In the case of viral production by PA cells viral 
(packaging and envelope) plasmids are not added to transfection mixture. Plasmid DNA generates 
calcium-phosphate–DNA co-precipitates with potassium from CaCl2 and phosphate from buffer. 
Calcium phosphate facilitates the binding of the condensed DNA in the co-precipitate to the cell surface, 
and the DNA enters the cell by endocytosis. The transfection mixture was added drop wise to the cells 
and they were incubated 6-8 hours. After incubation in transfection medium it was replaced with post-
transfection medium (growth medium with HEPES buffer). Medium with produced viral particles was 
collected 48h and 72h post transfection when cell confluence was 70% and 90% respectively. Upon 
collection viral containing media were centrifuged, filtered through 0,22 µm sterile filter and stored at 
-80⁰C. Since virus related work belongs to biosafety level 2 (S2 work) higher precautions must be met 
than in regular cell culture work. From the moment of adding transfection mixture to the cells 
recommendation prescribed for the S2 work must be followed. 
2.1.4.2 Virus titer determination 
In order to determine the number of viral particles in the medium of virus producing cells we used easily 
transducable cell line C3H10T1/2, murine mesenchymal cells. Cells are cultured in DMEM 
supplemented with 10% FCS and 1% P/S. 12 to 24 hours prior to transduction 10.000 cells were seeded 
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per well in 12 well plate and incubated overnight in incubator with 37°C and 5% CO2. On the next day 
average number of cells per well was counted by counting the number of cells in 2-3 wells. Transduction 
medium is growth medium with 4 µg/ml polybrene, which increases retrovirus gene transfer efficiency 
by enhancing receptor-independent virus adsorption on target cell membranes. Serial dilution of virus 
containing medium was added to transduction medium and to cells according to the scheme in the table 
1. Cells were incubated with virus-polybrene-containing medium 12-16 hours after which medium was 
exchanged with regular growth medium. 48 hours after cells were harvested and fixed using 1% PFA. 
After 10 minutes incubation in 1% PFA, all the viruses are dead and cells were analyzed on FACS. 
For (multiplicity of infection) MOI calculation the well with 10-20% fluorescent cells (positive in FACS 
analysis) was taken. The MOI is calculated from the following equation: 
Positive x N x DF = IU/ml 
Positive - percentage of positive cells 
N – number of cells at the time of transduction 
DF – dilution factor 
IU – number of infectious units 
Table 1: Dilution scheme for native viral SNTs, the indicated volume refers to one well of a 12 well plate 
Dilution factor Virus supernatant [µl] Polybrene containing medium [µl] 
Non-transduced 0 1000 
Undiluted 1000 0 
5 200 800 
10 100 900 
50 20 980 
100 10 990 
500 2 998 
 
2.1.4.3 Generation of the microvascular niche 
Microvascular niche is a co-culture of hMSCs and endothelial cells that form a fine continual 
microvasculature net. hMSCs were isolated and propagated as described. Human Umbilical Vein 
Endothelial Cells (HUVEC) transduced with adenoviral E4ORF1 gene, as well as H2B-GFP-T4-2 
breast cancer cell line were a generous gift from Dr. Cyrus Ghajar, Laboratory for the Study of 
Metastatic Microenvironments, Fred Hutchinson Cancer Research Center, Seattle, USA. Introduction 
of E4ORF1 gene into human HUVECs increased the long-term survival of these cells in 
serum/cytokine-free conditions, while preserving their in vivo angiogenic potential for tubulogenesis 
and sprouting (Seandel et al., 2008).  
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Before seeding MVNs HUVECs were transduced with pBMN/mCherry plasmid in order to generate 
stably expressing mCherry endothelial cells (Ghajar et al., 2008) and cultured to achieve post-
confluence (Figure 6). For MSC or MVN generation MSCs were seeded alone at a density of 5x104 
cells/well in 96-well culture plates or with mCherry-E4-ECs at a 5:1 ratio to generate stromal or bone 
marrow-like microvascular niches, respectively. Cells were suspended in EGM-2 medium at a 
concentration 5x104 cells/100 µl (stroma only) or 6x104 cells/100 µl (stroma + ECs). After depositing 
100 µl of cellular suspension per well of a 96-well plate, plates were left undisturbed on a flat surface 
for 20 min to allow even cell seeding prior to incubation. Cells were always inspected under the 
microscope for even distribution in the well prior to transferring into incubator. Growth medium was 
changed regularly every two days. After ten days the cultures were inspected and when they formed 
nice continuous vascular net (Figure 6), breast cell line cells were added. GFP labeled MCF10A or 
H2B-GFP-T4-2 cells were trypsinized and carefully counted. The density of cells was adjusted to have 
determined number of cells in 100 µl EGM-2 medium and 100 µl of cell suspension was seeded in each 
well with stromal (control) or microvascular niche. Cells were allowed to settle for 15 min at room 
temperature, then a 100µl of Cultrex Basement Membrane Extract (BME) in DMEM/F12 was slowly 
added to each well (final concentration = 20%). BME was left to condense for 10 min at room 
temperature before polymerizing fully at 37ºC. Cultures were maintained with media changes every 
three days and further analyzed at day 10. 
For cell growth measurement MSC and MVN cultures were imaged and quantified. The same ROI 
(surface area marked and surrounded) was applied to all the wells and gave the level of GFP 
fluorescence. Statistical analysis was performed using GraphPad Prism software. 
 
Figure 6: Left panel: post-confluent HUVECs, before seeding MVN; Right panel: Microvascular net at day 7 after seeding 
 
2.1.4.4 Isolation of the single breast cancer cells from MVN and MSC niches 
To isolate breast cancer cells we first collected the gelatinous layer of BME using p200 tip and Gilson 
pipette. Then, each well was washed three times with ice-cold 1x PBS to remove residual BME. After 
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that only thin layer of the artificial tissue was left in the well. We added 200 l of ice-cold 1x PBS to 
the well, scratched gently the “tissue”, collected using p200 tip and transferred to 1,5 ml microcentrifuge 
tube. Next we mixed the cell suspension using a syringe with 19 gauge needle to mechanically separate 
the cells. All the steps were performed on ice, because residual BME quickly polymerizes and makes 
gelatinous suspension. This suspension was then transferred to picking slides and GFP-positive cells 
were isolated. 
2.1.5 Osteoblastic niche 
2.1.5.1 Isolation and cultivation of hMSCs from cancer patients 
Isolated human bone marrow was centrifuged on 65% Percoll gradient and interphase was washed once 
with 1X PBS. 2x106 cells were plated per 75 cm2 flask in 15 ml of media (low glucose DMEM 
supplemented with heat inactivated FBS, 2 mM L-Glutamine and 1% Penicillin/Streptomycin). 
Medium was changed weekly and when clusters formed, cells were trypsinized to achieve homogeneous 
distribution. After 3-4 weeks of culturing 1-1,3x106 cells were harvested from each flask. This is 
Passage 0 (P0) of the cells. Numerous freeze-thaw cycles as well as long culturing time were avoided 
with these cells. 
2.1.5.2 Osteoblasts differentiation from MSCs and co-culture with MCF10A cells 
200.000 human mesenchymal stromal cells (hMSCs) from 80% confluent flask cells were seeded pro 
well of 6 well plate and cultivated in hMSCs medium for three days until achieved 95% confluence. 
After achieving confluence cells were moved to incubator with 3% O2 and 5% CO2 and medium was 
changed with medium for osteogenic differentiation (high glucose DMEM without Sodium-pyruvate 
supplemented with 10% FBS, 0,1 µM Dexamethasone, 25 µg/ml L-ascorbic acid and 3 mM 
Monosodium phosphate (NaH2PO4)). Medium was changed every 2-3 days for 21 days. After 21 days 
osteogenic differentiation was confirmed by Alizarin Red staining. After 21 days of differentiation of 
OBs, MCF10A cells were stained with CFDA-SE and seeded on top of osteoblasts and cultivated in 
growth medium in incubator  with 3% O2, 5% CO2. For FACS analysis cells were washed with 1X PBS, 
trypsinized 5 minutes with 0,05% trypsin and scraped using cell scraper. Intensive pipetting with Gilson 
p1000 pipette was applied in order to break clusters and get single suspension. After washing with 1X 
PBS cells were filtered through 40 µm cell strainer, stained and analyzed by FACS. 
2.1.5.3 Co-cultures of MCF10A with MSCs, OBs, HUVECs 
MSCs and HUVECs were plated at a density of 4x105 cells/well of a 6 well plate (Corning, Germany) 
in their growth medium. The next day, medium was exchanged to MCF10A growth medium and 1x105 
MCF10A-GFP cells were added to each well. In case of co-cultures with OBs, 4x105 MSCs per 9.6 cm2 
surface of a 6 well plate were plated and differentiated into OBs for 21 days. On day 22 medium was 
25 
 
exchanged to MCF10A growth medium and 1x105 MCF10A-GFP cells were added to each well. For 
cultures with transwells, MSCs were plated at 1.75x105 cells per 4.2cm2 of a 6-well transwell insert. 
2.1.5.4 Selective activation/inhibition of individual IL-6 signaling 
MCF10A cells were cultured as mammospheres in the presence of 10 ng/ml IL6, 10 ng/ml IL6 + 0.1 
ng/ml rh sgp130-Fc or 20 ng/ml Hyper-IL6 for 12 and 24 hours. Triplicates were seeded for all 
conditions and time points. After 12 and 24 hours, cells were collected by centrifugation for 5 min at 
500xg and RNA was isolated using RNeasy Mini Kit according to the manufacturer’s protocol. 
Microarray analysis was performed using the Whole Human Genome Microarray Kit, 4x44K (G4112F) 
and Agilent chips. For transcriptome analysis of BM-DCCs of metastasized and non-metastasized 
patients, cDNA was generated from manually isolated single cells using whole-transcriptome 
amplification. 
Labelling of cDNA was performed by PCR with Cy5-labelled primers. Reaction mix contained 5 μl of 
buffer I, 3% (v/v) deionized formamide, 0,35 mM each dNTP, 2,5 μM 5'-
U*CAGAAU*TCAUGCCC*CCCC*CCCC*C-3' primer (*denotes nucleotides conjugated with Cy5 
fluorophore; Metabion), 3,75 U of PolMix and 1 μl of WTA-product or 100 ng cDNA from bulk RNA 
preparations of MCF10A cells in a final volume of 49 μl. PCR parameters were: one cycle with 1 min 
at 95 °C, 11 cycles with 15 s at 94 °C, 1 min at 60 °C, and 3 min 30 s at 65 °C, 3 cycles where the 
elongation time was increased 10 s per cycle, and finally one cycle with an elongation time of 7 min. 
Labelled products were purified using a PCR purification kit according to the instructions of the vendor. 
Purified Cy5-labelled DNA was denatured by incubation for 5 min at 95 °C followed by incubation on 
ice. Hybridization solution was prepared by mixing 42 μl of denatured Cy5-labelled DNA, 55 μl of 2x 
HiRPM hybridization buffer, 11 μl of 10 × GE Blocking agent, 4 μl of 25% (v/v) Tween-20, and 4 μl 
of 25% (v/v) Igepal. Four 100 μl samples of hybridization mix were overlaid on 4 hybridization fields 
of Agilent Whole Human Genome (4x44K) Oligo Microarray with SurePrint (G4122F) microarray 
slides and incubated for 17 h at 65 °C under constant rotation. After hybridization, slides were washed 
in Agilent Wash buffer 1 for 1 min on a shaker in the dark and incubation continued in Agilent Wash 
buffer 2 pre-warmed to 37 °C. Slides were dried by washing for 30 s in acetonitrile and scanned on a 
GenePix 4400 A scanner. Numerical readouts of fluorescence intensities (GPR files) were generated 
using GenePixPro 7. 
2.1.6 Staining procedures 
2.1.6.1 CFDA-SE staining 
CFSE (5-(and 6)-Carboxyfluorescein diacetate succinimidyl ester, CFDA SE) is cell division tracking 
dye and is a golden standard in proliferation tracking in label retention assays. Cells were washed once 
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with 1X PBS, resuspended in 4 µM CFDA-SE diluted in FACS buffer (1% FCS in 1X PBS) and 
immediately vortexed and incubated 10 minutes in water bath on 37°C (in dark). After incubation cells 
are washed with 50 ml medium containing 10% FCS and afterwards with 50 ml PBS. 
2.1.6.2 PKH26 staining 
PKH26 is a general cell membrane labeling dye that is visible under Cy3 filter. Cells isolated from 
human mammary tissue were washed once in 1x PBS and centrifuged 5 min at 500xg to remove any 
traces of serum. The supernatant was discarded and the cell pellet was resuspended in 1 ml Diluent C. 
to make 1:25 dilution from recommended by vendor we mixed 2 μl of PKH26 with 48 μl of ethanol and 
from that suspension we took 4 μl and added to 996 μl of Diluent C solution. The dye solution was 
added to the cell suspension, mixed quickly because the binding of the dye to the cell is immediate and 
incubated for 5 min. The staining reaction was stopped by adding 2 ml of medium containing 10% FCS 
for 1 min and centrifuged 5 min at 500xg. After discarding the supernatant, the pellet was resuspended 
1x PBS and centrifuged again for 5 min at 500xg. The cells were washed in total 3 times with 1x PBS 
to remove unbound dye. 
2.1.6.3 Staining of cell surface markers for FACS analysis 
To reduce non-specific binding single cell suspensions were incubated for 5 min at 4°C with PBS/10% 
AB-serum, subsequently stained with fluorescence-labeled or biotinylated antibodies for 15 min at 4°C 
and washed once with PBS/2% FCS/0.01% NaN3. In case of biotinylated primary antibodies, PE-
labeled streptavidin was used as secondary staining reagent. Cells were stained using the following 
antibodies:, anti-human CD44-V450 (G44-26), biotinylated anti-human IL6R (UV4),  isotype control 
mouse IgG2a-APC (MOPC-21), isotype control mouse IgG2b-V450 (MOPC-21), isotype control IgG1-
biotin (MOPC-21) (all purchased from BioLegend, Germany) and anti-human EpCAM (HEA-125). 
Viability dye eFlour 780 was used for live/dead cell discrimination. Cells were analyzed on a LSR II 
machine equipped with FACS DIVA 5.03 software and data was analyzed with FloJo 8.8.6 or 10.1. 
2.1.7 T cell experiment 
2.1.7.1 T cell isolation and stimulation 
50ml of blood was drawn from a healthy individual in heparin pre-coated syringe and washed once with 
double volume of Hanks Salt solution. Yellow supernatant containing fat and platelets is removed and 
washed blood was slowly subjected to gradient centrifugation on 65% Percoll (1:1 volume). After 
20min centrifugation at 1000xg the interphase with target cells was collected and washed. For cell 
labeling CD8+ T cell Biotin-Antibody Cocktail was incubated with the cells for 5 minutes at 4°C. After 
washing and adding CD8+ T cell MicroBead Cocktail cells were incubated for 10 minutes at 4°C and 
washed. Magnetic separation was performed using MACS columns. Cell suspension was applied to the 
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MACS column (prepared by rinsing with MACS buffer) and washed twice with 1 ml of MACS buffer. 
Antibodies are labeling all the other cells except of CD8+ T cells, so the aimed CD8+ T cells are 
enriched in flow-through. Cells were counted and 100.000 cells were taken to check the purity of 
isolated cell suspension (by FACS analysis). Cells were cultured in RPMI medium supplemented with 
10% FCS, 1% Penicillin/Streptomycin (P/S) and 50 µM β-mercaptoethanol. For PMA/ionomycin 
stimulation, cells were incubated with PMA (20 ng/ml) and ionomycin (1 µM) 6-8 hours. After 
stimulation cells were collected and washed trice with 50 ml prewarmed complete growth medium. 
Cells were cultivated for 48h before cell cycle analysis. 
2.1.7.2 DNA staining for cell cycle analysis (DAPI and Hoechst 33342) and cell sorting 
Cells were checked under microscope. In stimulated cultures can be seen many small cell clusters of 
proliferating cells. Cells were collected, centrifuged 5 minutes at 500xg and resuspended in prewarmed 
medium with 10 µg/ml Hoechst 33342 (for pilot experiment 5 µg/ml DAPI was used). After incubation 
at 37°C for 40 min in the dark viability dye (7-AAD) was added to final concentration of 0,5 µg/ml and 
cells were incubated additional 10 minutes at 37°C in the dark. After incubation cells were analyzed 
and sorted on BD LSR II. 
2.1.8 Whole transcriptome amplification and PCR 
2.1.8.1 Whole transcriptome amplification (WTA) of single cells  
Target cells were stained for EpCAM or other marker of interest. For live/dead cell discrimination cells 
were stained with DAPI and single viable cells showing the phenotype of interest were isolated with a 
micromanipulator. Whole transcriptome amplification of single cells was performed as previously 
described (Hartmann and Klein, 2006). The quality of WTA products was assessed by expression 
analysis of three housekeeping genes: β-actin, GAPDH and EF-1α. Only samples which were positive 
for at least two of three analyzed markers were used for downstream analyses. 
2.1.8.2 Gene specific end-point PCR 
Endpoint PCR was conducted to verify the presence of selected genes of interest in WTA products. 
Template (1 l) was mixed with 1 µl of 10x Fast Start buffer, 0,2 l dNTP Mix (10 mM each), 0.5 µl 
of forward and reverse primer (8 µM each), 0.2 µl BSA, 0.1 µl Fast Start Taq Polymerase and HPLC 
Grade H2O to a final volume of 10 µl (6,5 l). PCR was run using the following program: initial 
denaturation of 4 min at 95°C was followed by 40 cycles of 30 s at 94°C, 30 s at predetermined 
annealing temperature, 90 s at 72°C and a final elongation step for 7 min at 72°C. Positive and negative 
control was included in every PCR run. Annealing temperature used for three housekeeping genes was 
58ºC. 
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2.1.8.3 IL6, IL6RA, gp130, MKI67 and MCM2 mRNA expression analysis 
IL6, membrane IL6 receptor and spliced IL6 receptor expression was assessed by PCR using the MJ 
Research Peltier Thermal Cycler Tetrad with the following primers: IL6 (forward primer: 5'-GAG AAA 
GGA GAC ATG TAA CAA GAG T-3', reverse primer: 5'-GCG CAG AAT GAG ATG AGT TGT-3', 
annealing 62°C, amplicon size 388 bp), membrane versus spliced IL6RA (forward primer: 5'-CTG CAA 
ATG CGA CAA GCC TC-3', reverse primer: 5'-GTG CCA CCC AGC CAG CTA TC-3', annealing 
62°C). The spliced and membrane-bound IL6 receptor were distinguished according to their PCR 
product size: mIL6RA 380 bp, spliced IL6RA 286 bp. gp130 expression was assessed by end-point and 
quantitative PCR that was performed on a LightCycler 480 (Roche, Germany) using following primers: 
for end-point PCR forward primer: 5'-GGA CCA AAG ATG CCT CAA CT-3', reverse primer: 5'-GGC 
AAT GTC TTC CAC ACG A-3', annealing 58°C, size of the amplicon 280 bp, and for qPCR forward 
primer: 5'-ATA TTG CCC AGT GGT CAC CT-3', reverse primer: 5'-AGG CTT TTT GTC ATT TGC 
TTC T-3', annealing 57°C, size of the amplicon 125 bp.  
MKI67 (Ki-67) and MCM2 expression was assessed by end-point and quantitative PCR with the 
following primers: MKI67 forward 5’-GCGGAGTGTCAAGAGGTGT-3’ and reverse 5’-
CAGACCCAGCAAATCCAAAGT-3’ (amplicon length 247 bp); MCM2 forward 5’-
GAAGCAGTTAGTGGCAGAGC-3’ and reverse 5’-CATAGGGCCTCAGAACTGCT-3’ (amplicon 
length 217 bp). Annealing temperature for both genes was 58°C.  
2.1.8.4 Agarose gel electrophoresis  
Amplified products of the specific PCR were separated with gel electrophoresis, on 1.5% agarose in 
TBE buffer with ethidium-bromide (0,5 μg/ml). Samples were mixed with a loading dye and loaded in 
the gel. PCR amplicons were separated at 160 V for 45 min. IL-6 and IL-6R amplicons were separated 
on 2% agarose gel for at 160 V for 60 min. 
2.1.8.5 Re-amplification of primary WTA single-cell products 
Re-amplification of primary WTA products was performed in a reaction volume of 50 µl comprising 5 
µl Expand Long Template Buffer 1, 6 µl of CP2-15C or CP2-9C primer (2.88 µM), 1.75 µl dNTPs (10 
mM each), 7.5 µl 20% Formamide, 1.5 µl DNA Pol Mix (5 U/µl, Expand Long Template PCR System), 
27.25 µl PCR HPLC Gradient Grade H2O and 1 µl template (primary WTA product). Re-amplification 
was run on PTC DNA Engine 2 Tetrad Thermocycler using the following program: 1 min at 95°C, 5 
cycles comprising 15 s at 94°C, 1 min at 60°C and 3 min 30 s at 65°C, 3 cycles of 15 s at 94°C, 1 min 
at 60°C and 3 min 30 s at 65°C (elongation step was extended by 10 s per cycle) and a final elongation 
step of 7 min at 65°C. Negative control was included in every run. Quality of re-amplified product was 
examined using the same endpoint PCR assay as the one used for primary WTA products (see above). 
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2.1.8.6 Purification of WTA products 
Purification of WTA samples was conducted to remove buffer and remaining WTA reagents (dNTPs, 
proteins and primers) that may negatively influence downstream processes (i.e. cDNA yield 
quantification and qPCR). 15 µl of primary or re-amplified WTA product was purified using QIAquick 
PCR Purification Kit according to the manufacturer’s instruction with several changes: (i) No pH-
indicator was added to the PB buffer. (ii) Purified cDNA was eluted from the purification column using 
HPLC Gradient Grade H2O instead of EB buffer provided by the manufacturer of the kit. (iii) PCR 
HPLC Gradient Grade H2O (typically 20 µl) used for elusion was pipetted on the silica membrane of 
the column, followed by 5 min incubation at room temperature prior to the final centrifugation (elution) 
step. To allow a more optimal distribution of elution liquid in the silica membrane on the purification 
column, spin assembly was centrifuged at 500 rpm for 30 s followed by the final centrifugation at 
13.000 rpm for 60 s. Concentration of each purified sample was measured using NanoDrop 2000c. 
2.1.8.7 Quantitative Real-Time PCR  
Quantitative PCR (qPCR) was performed for selected genes of interest (gp130, MKI67 and MCM2) 
using a LightCycler 480 instrument (Roche). Each qPCR comprised 5 µl of the template cDNA, 10 µl 
iQTM SYBR® Green Supermix (Bio-Rad), 1 µl of each forward and reverse primer (8 µM each) and 
3 µl PCR HPLC Gradient Grade H2O. QPCR was run using the following program: 1 cycle for 5 min 
at 95°C (temp. ramp of 4.4°C/s), 38 cycles for 20 s at 95°C (ramp 4.4°C/s), 15 s at 58°C (ramp 2.2°C/s) 
and 15 s at 72°C (ramp 4.4°C/s; fluorescence signal was measured at the end of each elongation step). 
Subsequently, melting curves were generated using the following procedure: 1 cycle for 5 s at 95°C 
(ramp 4.4°C/s), 1 cycle for 1 min at 50°C (ramp 2.2°C/s), 1 cycle of DNA melting, wherein temperature 
was continuously increased to 95°C with a ramp of 0.11°C/s with continuous fluorescence measurement 
5 times/s) followed by a final cooling to 40°C for 30 s (2.2°C/s). Melting plots were examined to 
validate the specificity of PCR amplification. Crossing point (Cp) values were determined with the 
LightCycler 480 Software using the second derivative maximum method applying the high sensitivity 
algorithm. All single-cell WTA products were analyzed in technical triplicates. Cp-values were 
averaged across the technical replicates before further data processing. Samples with average Cp-values 
>33 were considered as negative. No template control was included in any qPCR run.  
2.1.8.8 Absolute qPCR quantification analysis  
Quantification of cDNA yields in the individual samples was spectrophotometrically conducted using 
the NanoDrop 2000. To allow an accurate measurement of cDNA, yields of WTA products were 
purified (see section 2.1.8.6). DNA input for each qPCR was normalized to 5 ng and run as described 
above. The obtained Cp-values generated by the LightCycler 480 Software (Roche) were converted into 
log10 copy numbers. For this, a standard curve measurement was conducted with serially diluted cDNA 
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standards comprising amplicons of the target transcript. Concentrations of the standards ranged from 
10-8 to 10-4 ng/µl covering copy numbers from 3x102 to 3x106 molecules/µl.  
2.1.9 Gene expression analysis using micro array 
2.1.9.1 Mammary cell subpopulation mRNA microarray data. 
Human mRNA expression data from Lim et al. based on Illumina HumanWG-6 v3.0 BeadChip 
microarrays were downloaded from the Gene Expression Omnibus (GEO) (series GSE16997). 
2.1.9.2 LRC/QSC/nLRC mRNA microarray data. 
Agilent 44kx4 v1 microarrays (Design ID 014850) for 8 LRC, 10 QSC and 5 nLRC samples were 
hybridized. All chips passed quality assessment and were preprocessed as described for MCF 10A cells 
above. Annotation was retrieved from the Agilentarray platform (June 2015). Using the 6000 genes 
with the highest variation across all samples, unsupervised consensus clustering (R-package 
ConsensusClusterPlus, method k-means 55 was applied assuming three clusters. From the clustering 
results it was concluded that the LRC and QSC groups respectively consist of two sub-groups, resulting 
in five groups in total (LRC1, LRC2, QSC1, QSC2, nLRC). Differentially expressed genes were then 
determined according to a linear model (limma R-package) including all pairwise contrasts between the 
five groups and an FDR threshold of 0,05. Pathway enrichment analysis was performed employing the 
R-package enrichR (version 1.0). 
2.1.10 Statistical analysis 
Statistical analysis was done using GraphPad Prism 6.0 software (GraphPad Software, Inc., USA). 
Differences in medians between groups were analyzed by Student’s t-test, one-way ANOVA and 
multiple t-test with correction for multiple comparisons (Holm-Sidak’s) or fisher’s exact test where 
appropriate. When data did not follow normal distribution corresponding non-parametric tests were 
used. All tests were performed two-sided. A p-value of less than <0.05 was considered to be statistically 
significant. 
2.2 Material 
2.2.1 Reagents 
Product Manufacturer Cat. Number 
2-Log DNA-Ladder 1kb  NEB N32005 
7-AAD BioLegend 420403 
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AB-Serum  Bio-Rad 805315 
Acetic acid Merck, Darmstadt 100063 
Agarose  Sigma Aldrich GmbH  A3038 
Ampicillin AppliChem GmbH A0839 
B27  Invitrogen 17504-44 
BCIP/NBT  BioRad 1706432 
B-estradiol  Sigma Aldrich GmbH E4389 
bFGF  Sigma Aldrich GmbH F0291 
Bovine serum albumin (BSA), 20 mg/ml Roche 10711454001 
BSA  Roche 1071145001 
CaCl2 Sigma Aldrich GmbH C5080 
CFDA-SE  eBioscience 65-0850-84 
Chloroquine Sigma Aldrich GmbH C6628 
Cholera toxin Sigma Aldrich GmbH C9903 
Collagen I Sigma Aldrich GmbH C3867 
Collagenase Sigma Aldrich GmbH C0130 
Cultrex Basement Membrane Extract (BME)  Trevigen 3432-001-01 
DAB  DAKO K3468 
DAPI Roche Dignostics 32670 
DEPC-H2O  Invitrogen  750023 
DMEM high glucose Pan-Biotech P04-03500 
DMEM low glucose Life Technologies GmbH 11885-084 
DMEM/F12  Pan-Biotech P04-41500 
DMSO Sigma Aldrich GmbH 41640 
EGF Sigma Aldrich GmbH E9644 
EGM-2 Kit Lonza CC-3162 
Eosin  Sigma Aldrich GmbH 54802 
b-Estradiol Sigma Aldrich GmbH E2758 
Ethanol absolute  J.T. Baker 8006 
Ethidium bromide (1 %)  Sigma Aldrich GmbH E8751 
Eukitt (Mounting gel)  Sigma Aldrich GmbH 03989-100ML  
Expand Long Template Enzyme Mix Roche Dignostics 11 759 060 001 
FastStart Taq-Polymerase  Roche Dignostics 11435094001 
FCS  PAN Biotech P30-3702  
Fetal bovine serum (FBS) Pan Biotech, Aidenbach P30-1506 
Formaldehyde Merck, Darmstadt 104003 
Formamide Merck, Darmstadt 344 205 
Formamide, deionized Sigma Aldrich GmbH F9037 
Glutamine PAA Laboratories GmbH M11-004 
Goat serum DAKO X0907 
GRO-α RnDsystems 275GR 
Hematoxylin Sigma Aldrich GmbH MHS16 
Heparin Sigma Aldrich GmbH H3149 
HEPES buffer Sigma Aldrich GmbH H7523 
Hexadimethrine bromide (Polybrene) Sigma Aldrich GmbH H9268 
HIL-6 A gift from Dr. Rose-John  
Hoechst 33342 Sigma Aldrich GmbH B2261 
Horse Serum Sigma Aldrich GmbH H1270 
Hyaluronidase Type IV-S Sigma Aldrich GmbH H4272 
Hydrocortisone Sigma Aldrich GmbH H0888-1gr 
Igepal  Sigma Aldrich GmbH I3021-50ML 
Insulin Sigma Aldrich GmbH I9278 
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Isopropanol  Fluka 59300-2.5ML 
Levamasol Sigma Aldrich GmbH L9756 
L-Glutamin (200 mM)  Pan-Biotech P04-80100 
Matrigel BD Biosciences 356231 
MEBM Lonza CC-3151 
Methyl cellulose Sigma Aldrich GmbH M0512-100G 
Mouse serum  DAKO X0910 
Paraformaldehyde VW 104005 
Penicillin/Streptomycin (10 U/µL)  Pan-Biotech P1-010 
Percoll  Amersham Biosciences 17089102 
PKH26  Sigma Aldrich GmbH MINI26-1KT 
Polyhydroxyethylmethylacrylate  Sigma Aldrich GmbH P3932 
Progestrone pellet Innovative research of America P-131 
PureCol Cell systems 5005 
RankL Abcam plc ab151200 
RPMI 1640  Pan-Biotech P05-17500 
Sodium-selenite Sigma Aldrich GmbH S5261 
apo-Transferrin Sigma Aldrich GmbH T2252 
Trypsin/EDTA Anprotec AC-EZ-0020 
Trypsin neutralizing solution (TNS) Lonza Verviers SPRL CC-5002 
SB203580 (p38i) Calbiochem S1076 
SB431542 (ALK5i) Calbiochem S1067 
S1042 (RTKi) Calbiochem S1042 
Wnt4 R&D Systems 475-WN-005 
Xylol  Roth 9713.3 
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2.2.2 Consumables 
Product Manufacturer Cat. Number 
6 well plates Corning CLS3516 
6-well transwell insert  VWR 353090 
100 mm Transwell with 0,4 µm Pore Polycarbonate 
Membrane Insert Corning 3419 
Adhesion slides Roth   H8701 
Cell culture flasks Sarsted 831.810.302 
Cell culture plates Schubert and Weiss, OMNILAB FALC351007 
Cell strainer 100 mm Corning 431752 
Cell strainer 40 mm Corning 431750 
Filter (0.22 µm) Roth   P666.1 
Glass slides Langenbrinc 03-0001 
MACS separation LD columns Miltenyi Biotec 130-042-901 
MACS separation LS columns Miltenyi Biotec 130-042-401 
Reaction tubes 0,2 ml Abgen AB-0337 
Reaction tubes 1,5 ml  CLN Gmb CLN-BÖT1.5 
Syringe needles (26G) Braun  C7181 
 
2.2.3 Kits 
Kit Manufacturer Cat. Number 
ABC (Avidin-Biotin Complex) Linaris AK-5000 
ABC-HRP-System  Vector Laboratories PK-4000 
CD8+ T cell isolation kit Miltenyi Biotec 130-096-495 
DAB-System  DAKO K3468 
DNA extraction Mini Kit  Qiagen 51304 
DNA Gel Extraction Kit Qiagen 28706 
ECL  Detection kit for western blotting GE Healthcare RPN2109 
Expand Long Template PCR System Roche Diagnostics GmbH 3321053103 
FastStart PCR Roche Diagnostics GmbH 11435094001 
Mouse CD45 depletion Miltenyi Biotec 130-097-153 
MTT Roche 11465007001 
Pierce BCA protein assay Thermo scientific 23227 
PKH26 general cell membrane labeling Sigma-Aldrich PKH26GL 
Plasmid purification Qiagen 12381 
QIAquick PCR Purification Kit  Qiagen 28106 
Revers trascript Qiagen 205311 
RNeasy mini-kit Qiagen 74104 
SYBR® Green Supermix  Bio-Rad Laboratories GmbH 170-8885 
Whole Human Genome Microarray Kit Agilent G4845A 
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2.2.4 Devices 
Device Company 
Balance Kern, Balingen 
BD LSR II BD Bioscience, USA 
BenchMark Ultra Ventana, USA 
Capillary holder for micromanipulation Eppendorf, Hamburg 
Cauterizer Fine Science Tools, Hedelberg 
Cell culture incubator Heraeus, Hanau 
Cell culture incubator Heraeus  
Cell culture laminar flow Heraeus, Hanau 
Centrifuge Heraeus, Hanau 
Centrifuge Eppendorf, Hamburg 
Centrifuge, tabletop Grant Bio, USA 
Centrifuge, tabletop Eppendorf, Hamburg 
Cytospine Centrifuge Hettich, USA 
Dissection tools for murine surgery Heiland 
DM RXA Fluorescence microscope Leica, USA 
Electrophoresis gel chamber Biostep, Jahnsdorf 
Flourescence microscope Leica  
Heat block thermo mixer 5436 Eppendorf 
Imagequant LAS 4000 GE Healthcare 
Inverted microscope Leica  
Magnetic stirrer VELP Scientifica 
Micromanipulator Microinjector 5242 Eppendorf 
Mini-PROTEAN Tetra Cell Bio-Rad 
MJ Research Peltier Thermal Cycler Tetrad Bio-Rad 
MJResearch  Peltier Thermal Cycler PTC-200 Bio-Rad 
Multipipette Stream Eppendorf, Hamburg 
Neubauer chamber - Cell counter Schubert und Weis, Munich 
Optical microscope Optech, Canada 
pH-meter Eutech Instruments, The Netherlands 
Photometer, GeneQuant II Pharmacia Biotech, USA 
Pipette controller Brand, Wertheim 
Pipettes (2 µl, 20  µl, 200  µl, 1000 µl) Eppendorf, Hamburg 
Power supply for gel chamber electrophoresis MRC, Israel 
StuartTM Scientific roller mixer Stuart Scientific, UK 
Thermo mixer Eppendorf, Hamburg 
UV illuminator Intas, Gottingen 
Vortex mixers VELP Scientifica, Italy 
Water bath Memmert, Schwabach 
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3 Results 
3.1 Overview of the research rationale 
Studying the state of cellular dormancy in DCCs from breast cancer patients required addressing the 
following aspects, (i) modeling in vitro the conditions in which dormant cells survive, (ii) gene 
expression profiling of dormant DCCs and (iii) analyses of the pathways relevant for tumor cell 
dormancy. Most important was to find the appropriate in vivo and in vitro model(s). Therefore, 
previously published models were tested and adapted, and novel methodological strategies and 
approaches had to be developed and previously published models were tested and adapted. After having 
identified the ´ best suited` model inducing dormancy in single cells, molecular analyses were performed 
resulting in distinct “stem cell” and “dormancy” gene signatures. Further pathway analysis followed by 
functional analysis revealed the involvement of an inflammatory signaling pathway in controlling cell 
hierarchy and stem cell function. The key steps of my investigation and workflow are outlined in the 
Figure 7. 
 
Figure 7: Workflow outlining steps of investigation of dormancy in DCCs from breast cancer patients. 
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3.2 Balb-NeuT as an in vivo model of tumor cell dormancy 
3.2.1 Short background information of previous work with the Balb-
NeuT model as the starting point of the experiments 
In some breast cancer patients DCCs are detected in the BM at the time of the primary tumor removal, 
and can be detected in post-operative BM biopsies, but these patients never develop metastases. Similar 
is seen in Balb-NeuT mouse model, which was extensively studied in our group in previous years. 
DCCs can be detected in the BM of the very young transgenic mice and they stay there and do not 
proliferate over the whole lifespan, but they stay dormant. Opposite to BM-DCCs, in lung, which is 
another metastatic organ, DCCs were actively proliferating and gave rise to metastases. That prompted 
us to isolate and study dormant DCCs from Balb-NeuT mice and learn about the dormancy 
phenomenon. Relevant literature and previous results needed for understanding in vivo experiments in 
my work are summarized in next few pages. 
Balb-NeuT mice express rat Her2 (NeuT) oncogene in a Balb/c background under the control of the 
mouse mammary tumor virus (MMTV) promoter (Cornelissen et al., 2014; Pannellini et al., 2004). In 
this model (1) independent tumors develop in each of the 10 mammary glands; (2) breast tumor 
development is followed by dissemination of cancer cells to lung and bone marrow; (3) lung metastases 
are found in later stages of tumor development. The MMTV promoter is activated by progesterone, 
therefore expression of the transgene starts around the age of 4 weeks and disseminated cancer cells 
(DCC) can be detected in the bone marrow of mice shortly after activation of the Her2-transgene 
(Husemann et al., 2008). At this time point the mammary ducts are not yet completely formed, but 
increased proliferation can be detected in them. From the sixth week on expanding buds completely 
form mammary ducts and give rise to atypical ductal hyperplasia (ADH). As of week 13, carcinoma in 
situ can be detected by manual palpation. These lesions become invasive around week 19, while overt 
metastases can be detected in lungs as of week 26 (Figure 8). 
 
Figure 8: Development of mammary tumors in Balb-NeuT mice over life time. From the 4th week of life production of 
progesterone and consequently activation of the MMTV promotor and Her2 transgene expression starts. Protein product of 
NeuT transgene is constitutively active inducing hyperproliferation and development of mammary tumors as described on the 
time line (Husemann et al., 2008) 
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DCCs in bone do not give rise to metastases but stay solitary over the whole life time of mice. Therefore, 
the lung is considered the permissive environment supporting the outgrowth of DCCs and bone marrow 
is the non-permissive niche that imposes the quiescent state. 
DCCs are detected as cytokeratin (CK)- or Her2-expressing cells among the peripheral blood leucocytes 
(PBLs) isolated from the bone marrow samples of analyzed mouse models. Dissemination was shown 
to occur early during breast cancer development, in Balb-NeuT model already at the age of 4 weeks 
(Figure 9) (Hosseini et al., 2016a). No change in the number of CK+ and Her2+ cells in the bone marrow 
of Balb-NeuT mice was observed from the early stage of cancer development (week 4) up to the stage 
of invasive carcinoma (week 27-30) (Figure 9) indicating the existence of the mechanism that prevents 
outgrowth of these cells and keeps them in the state of dormancy. 
    
Mammary origin of the DCCs in the bone marrow was proved using the transplantation model. Single 
mammary glands were transplanted from young transgenic donors (3- to 12-week old) to 3-week old 
wild-type siblings (Balb/c mice) and 7-26 weeks later their bone marrow was examined for the presence 
of CK+ and Her2+ DCCs. Total number of DCCs detected in the bone marrow of recipients of the 
transgenic mammary gland animals was significantly lower than in transgenic mice (Figure 10A), which 
is most likely a consequence of seeding from only one transplanted mammary gland, opposite to ten 
mammary tumors in Balb-NeuT mice. Analogous to the transgenic model, the number of DCCs detected 
in the bone marrow of transplantation model did not change during progression of primary tumor 
(Figure 10B) confirming the existence of mechanism controlling the progression of DCCs in the bone 
marrow. 
 
In both, CK+ and Her2+ cells isolated from bone marrow of different mouse models, multiple 
chromosomal aberrations were detected by CGH analysis, confirming their malignant origin. 
Phylogenetic analysis in the Balb-NeuT model showed that 79,5% of lung metastases originate from 
Figure 10: Number of CK+ and HER-2+ cells detected 
per 500.000 cells isolated from the bone marrow of (A) 
Balb-NeuT, Balb/c (controls) and recipients of 
transgenic mammary gland. (B) Box plots representing 
the number of DCCs detected in the bone marrow of 
recipients of the transgenic mammary gland at the 
different phases of tumor development (Atypical ductal 
hyperplasia, ADH and invasive carcinoma, IC) 
(Husemann et al., 2008). 
Figure 9: Number of CK+ (red dots) and HER-
2+ (blue dots) cells detected per 500.000 cells 
isolated from the bone marrow of Balb-NeuT 
mice. Dashed blue-red line marks the result of 
the analysis of non-transgenic control mice 
(Husemann et al., 2008) 
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the cancer cells that leave the primary site in the early phases of tumor development (early DCCs) 
(Hosseini et al., 2016a). The mechanism of an early dissemination of cancer cells was addressed in the 
work of Hosseini and colleagues (Hosseini et al., 2016a) who found that the same signals activate 
different responses in the non-advanced cells from early cancerous lesions and in advanced primary 
tumor cells. Progesterone induced signaling mediated by Wnt and RANKL, induces migrating and 
stem-like phenotype (determined as a capability of sphere formation) in cells from early cancerous 
lesions (Figure 11), but in advanced tumor cells it induces proliferation. This switch is found to be 
regulated by increased Her2 expression and tumor-cell density. Analysis of human DCCs isolated from 
the bone marrow of breast cancer patients, whose malignant origin was confirmed by CHG analysis, 
showed that none of 26 analyzed cells displayed progesterone receptor, confirming the lack of the 
signaling that induces its outgrowth (Hosseini et al., 2016a). This confirmed the findings from Balb-
NeuT model can also be applied to humans. 
 
In the search for the mechanisms to “wake up” dormant DCCs, Hüsemann and colleagues transplanted 
the bone marrow of young Balb-NeuT mice (9 weeks) to lethally irradiated age mated Balb/c recipients 
what resulted in an outgrowth of the dormant DCCs that exist within transplanted bone marrow cells 
and led to the development of the bone marrow carcinosis (10-31% of CK+ cells in bone marrow) 
within 19-22 weeks upon transplantation ((Husemann et al., 2008), Figure 12). 
 
Figure 12: Balb-NeuT bone marrow transplantation to Balb/c recipients induces outgrowth of DCCs inducing bone marrow 
carcinosis. Data from Hüsemann et al. Bone marrow was taken from three donor mice (D-1 to D-3). At the time of 
transplantation cells suspension frombone marrow was applied on glass slides, which were later stained using anti-CK 
antibody. The number of CK+ cells was used for calculation of the absolute number of transplanted DCCs. All recipients of 
the bone marrow from transgene mice (M1-1 to M3-3) were sacrificed 19-22 weeks after transplantation when first signs of 
disease were detected. The percentage of CK+ cells was determined also by CK-staining of bone marrow cell suspension 
applied to glass slides. 
 
Figure 11: Progesterone induces migration and 
sphere formation of early lesion cells. (A) Early 
lesion and primary tumor cells respond to 
progesterone or its mediators (WNT4, RANKL) 
with increased (early lesions, EL) or decreased 
(primary tumors, PT) migration. (B) 
Mammosphere formation depends on the age of the 
mice (Hosseini et al., 2016a). 
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Having in mind all these findings we decided to use the transplantation model in which we isolated 
mammary tissue from young Balb-NeuT female mice, cultured cells as mammospheres (i.e. in 
anchorage independent conditions) and transplanted them to age matched wild type (wt) siblings. The 
goal of our work is to model human disease. Therefore, we aimed to isolate and analyze human and 
mouse DCCs from the analogous stages of disease. As the isolated DCCs in our collective originate 
from the bone marrow of patients, we wanted to get cancer cells from the same distant organ of our 
mouse model. For this purpose we used only DCCs isolated from bone marrow of transplanted mouse 
models. 
3.2.2 Search for good candidate marker for isolation of BM-DCCs 
In described analyses, DCCs were detected by CK staining, which is unsuitable method for isolation of 
living cells, which we aimed. To detect disseminated cancer cells in our model, we used GFP as a 
marker to label mammary cancer cells before transplantation to wt recipients. Transduction of the intact 
spheres resulted in lower efficiency than transduction of disaggregated spheres with 7% and 21% of 
GFP+ cells, respectively (Figure 13) in cells derived from second generation mammospheres. 
 
Figure 13: In a pilot experiment Balb/c-NeuT-derived mammospheres were transduced with pRRL-CMV-GFP virus in two 
different ways: (i) Intact primary mammospheres were transduced or (ii) primary mammospheres were disaggregated to single 
cells and then transduced. Efficiency of transduction was determined by FACS as percentage of GFP+ cells in disaggregated 
second generation mammospheres. 
Next, we transplanted GFP-labeled ADH-derived mammospheres to wt recipients (Figure 14) at the age 
of 4-6 weeks. After 8 weeks no tumor formation was detected in any recipient and no GFP+ cells were 
found in the bone marrow of recipients. These data are consistent with observations that GFP is highly 
immunogenic in Balb/c mice, meaning that GFP marked cells do not survive and cannot be accurately 
traced over time when transplanted to Balb/c recipients (Ansari et al., 2016; Gambotto et al., 2000).  
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Figure 14: GFP-labeled mammosphere: Mammary cells were isolated from a young Balb-NeuT donor (8 weeks) and 
propagated in anchorage independent conditions. After 12 days spheres were disaggregated, transduced with pRRL-CMV-
GFP virus and propagated for additional 16 days. Scale bar 100µm. 
To avoid immune rejection, we transplanted GFP-labeled ADH-derived mammospheres into NSG mice 
and waited for 8 weeks. Primary tumors were detected in the fat pad of the recipients with an increase 
in tumor formation rate upon implantation of a progesterone pellet. In the group that received 
progesterone all mice (n=3) developed tumors opposite to the control group (n=3), where very small 
tumor was detected in only one out of three recipients (Table 2). We also noticed that in the group 
treated with progesterone, detected primary tumors were also bigger. 
 
Table 2: Summarized data of mice transplanted with GFP-labeled mammospheres 
 
Analysis of the CD45- subset of bone marrow cells of Balb/c and NSG recipients displayed no GFP+ 
tumor cells. From this we concluded that dissemination of mammosphere derived cells to BM did not 
occur over the course of four weeks. Hence, we decided to look for a new approach and chose look for 
another marker for detection and isolation of DCCs from bone marrow samples. 
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3.2.3 Improvement of detection and isolation of DCCs from the bone 
marrow 
Since GFP labeling of the cancer cells in transplantation models did not enable isolation of living DCCs, 
we focused again on our Balb-NeuT model. Epithelial cell adhesion molecule (EpCAM) is regularly 
used as a marker for selection and isolation of living DCCs from bone marrow of cancer patients. 
EpCAM-positive (EpCAM+) cells are found not only in bone marrow samples of cancer patients, but 
also in the bone marrow of people without any evidence for tumor presence (Guzvic et al., 2014). Still 
many studies showed that increased EpCAM expression is associated with poor prognosis in different 
cancers, amongst others breast cancer (Cimino et al., 2010) which makes it the best of all known 
markers for detection of tumor cells of epithelial origin in predominantly mesenchymal organs, such as 
bone marrow and lymph nodes. Similarly, although the number of EpCAM+ cells is higher in the bone 
marrow of Balb-NeuT mice, they were also detected in wt Balb/c mice. The average fluorescent signal 
of all EpCAM+ cells seems stronger in Balb-NeuT mice, but it cannot be used for true discrimination 
of DCCs and EpCAM+ haematopoietic cells. Individual EpCAM+ cells from BM of Balb/c and Balb-
NeuT mice cannot be distinguished due to high variance of fluorescence intensity in both models 
(Figure 15). 
 
Figure 15: Detection of EpCAM+ cells in bone marrow samples isolated from Balb/c and Balb-NeuT mice. Mononuclear bone 
marrow cells were isolated by centrifugation on 60% Percoll and stained using anti EpCAM antibody. No significant difference 
in terms of morphology and staining intensity was seen between cells isolated from wt and transgenic mice. Scale bar 20µm. 
3.2.4 CD45 expression enables discrimination between DCCs and 
EpCAM-positive hematopoietic cells 
In human samples, EpCAM is mainly expressed by epithelial cells, but some cells from the erythroid 
lineage also express it during early phases of their development (Choesmel et al., 2004). To investigate 
this in mice samples and to discriminate between epithelial EpCAM+ cells and hematopoietic EpCAM+ 
cells, we isolated bone marrow from Balb/c and Balb-NeuT mice of different age, separated CD45+ 
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from CD45- cells by CD45-depletion, stained both, CD45+ and CD45- fractions using FITC conjugated 
anti-EpCAM antibody and picked EpCAM+ cells from both subsets of cells. No EpCAM+ cells could 
be detected in the CD45- population of bone marrow cells of two Balb-NeuT and two Balb/c mice 
younger than 10 weeks. In the bone marrow of Balb-NeuT mice of 14 weeks and Balb/c mice of 13 
weeks we detected and isolated both CD45+/EpCAM+ and CD45-/EpCAM+ cells. EpCAM+ cells from 
the CD45+ fraction had lower fluorescence intensity than EpCAM+ cells from the CD45- fraction 
(Figure 16). 
 
Figure 16: Isolation of EpCAM+ cells from CD45+ population (A) and CD45- population (B) isolated from bone marrow of 
Balb/c mice. Scale bar 20 m. 
To further profile “true” DCCs and discriminate them from hematopoietic EpCAM+ cells we isolated: 
(i) 14 CD45+/EpCAM+ and 11 CD45-/EpCAM+ bone marrow cells from one Balb/c mouse and (ii) 20 
CD45+/EpCAM+ and 29 CD45-/EpCAM+ bone marrow cells from two Balb-NeuT mice. Mice were 13-
16 weeks old at the time of sacrifice. The cells with maximal quality of WTA products (7 
CD45+/EpCAM+ and 9 CD45-/EpCAM+ cells from Balb/c mouse and 15 CD45+/EpCAM+ and 22 
CD45-/EpCAM+ cells from Balb-NeuT mice) were analyzed using qPCR for CD45 expression to 
discriminate true hematopoietic from non-hematopoietic cells among picked ones. In cells isolated from 
Balb/c mice, CD45 mRNA was detected in 57% of CD45+/EpCAM+ cells but in none of CD45-
/EpCAM+ cells (Table 3). In CD45+/EpCAM+ population 33% expressed CD45 mRNA, whereas in 
CD45-/EpCAM+ population only 4,5% did (Table 3). 
Table 3: CD45 expression analysis in cells isolated from BM samples from Balb/c and Balb-NeuT mice. BM aspirates were 
divided using MACS depletion kit and from both, CD45+ and CD45- fraction EpCAM+ cells were picked and subjected to 
analysis of CD45 mRNA expression by qPCR 
 
Expression analysis of CD45 mRNA in CD45+ and CD45- populations of bone marrow cells showed 
that MACS depletion accurately separates CD45-expressing cells from cells that do not express those 
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hematopoietic cell markers both in Balb/c (p=0,0192) and Balb-NeuT (p=0,0306) mice (Fischer’s Exact 
test). 
3.2.5 Effect of progesterone on dissemination of cancer cells in the Balb-
NeuT mice 
Having in mind that dissemination occurs very early to bone marrow of Balb-NeuT mice and 
progesterone upregulates Her2 expression and consequently increases migration rate in early lesion 
cells as shown in Figure 11Figure 11 (Hosseini et al., 2016a), we tried to increase the number of DCCs 
for isolation. Therefore, young Balb-NeuT mice (5-8 weeks) were treated with progesterone. However, 
after 4-8 weeks there was no significant difference in the number of EpCAM-positive cells in the CD45- 
fraction of bone marrow samples of control and treated mice (Figure 17). 
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Figure 17: Number of detected EpCAM+ cells in the bone marrow samples of Balb-NeuT mice upon progesterone treatment. 
n=3, Student´s t-test, p=0,512. All error bars correspond to standard deviation (Mean ±SD). 
3.2.6 Bone marrow transplantation induces DCC outgrowth 
In routine patient analysis, disseminated cancer cells are isolated from bone marrow of breast cancer 
patients undergoing removal of the tumor and detected based on expression of cytokeratins (for genome 
isolation and analysis) and EpCAM (for transcriptome and genome isolation and analysis). The number 
of cells detected in the bone marrow of Balb-NeuT mice over lifetime (from week 4 until week 25-30) 
remains stable (Hosseini et al., 2016a), confirming that they reside in a state of dormancy. Since the 
number of cells in the bone marrow is very low, we aimed to increase the number of DCCs in bone 
marrow and/or to increase cell isolation efficacy. Transplantation of the bone marrow of young Balb-
NeuT mice (9 weeks) to lethally irradiated age matched Balb/c recipients results in an outgrowth of the 
dormant DCCs that exist within transplanted bone marrow cells and leads to bone marrow carcinosis 
(10-31% of CK+ cells in bone marrow) within 19-22 weeks upon transplantation (Husemann et al., 
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2008). We aimed to increase the number of dormant DCCs in our collective and decided to utilize this 
approach for DCC enrichment. 
We lethally irradiated young Balb/c and NSG recipients and transplanted them with bone marrow of 9-
week-old Balb-NeuT donors (Figure 18). 
 
Figure 18: Scheme of bone marrow carcinosis experiment: Bone marrow of 9 week old Balb-NeuT mice was isolated and 
transplanted to lethally irradiated age matched Balb/c mice. Starting from week 20 after transplantation recipient mice were 
sacrificed and the frequency of CK+ cells in bone marrow was determined. 
No recipient showed any sign of bone marrow disease 20 weeks after transplantation. The number of 
CK+ cells in the bone marrow of sacrificed recipients was in range of the number of CK+ cells in donors 
(few cells per 106 bone marrow cells) which was much lower (Table 4) than in the initial experiments 
(0-120 vs. 80-240 CK+ cells per recipient) questioning either immunohistochemical staining or 
dissemination.  
Table 4: Calculated number of CK+ DCCs transplanted to Balb/c and NSG recipients 
 
None of the recipient mice developed any symptoms of bone marrow disease. They were all sacrificed 
by week 58 (NSG) or 59 (Balb/c) after transplantation, but none of them showed an increase in the 
number of CK+ cells in the bone marrow. The fact that mice did not develop BM carcinosis supports 
our hypothesis that an impaired dissemination is a possible reason for decreased number of transplanted 
DCCs. 
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Since the number of transplanted CK+ DCCs was around 10 times lower than in previous work 
published by Hüsemann, Geigl et al., we depleted CD45+ cells from pooled bone marrow of 9 donors 
(11 weeks old) and transplanted them into Balb/c recipients (Figure 19) to increase the number of 
transplanted DCCs. Hematopoietic cells are competing with cancer cells for homing to bone marrow 
niches, as shown in prostate cancer (Shiozawa et al., 2011). Therefore, we decided to give an advantage 
to cancer cells by dividing bone marrow cells into two populations, CD45+ and CD45- and injecting 
CD45- cells a day before the rest of bone marrow cells, the CD45+ fraction. Although we seemingly 
reached a higher number of transplanted DCCs (98 DCCs vs. 80-240 CK+ cells per recipient, Table 4), 
recipient mice did not develop bone marrow disease by the time of sacrifice of the last recipient, 36 
weeks after transplantation. All these findings confirmed the hypothesis that dissemination of cancer 
cells is impaired. 
 
Figure 19: Enrichment of bone marrow with DCCs: Pool of bone marrow samples from 9 mice was subjected to CD45 
depletion using two MACS columns. After the first column, purity of CD45- fraction was not high enough (90%). However, 
after the second column the fraction consisted of 99% of CD45- cells. This “pure” CD45- population was injected to Balb/c 
recipients. 
3.2.7 Analysis of DCCs in the lungs of BM recipient mice 
Dissemination was shown to occur not only from primary tumor to blood and distant organs, but also 
in opposite direction when CTC can colonize their tumors of origin (Kim et al., 2009). To investigate 
whether cancer cells transplanted with bone marrow of Balb-NeuT donors via tail vain can colonize 
other organs, we analyzed the lungs of the recipient mice, while lung is, next to bone the organ that is 
most frequently colonized by mammary cancer cells. Using Her2 as a marker for DCCs, we were not 
able to detect any Her2+ cells in any of the analyzed samples (Figure 20), indicating either impaired 
survival or colonizing ability of the transplanted DCCs or their absence in transplanted bone marrow. 
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Figure 20: Her2 staining of the lungs of recipients of BM from transgenic mice. Mice were sacrificed 20-36 weeks after 
transplantation. Primary tumor is a positive control and wt lung is negative control. Mice 6247 and 6249 are Balb/c recipients 
of naïve BM of Balb-NeuT donors, 6706 is a Balb/c recipient of enriched BM cell suspension and 6769 is NSG recipient of 
naïve BM of Balb-NeuT mice. From each mouse ten sections of 5m were cut. Three sections (sections 1, 5 and 10) from each 
mouse were analyzed. Scale bar 100µm. 
3.2.8 In vitro expansion of the mouse DCCs isolated from bone marrow 
Knowing that patients without detectable DCCs can develop metastases (Braun et al., 2005; Mansi et 
al., 1999), we concluded that some of the metastasis founder cells lack markers which are routinely 
used for their detection and isolation. To minimize the chance of missing these cells, we depleted CD45+ 
cells from the bone marrow samples of young Balb-NeuT mice and cultured the remaining negative 
fraction cells in ultra-low attachment plates, promoting the growth of cells with stem cell properties. 
Neither the naïve population (non-depleted BM cells) from Balb/c and Balb-NeuT mice, nor the 
depleted cell population cultured in anchorage independent conditions gave rise to mammospheres. We 
initially applied the medium broadly used for mammosphere culture (MEBM supplemented with 
insulin, heparin, B27, EGF and bFGF) (Dontu et al., 2003), which did not result in growth of 
mammospheres. We mined the literature and looked for the factors to promote mammary stem cell 
growth and supplemented the medium with different cytokines whose potent mitogenic effect was 
already shown, such as growth-related oncogene-α (GRO-α) (Bhat et al., 2017; Smith et al., 1995), HIL-
6 (Aden et al., 2016; Grivennikov et al., 2009) and a combination of Wnt4 and receptor activator of 
nuclear factor kappa-Β ligand (RANKL) (Hosseini et al., 2016a). GRO-α belongs to the CXCL1 family 
of chemokines and is known to have a potent mitogenic effect on the neighboring cells especially on 
premalignant epithelial cells (Coppe et al., 2010). IL-6 is a pro-inflammatory cytokine known to play a 
role in cell proliferation. It signals through two membrane bound receptors, specific IL-6R, and 
ubiquitously expressed non-specific gp130 that is bound to the activated IL-6R and transduces the signal 
to the cell. Hyper IL-6 (HIL-6) is a fusion protein, consisting of IL-6 and soluble IL-6R. While it already 
contains the specific part of the receptor it can also bind to the unspecific transducer, gp130 and 
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stimulate cells that do not express IL-6R (Fischer et al., 1997). Wnt4 (cytokine from WNT family, 
regulates female reproductive system development in human) and RANKL (a member of the tumor 
necrosis factor cytokine family binds to RANK on cells of the myeloid lineage and functions as a key 
factor for osteoclast differentiation and activation, but also regulates cell survival, proliferation, and has 
a role in immune system) are found to be main mediators of progesterone mitogenic and migratory 
effect in mammary cells (Hosseini et al., 2016a). Unfortunately supplementing the sphere cultures with 
any of these cytokines did not induce growth of the mammospheres. After 7, 10 and 15 days of culture 
no spheres were detected (Table 5). 
Table 5: Number of mammospheres and single cells in cultures from CD45-depleted bone marrow cells. Experiment with each 
mouse model performed once, in triplicates. Number of cells shows the range of detected survived single cells per plate. 
 
To increase the chances of finding cancer cells in bone marrow we isolated the bone marrow from mice 
with overt metastases in the lung. The CD45- fraction of the bone marrow was cultured in media with 
and without GRO-α and a combination of Wnt4 and RANKL (WR). We did not detect any spheres in 
these cultures, but at day 10 we could observe some surviving single cells whose number was increased 
in WR supplemented cultures (Table 5). On day 15 no more single cells could be detected. We 
concluded that stimulatory effect of Wnt4 and RANKL does not promote growth of murine BM cells 
in 3D conditions but might increase survival of CD45- cells isolated from the bone marrow of metastatic 
mice. 
3.2.9 Effect of Collagen I on sphere forming ability of mammary cells 
The most abundant extracellular protein in bones is collagen I that was shown to greatly enhance the 
capacity of ErbB2 cells (primary tumor cells isolated from the mammary tumor of MMTV-Neu(YD) 
mice, with a wild-type form of rat Neu under the control of the CMV promoter) (Guo et al., 2006) to 
form primary and secondary tumor spheres (Gao et al., 2016). We aimed to investigate its effect to 
mammary cells upon entering the BM. Therefore, we supplemented the mammosphere medium with 
collagen I and examined tumor sphere formation in our mouse model with Her2 driving oncogene. 
Single cells from mammary gland of Balb/c mouse and Balb-NeuT mice of different age were isolated 
and propagated in sphere medium with and without addition of collagen I. There was no significant 
difference in the number of mammospheres seeded in medium with collagen I compared to control for 
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any of the tested mice, meaning that neither cells from normal mammary gland, nor early lesion cells 
nor cells isolated from mammary tumors could be activated by collagen I (Figure 21). 
 
Figure 21: Collagen I treatment does not affect sphere formation of mammary cells from normal mammary tissue, early 
hyperplastic lesion and mammary tumors. Student’s t-test. non-significant. All error bars correspond to standard deviation 
(Mean ±SD). 
All different approaches we applied in our intensive in vivo work resulted in findings, which all brought 
us to one conclusion: Dissemination of cancer cells to BM is impaired, resulting in no DCCs in BM of 
Balb-NeuT mice. 
Encountering the problems in the finding and isolation of single dormant cancer cells from in vivo 
models, we next focused on establishing in vitro models of dormancy. 
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3.3 Establishment of the in vitro models of tumor cell dormancy 
Not being able to isolate DCCs from the BM of Balb-NeuT and transplantation model, we focused on 
in vitro models. Since DCCs in our collective originate from BM samples of breast cancer patients, we 
aimed to model these conditions and examine the effect of BM environment on mammary cells. Bone 
marrow environment comprises different subniches (osteoblastic, endothelial, and mesenchymal) 
consisting predominantly of hematopoietic cells, osteoblastic cells (OBs), mesenchymal stromal cells 
(MSCs) and endothelial cells that form blood vessels. All these cells release a myriad of different factors 
affecting the surrounding cells. We aimed to examine the influence of these different cells and niches 
on DCCs behavior. 
3.3.1 Implementation of the “stem cell model” for isolating dormant and 
proliferative epithelial cells from human mammary gland 
In the mammary gland one can discriminate stem and differentiated cells in the pool of mammary cells. 
These cells go through different phases during development. All differentiated cells originate from the 
stem cells, which in physiological conditions reside in a quiescent state (Cheung and Rando, 2013; 
LaBarge et al., 2007). Extracellular signals (mostly hormone signals during menstrual cycle or 
pregnancy) activate them and induce proliferation. Stem cell consequently divides once, gives 
progenitor cell and renews itself. This new stem cell re-enters the quiescent state. We aimed to analyze 
the quiescence associated to stemness and apply the analyzed results to patient derived DCCs. 
3.3.2 Overview of samples derived from mammary reduction surgeries 
Traditionally cell lines are used to study development of both normal mammary gland and breast cancer. 
With improvement of the techniques for isolation and propagation of the cells in vitro primary cells 
became prevalent models for studying the biology of mammary gland, using isolated cells from patients 
who underwent reduction mammoplasty. The drawback of this method is still the low viability of the 
isolated cells. To maximize the efficiency of cell isolation and improve viability we used a protocol 
performing slow digestion and differential centrifugation that was recently shown to result in the best 
yield and viability of cells isolated from human mammary gland (Zubeldia-Plazaola et al., 2015). 
For detection and isolation of single dormant cells we adapted the protocol in use for human mammary 
stem cell isolation. In brief, mammary tissues obtained from healthy donors that underwent reduction 
mammoplasty were first examined by a pathologist. Tissues suspected to have some neoplastic changes 
were not further processed, while the ones in which the absence of such changes was confirmed, were 
mechanically and enzymatically digested, centrifuged with differential centrifugation steps resulting in 
50 
 
separation of epithelial cells from fibroblasts and labeled with PKH26, a cell proliferation tracking dye. 
Cells which proliferate only limited number of times retain the PKH26 labeling (label retaining cells, 
LRCs) and can therefore be discriminated and separated from the cells that proliferate more and do not 
retain the labeling (proliferating non-label retaining cells, nLRCs). Epithelial cells were then propagated 
for 7 days in anchorage independent conditions. These conditions favor the growth of early 
progenitor/stem cells and enable removal of anchorage-dependent fibroblasts which escape anoikis only 
in the presence of serum (Koechli et al., 1994; McGill et al., 1997). After 7 days of culture, 
mammospheres and single cells were separated, and cell proliferation was estimated by the intensity of 
PKH26 fluorescence. Single non-proliferating cells (quiescent single cells, QSCs) were picked and the 
mammospheres were dissociated and cultured for additional 7 days. Second generation mammospheres 
were disaggregated and LRCs and nLRCs were manually picked for further molecular analyses. This 
strategy is depicted in Figure 22. 
 
Figure 22: Schematic overview of isolation and propagation of human mammary epithelial cells (HMEC) 
Cell isolation efficiency was not the only complication that was encountered during our work. The 
majority of the obtained samples could not be used for several reasons: (1) patient samples were 
delivered to us in semi sterile conditions which resulted in contamination in vitro, (2) some of the 
samples did not give rise to mammospheres, but they were forming clusters and (3) adult stem cells, 
which we aim to isolate, are very rare among the HMECs and their function decreases with age (Behrens 
et al., 2014; Pollina and Brunet, 2011; Wu et al., 2016). Therefore, exclusion criterion was the age of a 
donor above 45 years at the time of surgery. 
From a total number of 32 obtained samples 13 gave rise to spheres; in 9 of them only clusters could be 
detected in the second generation of spheres or in both; 4 samples came in inadequate conditions (in 
formalin or in unsterile bags); in 3 of them contamination was seen in days after HMECs isolation and 
from 3 of them only a non-sufficient number of cells could be isolated for downstream assays (Figure 
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23). In the cases where only clusters were detected after 7 days of cultivation we could not judge 
whether they were a result of cell division or clustering and therefore these samples were excluded from 
our study. Overall, 13 out of 32 samples deriving from patients younger than age 45 (37,5%) gave rise 
to mammospheres and were used for further assays and analyses. 
 
Figure 23: Examples of the sphere growth in the samples from different donors. Mammary tissue sample gave rise to the 
regular mammospheres in first generation (A) and to clusters in second generation (B). Mammary tissue sample giving rise to 
the regular mammospheres in both, first (C) and second (D) generation. Scale bar 50 µm. 
3.3.3 Optimization of the cell labeling procedure 
Stem cells reside in a quiescent state until stimulated with some extracellular signal, which induces their 
proliferation. For tracking the proliferation in specific cells fluorescent dyes are intensively used. They 
unspecifically label cytoplasmic proteins or cell membrane and are equally distributed to daughter cells 
upon division. For precise tracking of proliferation appropriate cell tracking dye had to be chosen and 
its optimal concentration needed to be determined. 
The "gold standard" among cell tracking dyes in proliferation analysis is CFSE (carboxyfluorescein 
diacetate succinimidyl ester) which easily crosses the plasma membrane, enters the cell and gives an 
amine-reactive product that binds to intracellular proteins and produces detectable fluorescence. In 
parallel with CFSE we tested PKH26, a more general membrane labeling dye. PKH26 is a lipophilic 
dye that stably incorporates into the lipid regions of the cell membrane and emits strong fluorescence. 
We labeled half of the isolated cells from one sample with each of these dyes and seeded them in ultra-
low attachment plates. On the first day after cell labeling the cultures were observed and we detected a 
more homogeneous staining within the cell population labeled with CFSE. Cells were propagated as 
described in Figure 22 and QSCs, LRCs and nLRCs were isolated at day 7 and day 14. Whole 
transcriptome was isolated and amplified from each isolated cell, followed by the quality control (QC) 
(Figure 24). Cells expressing 2 or 3 out of 3 tested transcripts of housekeeping genes were classified as 
“good quality cells” whereas those with 0 or 1 expressed genes were classified as “bad quality cells”. 
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Figure 24: Visualization of GAPDH (up), ACTB and EF-1 (down) gene expression in cells initially labeled with (A) PKH26: 
1-12: isolated single cells, 13-14: Negative controls; M – DNA-ladder and (B) CFSE: 1-12: isolated single cells, 13-14: Single 
cell pools, 15-16: Negative controls; M – DNA-ladder. 
Although CFSE displayed a more homogeneous staining, the quality of WTA products of isolated cells 
was significantly better in PKH26 labeled cells (Figure 25). Therefore, PKH26 labeling was chosen for 
further experiments. 
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Figure 25: Quality of the WTA products of isolated cell depends on the cell labeling tracker: CFSE labeled cells isolated 7 and 
14 days after cultivation in anchorage independent conditions showed significantly lower quality of the WTA products (cells 
expressing 2-3 housekeeping genes have good quality, while those expressing only 0-1 genes have bad quality) than cells 
labeled with PKH26. Fisher's exact test, two-tailed, **** p < 0,0001. 
Next, optimizing the concentration of the cell tracking dye was assessed, as the concentration of the 
PKH26 for cell labeling recommended by the vendor (2 M) was too high and after two weeks all the 
cells in the culture were still showing a very strong fluorescent signal. Towards this end, it was 
necessary to find the optimal concentration that would result in proliferating cells completely diluting 
the dye after 14 days of in vitro culture, while quiescent cells would retain the dye. To define the optimal 
concentration, several dilutions were tested: 1:2 (1 M), 1:5 (400 nM), 1:10 (200 nM), 1:25 (80 nM) 
and 1:50 (40 nM) dilutions from the concentration recommended by the vendor. 
Cultures were monitored on the day of labeling as well as on the first day after labeling to confirm the 
uniformity of staining. On day 7 and 14, spheres were observed before disaggregation as well as single 
cells from disaggregated spheres to determine whether the distribution of the staining was gradually 
distributed in the observed mammospheres and whether the single cells in the culture plates still retained 
the dye. 
53 
 
In the staining protocol recommended by the manufacturer, the final concentration of PKH26 is 2 M 
for staining 107 cells in a final volume of 2 ml. Cells labeled with dilutions 1:2 and 1:5 were 
homogeneously stained and showed a very strong fluorescent signal, both on the first day after staining 
and on the later time points. After sphere disaggregation on day 14 we could not detect any non-label 
retaining cells. On the other side, dilution 1:50 resulted in non-homogeneous staining on day 1. Many 
stained cells did not have any fluorescent signal. Dilutions 1:10 and 1:25 resulted in homogeneous 
staining. Further, we observed that staining results can also depend on the sample itself, as some of 
them took up more dye than others and cells were stained more intensively. Overall, a PKH26 
concentration of 80 nM (dilution 1:25, Figure 26) was chosen for all the following assays. 
 
Figure 26: A representative sample stained with PKH26, 80nM. Second generation of mammospheres before disaggregation 
(A) and LRCs and nLRCs after sphere disaggregation (B). Magnification as indicated on each picture. 
3.3.4 Density of cell seeding does not affect the frequency of sphere 
formation of HMECs 
We aimed to perform two different types of experiments with HMECs: (1) propagation in anchorage 
independent conditions in order to isolate and characterize stem cells, and (2) estimation of the stem 
cell function, measured by sphere counting. Adult stem cells are very rare, with maximum of 2% in 
adult mammary tissue (Spike et al., 2012). To increase the chances of finding and isolating those cells 
a very high number of HMECs is required. Therefore, HMECs needed to be cultured at higher density. 
However, adequate distribution and avoidance of sphere fusion is mandatory to investigate the number 
of formed mammospheres. Finding optimal conditions for high cell number without sphere fusion and 
equal sphere distribution requires the consideration of two factors: (1) high density of cells may result 
in fusion of mammospheres while (2) low cell density can reduce paracrine cell influences. To 
investigate the effect of cell density on sphere formation, HMECs were seeded in poly-HEMA coated 
petri dishes (see Material and Method) in 3 different seeding densities: 10.000 cells/ml, 50.000 cells/ml 
and 500.000 cells/ml. After 7 days spheres were counted. The final number of counted spheres (Figure 
27A) was normalized to 30.000 cells, corresponding to the number of cells in the plate with a seeding 
density of 10.000 cells/ml (Figure 27B). 
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Figure 27: HMECs were seeded in different densities and cultured for 7 days in anchorage independent conditions. The number 
of mammospheres was counted on day 7 (A) and normalized to 30.000 seeded cells (B) which is the number of cells in the 
plate with a seeding density of 10.000 cells/ml. No significant differences were detected in the multiple comparison. 
Experiment was performed with one tissue specimen in technical quadruplicates, one-way ANOVA. All error bars correspond 
to standard deviation (Mean ±SD). 
If sphere formation is not affected by the seeding density, then the numbers of obtained mammospheres 
in higher densities (50.000 cells/ml and 500.000 cells/ml) should correlate to the number of 
mammospheres obtained under 10.000 cells/ml condition multiplied by the seeding factor. The number 
of obtained mammospheres in 10.000 cells/ml condition was set as a reference for the mathematical 
prediction. For the mathematical prediction of the number of mammospheres in conditions with higher 
seeding densities, the number of counted mammospheres in 10.000 cells/ml conditions was amplified 
5 or 50 times for conditions with 50.000 cells/ml or 500.000 cells/ml, respectively (Figure 27B). 
Obtained experimental data were comparable with the mathematical prediction, confirming consistent 
sphere forming capacity of HMECs, irrespective of the tested density of seeded cells. 
The capacity of cells to form spheres did not differ between the cultures with different seeding densities, 
but the density and the observed fusion rate of the mammospheres was higher in plates where 500.000 
cells/ml were seeded (Figure 28). Since seeding density did not affect sphere forming ability of HMECs, 
but affected the fusion rate of mammospheres further experiments were performed in the following 
way: (1) propagation of HMECs in anchorage independent conditions for isolation of QSCs, LRCs and 
nLRCs was performed with a seeding density of up to 300.000 cells/ml, while (2) experiments in which 
the sphere number was assessed as a final readout, were performed with a seeding density of 50.000 
cells/ml. 
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Figure 28: The capacity of sphere formation and the size of formed mammospheres do not differ between the cultures with 
seeded 10.000 cells/ml (A) or 500.000 cells/ml (B), but the fusion rate is very high in cultures with high density of seeded 
cells. 
3.3.5 Separation of single cells from mammospheres 
After 7 days of culture in anchorage independent conditions, HMECs either form mammospheres or 
stay as a solitary, non-dividing cells. Separation of the spheres from single cells can be done in two 
different ways: (1) using a 40 µm cell strainer or (2) by differential centrifugation. To examine which 
of these methods is resulting in a higher yield, we engaged hTERT-HME1 cell line. Cells of this cell 
line form mammospheres which in regard to the size, morphology and frequency of sphere formation 
(Figure 29) correspond to the spheres deriving from primary mammary cells. 
 
Figure 29: HME EGFR cells express similar behavior like HMECs in anchorage independent conditions in regard to (A) 
frequency of sphere formation, p=0,204 and (B) morphology. Magnification 20X. 
We tested both methods on the hTERT-HME1 cell line that carries mutation in the receptor for 
epidermal growth factor (HME EGFR cell line). Therefore, cells were seeded in twelve 6 cm plates at 
a density of 10.000 cells/ml and cultured for 7 days in ultra-low attachment conditions. One half of the 
samples (pool of 6 plates) was subjected to separation using a cell strainer and the other half to 
differential centrifugation. After separation, mammospheres were dissociated and isolated cells were 
counted. This experimental outline is depicted in Figure 30. 
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Figure 30: Schematic overview of testing the separation methods of mammospheres from SCs in HME EGFR cultures 
Separation using the cell strainer and subsequent dissociation of mammospheres resulted in 5.000 cells, 
while differential centrifugation and subsequent dissociation produced 105.000 cells. In addition, in 
separation method based on centrifugation, mammosphere fraction was contaminated with 
approximately 25% of single cells (Figure 31), while the single cell fraction comprised of mostly single 
cells. Despite of contamination of sphere fraction, due to much higher yield we chose differential 
centrifugation as the method for separation of single cells from mammospheres in the following 
experiments. 
 
Figure 31: Separation of the mammospheres from single cells by centrifugation. Supernatant fraction (A) consists only single 
cells while mammosphere fraction (B) is contaminated with 25% from the total number of single cells next to the 
mammospheres. Magnification 10X. 
3.3.6 Dormant cells reside among non-divided single cells after 7 days 
The term “cellular quiescence” is very broadly used and indicates cell cycle inhibition that can be 
reversible (dormancy) or irreversible (senescence). To investigate the quiescent state in which HMECs 
reside, we cultured them in anchorage independent conditions for 7 days and then separated QSCs from 
mammospheres by centrifugation. Supernatant fraction, which contained only QSCs of different size 
was replated in new poly-HEMA coated plates and cultured for additional 7 days. After that period, we 
investigated sphere formation, which is a result of proliferation in anchorage independent conditions. 
We detected mammospheres in cultures originating from QSCs, indicating that these cells could be 
reactivated and re-entered the cell cycle (Figure 32A). 
57 
 
 
Figure 32: The number of mammospheres originating from QSCs and dissociated mammospheres. One-way ANOVA, stars 
indicating significance between groups in multiple comparisons. Statistically significant differences are marked with asterisks, 
* p<0,05, all error bars correspond to standard deviation (Mean ±SD). 
Next, we tested whether different inhibitors, whose mitogenic or pluripotency effects were previously 
shown, affect sphere formation in our culture conditions. After 7 days of cultivation mammosphere- 
and supernatant (QSC) fractions were separated. As in the first experiment supernatant fraction was 
immediately replated, while mammospheres from pellet fraction were first dissociated to single cells 
and then replated onto new poly-HEMA coated plates. Both single cells and mammosphere-derived 
cells were seeded at a density of 50.000 cells/ml and treated with the following inhibitors: (1) 
SB431542, a potent and a specific inhibitor of transforming growth factor-beta (TGF-) superfamily 
type I  activin receptor-like kinase (ALK) receptor, known to maintain pluripotency of stem cells 
(ALK5i) (Du et al., 2014; Nakashima and Omasa, 2016; Yook et al., 2011), (2) SB203580, an inhibitor 
of p38 MAPK pathway that is upregulated in dormant cells (p38i) (Aguirre-Ghiso et al., 2003; Aguirre-
Ghiso et al., 2001) and (3) S1042, a multi-targeted receptor kinase inhibitor (VEGFR, PDGFR, c-Kit) 
(RTKi). After additional 7 days of cultivation, we counted the mammospheres in the cultures. 
The treatment with inhibitors did not increase the number of mammospheres in the cultures originating 
from QSCs (Figure 32B), however p38 MAPK inhibitor treatment increased sphere formation in the 
cultures originating from dissociated mammospheres (Figure 32C). Treatment with other inhibitors did 
not alter sphere formation or number (Figure 32 B, C). We concluded that inhibition of the p38 MAPK 
pathway increased sphere forming ability of progenitor cells, since these cells are mostly contained in 
mammospheres. This indicates existence of dormant cells or cells ready to enter a dormant state among 
stem and progenitor cells originating from the mammospheres. Further, we showed that active 
dormancy program in these cells can be interrupted by inhibition of the p38 MAPK pathway. 
3.3.7 CD44 and CD24 expression in LRCs and nLRCs 
The aim of our study was to isolate both dormant and stem cells. Therefore, we used the label retention 
assay described in previous section that enables detection and isolation of stem and progenitor cells. 
Only stem cells can survive and give progeny in anchorage independent conditions and due to their 
asymmetric division, resulting spheres consist of few LRCs (stem-like cells) and many progenitor cells 
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(Figure 33). Labeling cells with proliferation tracking dye before seeding in anchorage independent 
conditions therefore results in mammospheres with different levels of retained dye. We were interested 
in the phenotype of the cells enriched in mammospheres culture. To answer that, we analyzed 
expression of stem cell markers in our cultures. 
 
Figure 33: Label retention assay: Cells are labeled before propagation. Stem cells are dividing rarely, and their division is 
asymmetric resulting in renewed stem cell and progenitor cell. Consequently, stem cells are most intensively stained, label 
retaining cells (LRCs) and their progeny retains less dye the more they proliferate. Cells which divided the most are weakly 
labeled and referred to as non-label retaining cells (nLRCs). 
For this purpose we again used HME EGFR cell line that we labeled using PKH26. Since these cells 
are proliferating, and therefore diluting the membrane dye, faster than primary mammary cells, we used 
higher concentration of the cell linker dye (200 nM). Cells were seeded in a density of 10.000 cells/ml 
and propagated in anchorage independent conditions for 7 days. Spheres were dissociated on day 7 and 
stained with anti-CD44-Pacific Blue and anti-CD24-APC antibodies. FACS analysis showed an 
enrichment of CD44hi CD24lo/- stem cells in the PKH26+ population of 24,7% compared to the PH26- 
population with only 7,58% (Figure 34). These findings confirm the enrichment of stem cells in 
mammosphere cultures. 
 
Figure 34: FACS analysis of CD44 and CD24 expression in single cells from dissociated PKH26 labeled spheres. PKH26hi/+ 
cells are enriched with cells expressing stem cell markers (bottom right graph) compared to PKH26lo/- cells (bottom left graph). 
3.3.8 Isolation of LRCs and nLRCs from mammosphere culture 
The final goal of the establishment of the stem cell model was the isolation of cells of distinct 
differentiation stages and proliferation status. To isolate single LRCs and nLRCs, second generation 
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mammospheres were dissociated using trypsin and manual dissociation using a pipette. This type of 
digestion resulted in a lot of small clusters that could not be completely disaggregated which 
complicated isolation of target single cells. Increased disaggregation time to 10 minutes with constant 
pipetting did not decrease viability of isolated cells but decreased the number of clusters. This 
disaggregation procedure was used in all following experiments except for the FACS analysis of IL-
6R. 
3.3.9 Transcriptional analysis of SCs isolated from mammary gland 
As we successfully established procedure for the isolation of single mammary cells from mammosphere 
cultures, we applied this method to mammary gland samples obtained from reduction mammoplasty 
surgeries. From five of the obtained mammary tissues with best sphere growth we successfully isolated 
single non-divided cells (QSCs) that did not give rise to mammospheres, as well as label retaining 
(LRCs) and non-label retaining (nLRCs) from disaggregated mammospheres of second generation. As 
already mentioned, these cells represent populations with distinct differentiation stages and proliferation 
status. It was shown that these populations in mammary gland display different transcriptional profiles 
(Colacino et al., 2018; Lawson et al., 2015) which led us to the idea to isolate and analyze transcription 
profiles of the isolated single mammary cells. Out of five specimens whole transcriptome amplification 
(WTA) products from 78/97 SCs, 46/55 LRCs and 58/82 nLRCs were used for further analysis. 
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3.4 The effect of the vascular niche on growth of breast cancer cells 
Breast cancer patients develop metastases predominantly in the skeletal system, which is highly 
vascularized. The vasculature plays an important role in the regulation of bone development, but also 
in hematopoiesis by providing niches for hematopoietic stem cells. These niches can also serve as the 
lodges for DCCs (Shiozawa et al., 2011). During the process of dissemination, cancer cells enter the 
bone marrow upon leaving the circulation. Ghajar et al. showed that whether DCCs will start to 
proliferate depends on their relative position and proximity to the blood vessels in and BM lung. Cells 
that lay close to neovascular tips proliferate while cells lying on the trunks of the blood vessels enter a 
dormant state. In the organotypic model of the bone marrow microvascular niche they further showed 
that the mature vasculature sustains the dormant state of breast cancer cells. (Ghajar et al., 2013). 
Opposite to these cultures, tumor cells seeded in mesenchymal stromal niches exhibit a highly 
proliferative phenotype. We aimed to isolate single cells from both of these models for further 
characterization. 
3.4.1 Microvascular niche does not affect the growth of breast cancer cells 
Having concluded that neither stromal nor vascular niches support proliferation of non-tumorigenic 
cells, we investigated the effect of MSC (mesenchymal stromal cell) and MVN (microvascular niche) 
cultures on the growth of tumor cells. Towards this, we used GFP labeled human breast cancer cells 
HMT-3522 T4-2 (T4-2) cells and cultured them on MSC and MVN niches for 10 days. On day 1 after 
seeding tumor cells, only single GFP-positive cells were detected in the niches, the same as was seen 
with the non-tumorigenic cells. Nine days later, tumor cell clusters as well as solitary cells were 
observed in both types of co-cultures. Cell number and proliferation were determined as GFP-emitted 
fluorescent signal. Measurement of the fluorescent signal showed equal growth of T4-2-GFP cells in 
both types of niches (Figure 35, Table 6). 
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Table 6: GFP fluorescence signal measured in MSC and MVN cultures. Fluorescent signal intensity indicates proliferation 
rate of T4-2 – GFP cells. Experiment was performed twice, with 10 replicates per group in each experiment. 
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MVN MSC 
1050,00 964,84 
1010,00 970,35 
1050,00 938,95 
1040,00 957,00 
956,34 972,74 
1030,00 1060,00 
915,76 1020,00 
921,62 984,07 
934,76 911,90 
866,92 838,85 
1040,00 853,46 
991,13 963,20 
1040,00 955,00 
1010,00 1020,00 
986,04 955,89 
880,02 1030,00 
903,35 993,75 
869,36 976,79 
881,43 942,33 
829,54 922,87 
Mean 960,3 961,6 
St dev 72,8 53,74 
 
Although there was no statistically significant difference between the growth rates of tumor cells in 
these two niches, we observed that some MSC niches were enriched with clusters of tumor cells and 
some microvascular niches had only few small clusters and many solitary cells. We collected MSC 
Figure 35: GFP labeled T4-2 cells were 
seeded on 10 days old MSC and MVN niches. 
After 10 days of cultivation in both niches, 
tumor cell growth was determined. No 
difference was measured in growth of tumor 
cells in MVN and MSC niches, Mann-
Whitney test, p=0,9478. 
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niches with high proliferating tumor cells (many cell clusters) and MV niches with predominantly 
solitary cells, disaggregated them and isolated single viable cells (Figure 36). 
 
Figure 36: Manual isolation of single cells from MSC and MV co-cultures. MSC cultures enriched with clusters and MV 
niches enriched with single cells were collected and disaggregated. Single GFP-positive cells were picked using a 
micromanipulator. Scale bar 50 µm. 
3.4.2 Non-transformed mammary cells neither grow in the stromal nor in 
the microvascular niche 
To examine the influence of endothelial cells on the growth of normal mammary cells we used the non-
tumorigenic mammary cell line MCF10A. GFP-labeled MCF10A cells were seeded on top of MSC and 
MVN cultures and observed. To create the niche with the most potential to induce dormancy in 
MCF10A cells, MVN cultures were grown for 10 days. After this period all the vessels are connected 
and there are no neovascular tips, promoting proliferation (Ghajar et al., 2013). On day 1 only single 
cells were detected, the same as on days 7 and 10. MCF10A-GFP cells neither grew nor died in MSC 
and MVN co-cultures (Figure 37). We concluded that both, stromal and vascular niches support 
survival, but not proliferation of non-tumorigenic MCF10A cells. 
 
Figure 37: MCF10A cells seeded in stromal (MSC) or microvascular (MVN) niche 7 days after seeding mammary cells. 
Endothelial cells (HUVECs) are labeled using pBMN/mCherry plasmid (red) (Ghajar et al., 2013) and MCF10A cells with 
GFP (green) using Histone H2B-GFP plasmid (Ghajar et al., 2013; Tanner et al., 2012) 
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3.4.3 Mammary cells isolated from MVN and MSC cultures provide low 
quality WTA products 
Isolated mammary cells from microvascular and stromal cultures were subjected to whole transcriptome 
(WTA) and genome (WGA) isolation. Obtained WTA products were further analyzed for expression 
of housekeeping genes. Quality control of isolated cDNA amplified products showed very low quality 
of cells isolated from these co-cultures. Only 4/39 (10%) of cells isolated from stromal niches and 8/33 
(24%) of cells isolated from microvascular niches expressed all three tested housekeeping genes. 
Therefore, we decided to include cells expressing two of three analyzed housekeeping genes in our 
further analysis. Of 39 cells isolated from stromal niche, 15 (38%) and 18/33 (55%) cells isolated from 
microvascular niche met this quality criterion and were included in further analysis (Table 7). Cells 
expressing minimum 2 of 3 analyzed housekeeping genes were taken for further analysis. 
Table 7: Quality of the WTA products of the cells isolated from stromal and microvascular niches. Expression of three 
housekeeping genes was examined using multiplex endpoint PCR. 
Number of expressed 
housekeeping genes 0/3 1/3 2/3 3/3 
Cells isolated from MSC niches 19/39 (49%) 5/39 (13%) 11/39 (28%) 4/39 (10%) 
Cells isolated from MV niches 8/33 (24%) 7/33 (22%) 10/33 (30%) 8/33 (24%) 
 
Although we succeeded to establish microvascular niches and cultivate the breast cancer cells in them, 
we could not detect any difference in the growth of mammary cells by observation. Still, we collected 
the breast cancer single cells from some of the MVN co-cultures where proliferation rate of the 
mammary cells was very low and MSC co-cultures where proliferation rate of the mammary cells was 
higher than in others. These findings indicated us that endothelial niche might not be involved in 
regulation of the dormancy in BM-DCCs and we continued our investigation into the direction of other 
type of niche in BM, osteoblastic niche. Cells isolated from both co-cultures were in later steps 
subjected to the analysis of the expression of Ki67 and MCM2, proliferation markers. 
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3.5 The effect of the osteoblastic niche on breast mammary cell 
growth 
Bone marrow is a semi-solid tissue primarily located in the spongy structures of the big bones. The 
most important function of the bone marrow is the production of hematopoietic cells. Located inside 
the bones, the bone marrow is confined by osteoblastic cells forming osteoblastic niches. Hence, 
osteoblasts (OB) are a very abundant cell type in bones, whose major function is bone formation, as 
well as the production of the organic matrix of the bones. They are specialized cells produced by 
terminal differentiation of mesenchymal cells. 
We aimed to investigate the role of osteoblasts in altering growth of mammary cells. It was previously 
shown that culturing human prostate cancer cells (PC3) with osteoblasts-like ST2 cells decreases the 
proliferative (Ki-67 positive) population of cells within 48h (Kim et al., 2013a). Knowing that DCCs 
compete with hematopoietic cells for stem cell niches (Shiozawa et al., 2011) and that osteoblasts are 
involved in stem cell niche formation, we aimed to examine the influence of osteoblasts on dormancy 
induction in mammary cells. 
To test the effect of OBs on mammary cells growth, we cultivated MCF10A cells on top of the confluent 
OB layer. To discriminate the effect of culture conditions on mammary cell growth from the specific 
effect of OBs on the growth of mammary cells, we first cultivated MCF10A cells -fluorescently labeled 
with Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE) in a flask confluent with unlabeled 
MCF10A cells (the same cell type, homotypic culture) for 72 hours. Proliferation of the MCF10A-
CFSE cells was slower in co-cultures with confluent MCF10A cells than in the control population 
cultivated in the wells without pre-seeded cells Despite slower proliferation we did not detect any 
dormant cells, indicating that all cells passed through division at least once within 72 hours (Figure 38 
A, B). This indicated that homotypic co-cultures (MCF10A labeled cells grown on top of confluent 
MCF10A culture) confer slower proliferation on the population level, but not dormancy in single cells. 
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Figure 38: Proliferation of MCF10A-CFSE as a function of fluorescence level of CFSE. By cultivation in co-cultures of 
MCF10A cells with MCF10A cells (A, B) and osteoblasts (C, D) cell proliferation was decreased, but constant compared to 
controls, but it was not completely inhibited. Experiment performed once in technical duplicates. MFI - Mean fluorescence 
intensity. A, C: FACS plots show constant proliferation of MCF10A cells upon cultivation with osteoblasts. Single dormant 
(label retaining) cells were not detected. Osteoblasts were separated from MCF10A cells by HLA-A2 staining as described in 
text. 
While we found out that MCF10A cells constantly proliferate, both alone and in confluent co-cultures 
with unlabeled MCF10A cells, we next asked whether OBs could stimulate the entry of mammary cells 
into a dormant state. To investigate this and isolate non-proliferating cells, we established co-cultures 
of MCF10A-CFSE cells and osteoblasts. As a reminder, non-proliferating cells are the cells which retain 
the initial level of CFSE fluorescence within several days of cultivation. MCF10A-CFSE cells were 
seeded on top of differentiated osteoblasts in a 1:10 ratio. Every consecutive day one co-culture was 
harvested and the CFSE level of mammary cells was measured. As described in Material and Methods, 
MSCs (and osteoblasts) derive from a patient with a HLA-A2 haplotype and MCF10A cells are HLA-
A2 negative. Thus, osteoblasts were separated from MCF10A cells by HLA-A2 staining and the CFSE 
level was examined in MCF10A cells. 
Although CFSE fluorescence in all the measurements from day 2 was higher in cells from co-cultures 
with OBs than in controls, indicating their slower proliferation (Figure 38D), we could not detect any 
non-cycling cell with the fluorescent signal equal to the initial fluorescence (Figure 38C). We concluded 
that although co-culture with osteoblasts slows down proliferation, it does not induce cell cycle arrest 
in MCF10A cells. Therefore, this model is not appropriate for studying dormancy of single mammary 
cells.  
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3.6 Analysis of the proliferation in single mammary cells 
Having established in vitro models which mimic the influence of different BM components to mammary 
cells we aimed to analyze isolated cells from these models. Therefore, we wanted to set up a PCR assay 
that enables us to discriminate proliferating from non-proliferating cells. This enables further analysis 
and profiling of dormant and proliferating cells in our model(s) and analysis of BM-DCCs from breast 
cancer patients. 
3.6.1 Establishment of proliferation marker analysis for single cells 
classification 
We base the analysis of single cells on the isolation of their transcriptome. Therefore, we decided to 
establish a proliferation assay that is based on transcriptome analysis in which expression of specific 
gene transcripts enables us to determine the proliferative status of analyzed cells. 
First, we established an endpoint PCR for chosen specific transcripts. As markers of proliferation 
MKI67 (antigen identified by monoclonal antibody Ki-67), MCM2 (minichromosome complex 
maintenance component 2), and PCNA (proliferating cell nuclear antigen) genes were selected and 
primers were designed. Restriction digestion of the PCR amplicons carried out after gene-specific PCR 
showed that designed primers amplified the desired sequence fragments and thus specifically detected 
the transcripts of MKI67, MCM2, and PCNA genes. The establishment of the primers for proliferation 
markers was carried out by Nina Patwary, as a part of her PhD project. 
Next, we validated the established markers in single cells of known proliferation status. We chose to 
test these markers in a population of naïve and activated CD8+ T-cells. Unstimulated CD8+ T-cells 
isolated from the blood of healthy individuals are non-proliferating cells, residing in the G0 phase of 
the cell cycle. Their activation results in the entry of the cell cycle and consequent proliferation. FACS 
analysis of cells stained with fluorescent DNA binding dyes, such as DAPI or Hoechst 33342, is one of 
the most direct ways of cell cycle analysis (cells are staged based on DNA content). Cell cycle analysis 
of unstimulated and stimulated CD8+ T-cells demonstrated that naïve cells reside in the G0 phase and 
stimulated cells are staged in all other cell cycle phases (Figure 39). 
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Figure 39: DNA histogram of cell cycle analysis in unstimulated (A) and stimulated (B) (activated) CD8+ T cells. In this case 
the x-axis represents the fluorescent signal of Hoechst 33342 and values on the y-axis represent the cell number. The bars 
within each phase indicate the narrow cell populations that have been sorted. 
In the pilot experiment naïve CD8+ T-cells (purity 88,5%) were stimulated with phorbol 12-myristate 
13-acetate (PMA) and ionomycin and analyzed 12h, 24h, 36h, 48h, 60h, and 72h after stimulation to 
determine the best time point for activation analysis (Figure 40). After 48h stimulation distribution of 
cells in different cell cycle phases was stabilized; thus, the 48h time point was chosen as the best one 
for the cell sorting experiment. 
 
Figure 40: Determining the best time point for cell cycle analysis. The fluorescence intensity of DAPI, which corresponds to 
the DNA content, is plotted on the x-axis. The y-axis represents the cell number, with the height of the curve corresponding to 
the number of cells. Unstimulated and PMA/ionomycin stimulated CD8+ T-cells were stained using DAPI at different time 
points. Blue bars represent unstimulated CD8+ T-cells whereas red bars represent stimulated cells. 
Since DAPI is a passively transported dye, that only labels dead cells, for our live cell sorting 
experiment we chose the dye that actively enters to the cells, Hoechst 33342. Since Hoechst 33342 is 
actively pumped in and out the cell, the profile of cell distribution was not completely fitting the profile 
seen with DAPI, where the dye was steadily bound to the DNA. Therefore, we picked cells from narrow 
populations comprising of the cells with average DNA content in the target population (Figure 39B) 
avoiding contamination with cells from other cell cycle phases. In total we isolated 21 single cells from 
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G1 phase and 20 single cells from other cell cycle phases. Since CD8+ T-cells are quiescent in the blood 
of a healthy donor, G0 phase cells were isolated from non-stimulated CD8+ T-cell population prior to 
stimulation. Transcriptomes of 16/20 (80%), 18/21 (86%), 17/20 (85%) and 16/20 (80%) isolated cells 
from G0, G1, S and G2 phases, respectively, satisfied quality criterion (expressing 3/3 analyzed 
housekeeping genes) and were subjected to further analysis, resulting in 16 naïve (G0) and 51 activated 
T-cells for proliferation marker validation (Table 8). 
Having confirmed that naïve CD8+ T-cells do not proliferate and upon stimulation enter the cell cycle 
(Figure 39 and Figure 40), cells sorted from all phases of the cell cycle were further analyzed for the 
presence of transcripts of previously selected proliferation markers. 
Table 8: The number of isolated single cells from different phases of the cell cycle and the outcome of quality control analysis. 
Cell cycle phase G0 G1 S G2 
Isolated cells 20 21 20 20 
Fulfilled QC requirements 16 (80%) 18 (86%) 17 (85%) 16 (80%) 
 
3.6.2 Validation of the established proliferation markers 
Transcriptome analysis showed that 100% of the activated T-cells from all cell cycle phases (51/51) 
expressed MKI67 and PCNA genes (Figure 41). The MCM2 transcript was detected in 62,75% (32/51) 
of the activated T cells. On the opposite, the expression of MKI67 and MCM2 was not detected in any 
of the naive T cells (Figure 41), but PCNA transcript was detected in one naive T-cell (1/16, 6,25%). 
Statistical analysis of the expression of proliferation markers in activated and naive T cells showed the 
significant differences in expression of these genes (MKI67: p <0,0001, MCM2: p < 0,0001, PCNA: p 
<0,0001, Fischer’s Exact test, two-tailed). Tests showed sensitivity of 100% for the MKI67 and PCNA 
genes and 62,75% for MCM2 and specificity of 100% for MKI67 and MCM2, and 93,75% for PCNA. 
Since specificity of the PCNA was not 100% we excluded this marker from the analysis. 
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Figure 41: Results of endpoint PCR analysis of proliferation markers in sorted T cells: A) unstimulated T-cells, activated T-
cells in G1 (B), S (C) and G2-phase (D) of cell cycle. Labeling system: 1 – Target transcript detected in the cell, 0 - target 
transcript was not detected in the cell. 
Expression of proliferation markers significantly differ in activated and naïve CD8+ T-cells (Figure 42) 
confirming that the chosen proliferation markers discriminate proliferating from non-proliferating 
single cells and can be used for determination of the proliferation status of single cells isolated from 
previously described models of dormancy. 
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Figure 42: Gene expression of MKI67, MCM2 and PCNA in naive and activated T cells. On the x-axis are proliferation markers 
in naïve and activated T-cells. On the y-axis is the percentage of naive or activated T cells expressing MKI67, MCM2, and 
PCNA respectively. Fisher’s Exact test, **** p<0,0001. 
After defining proliferative and non-proliferative cells we aimed to profile the state of dormancy in the 
cells we isolated from established in vitro models. 
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3.7 Determination of the proliferation status of cells isolated from 
dormancy models 
Successful validation of MKI67, MCM2 and PCNA as proliferation markers enabled us to study the 
proliferation status of single cells isolated from previously established stem cell and endothelial niche 
models (chapters 3.3 and 3.4). From these models we were able to isolate candidate proliferative and 
non-proliferative cells, which we could not from osteoblastic niche. Therefore, we further turned to 
these models and further analyzed mammary cells derived from them. 
3.7.1 Proliferation analysis of single cells isolated from stromal and 
vascular niches 
From the stromal and microvascular niches we isolated respectively 39 and 33 T4-2 cells. From all of 
them, only 38% (15/39) cells from the MSCs and 55% (18/33) from MVN had good quality and were 
further analyzed. Ki67 expression was detected in 2/18 (11%) cells isolated from microvascular niches 
and 2/15 (13%) cells isolated from stromal niches indicating that these are proliferating cells. These 
cells did not express MCM2. The rest 89%of the cells isolated from stromal niche and 87% of the cells 
isolated from the microvascular niche expressed neither Ki67 nor MCM2 transcripts, most likely 
representing cells residing in G0 phase. Statistical analysis showed that there is no significant difference 
in distribution of proliferating and non-proliferating cells in these two niches (Figure 43). This finding 
confirmed our initial observation that none of these niches specifically induced proliferation or 
quiescence in mammary cancer cells. Therefore, we continued further profiling using the stem cell 
model.   
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Figure 43: Percentage of proliferating and non-proliferating cells in stromal (MSC) and vascular (MVN) niches. Y axis 
represents the percentage of cells from all the analyzed cells from corresponding niches. There is no difference in frequency 
of proliferating and non-proliferating cells in MSC and MVN (Fischer’s exact test, two-tailed, non-significant). 
3.7.2 Proliferation analysis of QSCs, LRCs, and nLRCs isolated from the 
stem cell model 
The ultimate goal of our analysis is to discriminate proliferating from non-proliferating cells within our 
DCCs isolated from breast cancer patients, in order to recognize patients with higher risk of developing 
metastases. Since early DCCs that seed metastases (Hosseini et al., 2016a) harbor few genetic changes 
(Husemann et al., 2008) the best model resembling these cells are cells isolated from mammary gland. 
Therefore, for proliferation analysis in the stem cell model we chose cells of the three best specimens 
using following criteria: (i) Growth of the regular spheres in both generations, (ii) expression of EpCAM 
in QSCs population and (iii) clear distinction between PKH26+ and PKH26- cells in population of cells 
from secondary mammospheres. From the three specimens 45 QSCs, 19 LRCs and 31 nLRCs met 
required quality criteria and were used in following analysis (Table 9). 
Table 9: Overview of patient derived HMECs used for proliferation analysis. 
 QSC LRC nLRC 
Patient 1 14 8 9 
Patient 2 14 3 5 
Patient 3 17 8 17 
Total 45 19 31 
 
Proliferation analysis showed that 93% (42/45) of QSCs and 95% (18/19) of LRCs express neither Ki67 
nor MCM2, resulting in 7% of SCs and 5% of LRCs expressing any of proliferating markers. Among 
nLRCs the percentage of proliferative cells was higher with 23% (7/31) cells expressing at least one of 
the analyzed proliferation markers (Figure 1Figure 44). Pairwise comparison showed there is no 
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significant difference between percentages of proliferating and non-proliferating cells between QSCs 
and LRCs. The percentage of Ki67- and/or MCM2-positive cells is significantly different in the nLRC 
group compared to QSCs and LRCs, (p=0,0025 and p=0,0004 respectively) (Figure 44). This justifies 
the label retention assay as a relevant method for initial separation of proliferating and non-proliferating 
cells, but also emphasizes the necessity of additional analysis for the final answer whether a cell is in 
the proliferative state. 
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Figure 44: Analysis of the proliferative status of patient derived HMECs. Percentage of Ki67+ and /or MCM2+ is significantly 
different in nLRC group compared to QSCs and LRCs, but not between LRC and QSC groups (Fisher’s exact test, two-tailed, 
**p<0,01, ***p<0,001, ns non-significant). 
3.8 Profiling the state of cellular dormancy 
To select the best candidate cells for the proliferation analysis in mammary cells, we employed two 
tests. First, the label retention assay, where cells were classified in three groups (non-cycling QSCs, 
non-cycling LRCs and cycling nLRCs) was used. Second, we utilized the proliferation analysis based 
on the expression of the proliferation markers (as described in chapter 3.6). All label retaining (non-
cycling) cells which in addition did not express analyzed proliferation markers, as well as non-label 
retaining (actively proliferating) cells which expressed Ki67 or MCM2 were chosen as good candidates 
for gene expression analysis. Having in mind that PCNA was not specific only for activated, 
proliferating T-cells, we decided to use this gene only as exclusion marker, meaning the cells that 
expressed only PCNA were not considered non-proliferating and were eliminated for further analysis. 
On the other side these cells (that expressed only PCNA) were also not considered proliferating, since 
PCNA was expressed by one naïve (non-cycling, G0) T-cell. Therefore, for gene expression analysis 
only non-label retaining cells that expressed Ki67 or/and MCM2 were considered proliferative cells and 
label retaining cells that did not express any of the three proliferation markers were considered non-
proliferative cells. The selection process of candidate cells for gene expression analysis is depicted in 
the Figure 45. 
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Figure 45: Workflow depicting the selection of patient derived HMECs from different proliferation states (proliferating and 
non-proliferating cells) for gene expression analysis. Red highlighting labels the cells classified as non-proliferating and grey 
highlighting labels the cells classified as proliferating cells. Cells whose proliferation status from the label-retention assay was 
confirmed by proliferation analysis were taken for gene expression analysis. 
After this selection process, we had 26 QSCs, 8 LRCs and 5 nLRCs from three patients fulfilling the 
requirements (Table 10). From these 9 QSCs, 8 LRCs and 5 nLRCs were subjected to gene expression 
analysis using microarray analysis. Additionally, we analyzed three QSCs expressing only PCNA. 
Table 10: Number of selected cells for gene expression analysis representing different states of proliferation and quiescence 
in cells. 
Patient Patient 1 Patient 2 Patient 3 Total 
QSCs 7 9 10 26 
Non-proliferating LRCs 4 1 3 8 
Proliferating nLRCs 3 2 2 5 
 
3.8.1 Gene expression profiling discriminates 5 groups within HMECs 
Proliferating and non-proliferating cells have gene expression profiles specific to the state in which they 
reside. Therefore, different gene expression would enable us to discriminate proliferating from non-
proliferating cells. 
Unsupervised k-means clustering classified cells into 5 distinct groups (Figure 46). All proliferating 
nLRCs were classified in the same group (g1) and separated from non-cycling cells. Two distinct 
subpopulations within each of the QSC and LRC populations were identified. LRCs grouped into 
groups g2 and g4, and QSCs into groups g3 and g5. Interestingly, three PCNA+ QSCs (QSC1, QSC5 
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and QSC9) grouped together with other Ki67-/MCM2-/PCNA- QSCs, confirming that PCNA is not the 
optimal marker to determine the proliferative status of the cell.  
 
Figure 46: K-means clustering following microarray analysis of HMECs classifies cells into 5 separate groups. QSCs – g3 and 
g5 - non-proliferative differentiated cells; LRCs – g2 and g4 - stem-like, non-proliferative cells; nLRCs – g1 - proliferative, 
progenitor cells. 
3.8.2 QSCs, LRCs, and nLRCs belong to the populations of distinct 
differentiation states in mammary gland 
Next, we wanted to profile the stem-like cells (LRCs), progenitor cells (nLRCs), and EpCAM+ QSCs 
isolated from the stem cell model. Data coming from the gene expression profiles of these groups were 
transformed using quantile normalization and compared pairwise. Differentially expressed genes 
(DEG) represented the group of activated genes needed for transition (shift) of the cell from one state 
to another (or one population to another). 
We searched the literature for the analysis of mammary cells from distinct differentiation states and 
found that Lim and colleagues (Lim et al., 2009) isolated mammary cells (blood lineage marker negative 
cells) from a tissue of a healthy donor and sorted them based on EpCAM and CD49f expression in the 
following subpopulations: CD49f+EpCAM- mammary stem cells, CD49f+EpCAM+ luminal progenitors 
and CD49f-EpCAM+ mature luminal cells. These subpopulations were subjected to gene expression 
analysis. We compared their findings with ours and learned that LRCs from our analysis mostly 
correspond to mammary stem cell hierarchical level in the work of Lim and colleagues, nLRCs 
correspond to the progenitors and QSCs to mature luminal cells (Table 11). Additional confirmation of 
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the relevance of this approach was displayed the comparison of two groups of the same hierarchical 
level (Table 11, Column 5) in which no difference (hierarchical shift) was detected. 
Table 11: Accuracy of comparison of different groups (g1-g5) with cells from different hierarchical level. Accuracy higher 
than 50% indicates true similarity (50% accuracy is a result of randomized gene distribution) in comparison of the “shifts” 
between the groups. Highlighted field are the comparison that showed highest statistical significance. For simplicity, only 
representative comparisons between the groups of distinct differentiation states are shown.  
nLRC -> LRC1 nLRC -> QSC1 LRC2 -> QSC2 QSC1 -> LRC2 LRC1 -> LRC2 
ML -> MaSC; 
67%; p= 5,54e-13 
MaSC -> ML; 
50%; p= 0,9253 
MaSC -> ML; 
72%; p= 2,606e-19 
ML -> MaSC; 
62%; p= 1,283e-10 
ML -> MaSC; 
53%; p= 0,264 
LP -> ML; 
57%; p= 0,052 
LP -> ML; 
58%; p= 0,008 
ML -> LP; 
53%; p= 0,185 
ML -> LP; 
56%; p= 0,006 
ML -> LP; 
52%; p= 0,385 
LP -> MaSC; 
72%; p= 2,23e-20 
LP -> MaSC; 
55%; p= 0,049 
MaSC -> LP; 
75%; p= 1,679e-24 
LP -> MaSC; 
61%; p= 6,181e-07 
LP -> MaSC; 
53%; p= 0,585 
 
3.8.3 Pathway analysis determines signaling profiles of defined groups 
Next, we performed bioinformatical analysis of the activated cell signaling pathways and defined the 
profiles of deregulated signaling pathways in each of the previously defined five groups of cells. 
Pathway analysis resulted in a list of up- and downregulated pathways for each of the groups (Figure 
47). Both groups of LRCs expressed some of the stemness related pathways, such as non-canonical 
Wnt, PI3K/AKT, MAPK family (LRC1), PI3K/AKT, Wnt, Notch (LRC2). Interestingly, in nLRC 
group p38 signaling mediated by MAP kinases, MAP kinases signaling, TGF-, and Hippo pathways 
were upregulated, as well as many pathways related to progression through cell cycle. Unexpectedly, 
Wnt pathway, a signaling pathway connected to stemness, was upregulated in QSCs, which also 
overexpressed apoptotic pathways. One of the signaling pathways that was associated to stemness 
(upregulated in both LRC1 in LRC2 groups compared to others) was the IL-6 signaling pathway (Figure 
47). We decided to further investigate the mechanism of this pathway in regulation of stemness and 
dormancy in mammary cells. 
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Figure 47: Summarized cell-signaling pathway analysis of QSCs, LRCs and nLRCs isolated from mammary specimens of 
healthy individuals. Each bar indicates the number of comparisons in which that specific pathway was upregulated, i.e. PI3K-
Akt and IL-6 signaling pathway are upregulated in LRC1 group in 4 comparisons, meaning they are upregulated in this group 
compared to all others. 
3.8.4  IL-6 signaling in patient derived MC-DCCs 
Having found that IL-6 signaling plays a role in stem like cells (LRCs), we wanted to see how it is 
reflected in our DCC collective. We generated a “gene signature” consisting of the genes upregulated 
upon stimulation of IL-6 signaling in MCF10A cells (Figure 61) and IL-6 regulated genes that we found 
by mining the literature. We used this “gene signature” to analyze 21 MC-DCCs (15 M0-DCCs and 6 
M1-DCCs) with aberrant mCGH profiles that we subjected to deep   transcriptome sequencing. The 
supervised clustering discriminated three DCCs clusters, one comprising of a majority of M1-DCCs 
and two M0-DCCs subgroups with one M1-DCC each. IL-6 signaling pathway was activated in eight 
of 15 M0-DCCs, while seven of 15 M0-DCCs did not show an active IL-6 signaling pathway (Figure 
48).  
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Figure 48: Heatmap demonstrates selective IL-6 activation in subsets of aberrant MC-DCCs. M1-DCCs form separate group, 
while M0-DCCs comprise of two subpopulations, one with active and one with non-activated IL-6 signaling pathway. 
Ki67 and MCM2 expression, determined by qPCR, was significantly higher in group of cells with 
activated IL-6 signaling (Table 12) supporting our hypothesis that IL-6 signaling is one of the signals 
that plays a role in controlling the proliferation of DCCs in the bone marrow of breast cancer patients. 
Table 12: Expression of proliferation markers (Ki67 or MCM2) in M0-DCC subgroups with active/non-active IL-6 signaling. 
Number of proliferative (Ki67+ or MCM2+) cells is significantly higher in M0-DCCs with active IL-6 signaling pathway 
(Fisher’s Exact test, p=0,0406). 
 Ki67+ or MCM2+ Ki67- and MCM2- 
IL-6 active 7 1 
IL-6 non-active 2 5 
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3.9 IL-6 signaling in the mammary gland 
Our finding that majority of breast DCCs are non-proliferating fits well to the data that most of breast 
cancers never become metastatic. Only 15% of analyzed aberrant DCCs (4/26) were classified in a 
group of proliferating nLRCs. From all women diagnosed with early-stage breast cancer 30% develop 
metastatic disease (Redig and McAllister, 2013). A half of that number can be women with DCCs with 
proliferating profile. We asked whether the rest of cells with potential for metastatic outgrowth lie 
among LRCs, while 15% of analyzed DCCs were classified into this group. Accumulating evidence 
suggests that a subpopulation of stem-like cancer cells possess the capability to disseminate to distant 
organs (Liu et al., 2010; Liu et al., 2011). This prompted us to further explore IL-6 signaling pathway, 
which is activated in non-proliferating LRCs (stem-like cells). 
3.9.1 MCF10A cells express IL-6 and IL-6Ra 
To receive the IL-6 signal in a classical manner, the cell must express the membrane bound IL-6Ra. We 
therefore examined IL-6Ra protein expression in MCF10A cells. To analyze whether IL-6Ra expression 
is confined to the stem cell state, we examined its expression in a bulk of cells from 2D culture and in 
a cell pool from disaggregated mammospheres, which is enriched with stem cells (Dontu et al., 2003). 
Expression of IL-6Ra on the cell membrane (mIL-6Ra) of single MCF10A cells was examined by flow 
cytometry both in 2D and 3D cultures. We found that detection of the IL-6Ra protein was dependent 
on the proteolytic cleavage by trypsin for cell isolation (Figure 49). Trypsinization of 8 minutes 
negatively affected the detection of IL-6Ra indicating that this receptor is cleaved by trypsinization 
period. Therefore, 3 minutes incubation with trypsin, which did not affect IL-6Ra detection was used 
for further experiments. 
 
Figure 49: Flow cytometric analysis of IL6-Ra surface expression on MCF10A cells cultured under adherent conditions (2D) 
and in anchorage independent conditions as mammospheres (3D). Mammospheres were collected and disaggregated using 
trypsin. A 40mm cell strainer was used to separate single cells from remaining parts of non-disaggregated spheres. The data is 
representative of three independently performed experiments. 
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Next, we disaggregated patient-derived HMECs mammospheres and isolated single cells which were 
then subjected to analysis of IL-6Ra by flow cytometry. IL-6Ra was detected in single cells derived 
from HMEC-spheres neither after 3 nor 8 minutes trypsinization (Figure 50). 
 
Figure 50: Flow cytometric analysis of membrane bound IL-6Ra expression on HMEC cells cultured in anchorage independent 
conditions as mammospheres (3D). To avoid technical artefacts result was confirmed with different trypsinization time points 
(3 and 8 minutes). 
The IL-6 cascade can be activated even in cells that do not express IL-6Ra, if soluble IL-6Ra (sIL-6Ra) 
is present in the surrounding environment (Rose-John and Heinrich, 1994). Therefore, we investigated 
the presence of IL-6 and sIL-6Ra in adherent MCF10A cell cultures by ELISA. Both, IL-6 and sIL-6Ra 
were found in the supernatant of MCF10A cultures (Figure 51), showing that these cells fulfil the 
prerequisites to be stimulated not only by classical, but also by IL-6 trans-signaling. sIL-6Ra can be 
produced in two different manners, by alternative splicing (spliced IL-6Ra in further text) or by 
shedding. We further investigated which of the mechanisms are responsible for the production of 
different isoforms of IL-6Ra. 
 
Figure 51: IL6 and the soluble IL-6Ra were measured in cell culture supernatants of MCF10A cells cultured under adherent 
conditions (n=4 experiments, Mean +/- SD) on days 2, 3 and 4. A) Concentration of sIL6-R is elevated with increasing 
confluence. B) IL-6 and sIL-6Ra concentration in the supernatant of MCF10A cells at day 2, average of three independent 
experiments. 
To analyze whether expression of IL-6 and any isoform of IL-6Ra was confined to the same cell, we 
analyzed individually isolated single MCF10A cells (n=46 single cells) from adherent cultures (2D) 
using a unique primer pair for mIL6-Ra and spliced IL-6Ra analysis. The PCR-product of the spliced 
IL-6Ra transcript is shorter than of mIL-6Ra transcript (Figure 52A). We observed a heterogeneous 
80 
 
expression profile, with expression of IL-6 and IL-6Ra transcript in 0% (0/29) and 41% (12/29) of the 
cells, respectively (Figure 52B). Of the 41% IL-6Ra expressing cells, most cells expressed the 
membrane-bound form, 38% (11/29), with only 7% (2/29) expressing the splice-variant for the secreted 
receptor from which one cell expressed both mIL-6Ra and splice IL-6Ra and one expressed only splice 
IL-6R mRNA. The expression of the mediator of IL-6 signaling, gp130 was detected in 97% (28/29) of 
cells. Hence, only a small fraction of MCF10A cells is amenable to classical IL-6 signaling, but they 
can all be stimulated by IL-6 (via gp130) if sIL-6Ra is present in the environment. 
 
Figure 52: Expression of IL-6 and IL-6Ra mRNA in individually isolated MCF10A cells from adherent culture-conditions. A. 
The membrane-bound and spliced mRNA-form of IL6-R were discriminated according to the size of the specific PCR band. 
B. Y-axis represents the percentage of all cells expressing corresponding marker determined through end-point PCR (n=46 for 
IL-6 and IL-6Ra; n=29 for gp130 analysis). 
Next, we analyzed whether these cells co-express some of examined markers and found that 36% 
(10/28) of gp130 expressing cells co-express mIL-6Ra, both cells that express spliced IL-6Ra also 
express gp130. 
Since spliced variant of the receptor contributes only to a minor extent to the pool of sIL-6Ra, we 
concluded that majority of sIL-6Ra is produced by limited proteolysis through “a disintegrin and 
metalloproteinases” (ADAM proteases), ADAM-10 and ADAM-17 (Riethmueller et al., 2016). ADAM 
proteases shed the extracellular region of the transmembrane proteins. To investigate the role of limited 
proteolysis, we used TAPI-2, a potent inhibitor of matrix metalloproteinases, ADAM10 and ADAM17 
among the others. TAPI-2 mediated inhibition of ADAM-proteases reduced the level of sIL-6Ra, but 
not of IL-6 (Figure 53), confirming that both alternative splicing and limited proteolysis are the sources 
of the soluble form of IL-6Ra (sIL-6Ra). 
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Figure 53: MCF10A cultured under adherent conditions with or without 2 µM TAPI-2. Protein levels of soluble IL6-Ra and 
IL6 in the supernatant were determined by ELISA (n = 3 experiments, **** p<0,0001, two-sided student’s t-test, Mean ±SD). 
Taken together, the data show that non-tumorigenic mammary epithelial cells such as MCF10A cells 
express the membrane-bound IL-6Ra and therefore have potential to respond to classical IL-6 signaling, 
what we wanted to investigate next. IL-6 and sIL-6Ra detection in the environment confirms existence 
of a certain level of endogenous activation of IL-6 trans-signaling in these cells. 
3.9.2 IL-6 signaling regulates the frequency of stem-like MCF10A cells 
To test the effect of IL-6 signaling on the self-renewal capacity of MCF10A cells (i.e. their stem-cell 
like phenotype) we subjected these cells to a sphere-forming assay. Under these culture conditions, 
stem/progenitor cells from non-transformed mammary tissue can be expanded and generate 
mammospheres, which have a clonal origin (Dontu et al., 2003). In line with this, mammosphere-
derived cells from both, mouse and human mammary gland, were shown to have the highest ability to 
repopulate the cleared mammary fat pad in vivo (Cicalese et al., 2009; Pece et al., 2010). To elucidate 
the impact of classical and trans-signaling on mammosphere-formation, which is a stem cell function, 
we added activators of both pathways: (i) IL-6 to activate both, classical and trans-signaling and (ii) 
Hyper IL-6 (HIL-6) to activate trans-signaling only. In control cultures, the number of spheres at day 7 
represented 0,3% +/- 0,16% (Mean +/- SD) of the input number of MCF10A cells. In the presence of 
IL-6 and HIL-6 the sphere forming ability was significantly increased (Figure 54) indicating that IL-6 
signaling plays a role in the regulation of the stem cell pool not only in cancer (Marotta et al., 2011; 
Sansone et al., 2007) but also in non-transformed mammary epithelial cells. 
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Figure 54: MCF10A cells were cultured as mammospheres (30.000 per plate) in the presence of IL-6 or Hyper-IL6. Each 
group analyzed in triplicates (one-way ANOVA, * p<0,05, ** p<0,01, all error bars correspond to standard deviation (Mean 
±SD)) 
To discriminate between the influence of classical and trans- IL-6 signaling on the sphere-forming 
ability of the cells, we inhibited trans-signaling with the soluble form of gp130 (sgp130-Fc), which was 
shown to specifically inhibit IL-6 trans-signaling at a concentration of up to 100 ng/ml (Scheller et al., 
2005) with a suggested effective concentration of 0,1 ng/ml. At both tested concentrations (0,1 ng/ml 
and 10 ng/ml), the enhanced sphere formation was abolished, showing that all IL-6 effect on sphere 
formation goes via trans-signaling (Figure 55). 
 
Figure 55: MCF10A cells were cultured in anchorage independent conditions, with or without IL-6 and IL-6 plus sgp130-Fc 
at the indicated concentrations. Spheres were counted at d7 (n = 2 experiments, each group in triplicates, one-way ANOVA, 
adjusted p-value **** <0,0001, all error bars correspond to standard deviation (Mean ±SD)). One representative experiment 
displayed. 
3.9.3 Expression of IL-6 and IL-6Ra in stem-like and progenitor cells 
from MCF10A-spheres 
To further elucidate the role of IL-6Ra expression by stem and progenitor cells, we analyzed expression 
of IL-6 and IL-6Ra mRNA in label-retaining (LRCs) and non-label-retaining cells (nLRCs) isolated 
from disaggregated MCF10A-spheres. Prior to seeding cells in mammosphere conditions, they were 
labeled using CFSE (proliferation tracking dye) which is being diluted upon every division. Spliced IL-
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6Ra was not expressed by any of analyzed cells, IL-6 mRNA was detected in very few samples, while 
mIL-6Ra and gp130 were detected in more samples (Table 13), corresponding to expression detected 
in MCF10A cells from adherent cultures (Figure 52). 
Table 13: Expression of IL-6, IL-6Ra (membrane and spliced) and gp130 mRNA in single LRC and nLRC isolated from 
MCF10A spheres at day 7 (LRC: n=16; nLRC: n=48) determined by end point PCR. Neither IL-6 nor IL-6Ra expression was 
confined to LRCs or nLRCs. 
 
 
Another approach to study the expression of IL-6 and its receptor in stem-like and non-stem cells is 
utilization of the stemness markers, CD44 and CD24 expression. Stem-like cell function has been 
attributed to mammary epithelial cells expressing high levels of CD44 and low levels of CD24 
(CD44hi/CD24lo). We analyzed the percentage of CD44hi/CD24lo stem-like cells in MCF10A spheres at 
day 7 and observed that exogenous IL-6 stimulation significantly increased the percentage of these cells 
(Figure 56), with HIL-6 stimulated cultures showing the highest increase. In contrast to the results of 
the mammosphere assay (Figure 55) where increase in the sphere number indicates increase in number 
of cells with ability to give rise to mammospheres in non-adherent conditions (stem-like cells), no 
significant difference was observed in the percentage of CD44hi/CD24lo (markers of stem-like cells) 
cells between IL-6 and IL-6+sgp130 treated cultures. We concluded that stem cell markers do not define 
stem cells faithfully as sphere formation (function of stem cells). 
 
Figure 56: MCF10A spheres were analyzed by flow cytometry at day 7 for the expression of CD44 and CD24. The percentage 
of CD44hiCD24lo (stem-like) and CD44low/intCD24hi (non-stem) expressing cells was determined. B) Quantification of the data 
from A. The data represents the cumulative results of three independently performed experiments (n=3 experiments with 
pooled analysis of triplicates, one-way ANOVA, **p<0,01, ****p<0,0001) 
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3.9.4 Effect of IL-6 classical- and trans-signaling on proliferation and 
survival of cells 
In the mammosphere assays with the same activators of IL-6 signaling cascade as in Figure 56, we 
observed the increase in the size of mammospheres in IL-6, IL-6+sgp130 and HIL-6 treated cultures 
compared to control spheres (Figure 57). 
 
Figure 57: MCF10A mammospheres after 7 days cultivation in anchorage independent conditions with or without IL-6, IL-6 
plus sgp130 and Hyper-IL6. Scale bar 100 m. 
Next, we assessed cell proliferation of CFSE labelled MCF10A mammospheres, cultured without or 
with IL-6, IL-6 + sgp130-Fc and HIL-6. After 4 days, proliferation as function of CFSE-dilution was 
determined by flow cytometry. Interestingly, CD44hi/CD24lo cells proliferated faster than 
CD44lo/CD24hi cells (Figure 58), and irrespective of the signaling-pathway, i.e. classical or trans, IL-6 
showed a tendency to increase the percentage of living cells in MCF10A-spheres (Figure 59). 
 
Figure 58: CFSE-labelled MCF10A cells were cultured in anchorage independent conditions with or without activators of 
classical and trans-signaling and in presence of inhibitor of trans-signaling. At day 4, mammospheres were collected, 
disaggregated and analyzed. CFSE-dilution of CD44hiCD24lo and CD44lowCD24hi was determined at day 4 by flow cytometry. 
Data is representative for 3 independently performed experiments. 
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Figure 59: The percentage of viable cells was determined at day 4 by flow cytometry (n=3 experiments, pooled analysis of 
triplicates in each group). 
To examine the population that was mostly affected by IL-6 stimulated proliferation, we needed a 
reference population, i.e. latex beads. Therefore, after disaggregation of the mammospheres and 
staining markers for the markers CD44 and CD24, we added the same number of beads to every sample 
to determine the absolute numbers of CD44hi/CD24lo and CD44lo/CD24hi expression and compare their 
number in response to stimulation with IL6, IL6-spg130, HIL6. The percentage of LRCs (mainly 
comprising of CD44hi/CD24lo cells) in the analyzed population was not decreased upon activation of 
IL-6 signaling (both, only classical or trans) indicating that IL-6 stimulation does not activate 
proliferation of stem-like cells, but rather of progenitor cells (nLRCs). (Figure 60). 
 
Figure 60: A) CFSE-labelled MCF10A cells were cultured in anchorage independent conditions with or without activators of 
classical and trans-signaling and in presence of inhibitor of trans-signaling. CFSEhi cells were mostly comprised of 
CD44hiCD24lo cells. B) The percentage of stem-like LRCs upon IL-6 stimulation showed as ratio of the absolute number of 
LRCs in control and stimulated cultures to the constant number of beads. Data is representative for 3 independently performed 
experiments. 
These findings corroborate the observed increase in sphere size in IL-6 (classical + trans), IL-6 +sgp130 
(only classical) and HIL-6 (only trans) treated cultures (Figure 57), is not achieved by activation of 
LRCs, meaning the pool of stem-like cells is not changed upon IL-6 stimulation. 
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3.9.5 Signaling pathway analysis in MCF10A cells upon stimulation of IL-
6 signaling 
The finding that IL-6 trans-signaling is responsible for stem-cell function prompted us to further 
investigate differences in signaling cascades activated by only classical, only trans and both pathways. 
For that purpose we cultured MCF10A cells in anchorage independent conditions alone (group A) or 
supplemented with IL-6 (group B, activation of both pathways), IL-6 + sgp130-Fc (group C, classical 
signaling only) and HIL-6 (group D, trans-signaling only) for 12h and 24h. After that we collected the 
whole cultures, isolated mRNA, and performed a gene expression analysis using microarray. Despite 
phenotypical differences (Figure 55) we did not detect any other signaling pathways activated by 
different IL-6 signaling components (classical or trans). Gene expression analysis of the microarray 
data showed that activation of Jak-STAT, MAPK, inflammatory genes was consistent across all 
stimulated groups (Figure 61) implying that all IL-6 signaling branches activate the same cascade, but 
with different signal strength.  
 
Figure 61: Heatmap depicting the differentially expressed gene (DEG) signature upon activation of IL-6 signaling pathway in 
MCF10A cells. Non-treated cells (group A) were analyzed at 12h and 24h upon seeding and compared to cells stimulated 
using activator of both classical and trans signaling (IL-6, group B), only classical signaling (IL-6+sgp130, group C) and only 
trans-signaling (HIL-6, group D) at 12h and 24h after seeding. The same genes are activated irrespective of the stimulation, 
but with different strength of the signal. 
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3.9.6 IL-6 trans-signaling increases sphere formation of HMECs  
As we found that IL-6 mediates an increase in stem-like properties among mammary epithelial 
MCF10A cells, we decided to test primary mammary epithelial cells, HMECs, isolated from reduction 
mammoplasties of three healthy women and subjected them to the mammosphere-assay in the presence 
of anti-IL-6, IL-6, and HIL-6. In line with the data from MCF10A cells, HIL-6 significantly increased 
the sphere-forming ability of primary mammary epithelial cells and the diameter of individual spheres 
(Figure 62). In contrast, IL-6 did not induce a significant increase in the number of spheres, suggesting 
that sIL-6Ra was a limiting factor (these findings were presented in the PhD thesis of Dr. Milan 
Obradovic). 
 
Figure 62: (A) HMECs were cultured with or without IL6, an IL6 blocking antibody or Hyper-IL6. (n = 3 patients, each group 
in triplicates). One-way ANOVA; **** p<0,0001. All error bars correspond to standard deviation (Mean ±SD). (B) IL6 
influenced proliferation of single mammosphere measured by the fold change of the mammosphere diameter (p< 0,0001, two- 
tailed unpaired t-test). Results are obtained from 7 independent tissue specimens (n=7). 
3.9.7 Expression of IL-6 and IL-6Ra in LRCs and nLRCs from HMEC-
spheres 
To find out whether the expression of IL-6 or IL-6Ra was confined to any cell population within 
mammospheres, we analyzed the mRNA expression of IL-6 and IL-6Ra in individually isolated QSCs 
as well as in LRCs and nLRCs from disaggregated spheres. From 3 patients we tested 30 QSCs, 30 
LRCs and 30 nLRCs with for the expression of IL-6 and IL-6Ra. Like in MCF10A cells, we found that 
neither IL-6 nor IL-6Ra expression was confined exclusively to QSCs, nLRCs or LRCs (Table 14). 
Instead, in all the populations a similar percentage of cells were expressing IL-6 (QSC/LRC/nLRC: 
16,7%/20%/33%) and IL-6Ra (QSC/LRC/nLRC: 6,7%/10%/6,7%). Co-expression of IL-6Ra and IL-6 
was detected in only one nLRC (3,3%). Majority of cells from all the groups expressed gp130 
(QSC/LRC/nLRC: 83,3%/73,3%/66,7%). 
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Table 14: IL-6 and IL-6Ra mRNA expression was determined in QSCs, LRCs and nLRCs (n=30 in each group) isolated as 
single cells from secondary HMEC-mammospheres. Expression of neither IL-6 nor IL-6Ra was confined to QSCs, LRCs, or 
nLRCs. 
 
3.9.8 Expression of IL-6 and IL-6Ra in DCCs from breast cancer patients  
Further, we wanted to examine whether the IL-6 signaling pathway is activated in DCCs isolated from 
breast cancer patients. Early disseminated cancer cells show very few genomic changes, which makes 
them more similar to normal than to aberrant cancer cells deriving from late stage primary tumors. We 
chose 25 DCCs with an aberrant profile in mCGH analysis, isolated from bone marrow of the patients 
without metastases at the time of surgery (M0-DCCs) and 10 DCCs with an aberrant profile in mCGH 
analysis from patients with detectable metastases at the time of surgery (M1-DCCs). In line with the 
restricted expression of IL-6 and IL-6Ra in MCF10A cells and patient derived HMECs, we did not 
detect expression of IL-6 and IL-6Ra in 25 M0-DCCs (Figure 63) or 10 M1-DCCs indicating that 
classical IL-6 signaling cannot be activated in these cells. 
 
Figure 63: Visualization of IL-6 (A), IL-6Ra (B) and gp130 (C) gene expression in aberrant M0-DCCs from breast cancer 
patients. Size marker (L): 2-Log-DNA-ladder, WTA-control (+), Negative control (-) of WTA 
 
Gp130 primer pair specifically amplifies the fragment of 125 bp. All analyzed MCF10A single cells 
(10/10) were positive in this analysis confirming maximal sensitivity of primers. Analysis of the M0- 
and M1-DCCs showed that 16% (4/25) M0-DCCs and 30% (3/10) M1-DCCs express gp130 mRNA. 
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3.9.9 Quantitative PCR analysis of gp130 in DCCs from patients with 
breast cancer 
To precisely assess the expression level of target genes, we developed a quantitative PCR (qPCR) 
method enabling expression analysis of selected genes in a single-cell. The new protocol enabled the 
use of   either primary or re-amplified single-cell whole transcriptome amplification (WTA) products, 
providing re-usable source of material for downstream analyses. The method was established and tested 
in a proof-of-concept study on HER2 expression and presented in a bachelor thesis of Franziska Durst. 
Since this method is more sensitive than end point PCR, we repeated the expression analysis in M0-
DCCs using the second primer pair for gp130. In 40% (10/25 cells) of aberrant M0-DCCs the specific 
amplicon with Ct values lower than 33 was detected. Two cells in which the specific amplicon was 
detected by end-point PCR did not show a specific melting curve, indicating the absence of a specific 
amplicon. Overall gp130 expression was detected using either end-point or qPCR in 48% (12/25) of 
aberrant M0-DCCs and in 40% (4/10) of aberrant M1-DCCs. 
Next, we expanded the analysis to a bigger collective of 147 M0-DCCs and 49 M1-DCCs whose mCGH 
status was not determined, but their gene expression profiles classified them to a group of “true DCCs” 
(PhD thesis of Nina Patwary). In total we detected the gp130 amplicon (Cp<33) in 84% (123/147) of 
M0-DCCs and 86% (42/49) of M1-DCCs, indicating that mammary DCCs rarely downregulate gp130 
after dissemination. For comparison, we employed the same sensitive method to assess the expression 
level of gp130 in non-tumorigenic mammary cells, MCF10A. Additionally, we included the MCF7 cell 
line originating from pleural effusion of breast cancer patient. Although present, the level of gp130 
expression was significantly lower in MC-DCCs compared to both, MCF10A and MCF7 cells (Figure 
64) indicating that the bone marrow environment can have an impact on the expression level of gp130 
in mammary DCCs. 
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Figure 64: gp130 mRNA expression in MCF10A, MCF-7 and DCCs from breast cancer patients with (M1) and without (M0) 
distant metastases (M0-DCCs, n=122; M1-DCCs, n=40; MCF7, n=22; MCF10A, n=8). One-way ANOVA, **** p<0,0001. 
3.9.10 Regulation of the gp130 expression in DCCs by the bone marrow 
environment 
The bone marrow environment is mostly comprised of mesenchymal stromal (stem) cells (MSCs), 
osteoblasts (OBs), endothelial cells (HUVECs) and hematopoietic cells. To test whether bone marrow 
stromal cells modulate the ability of mammary cells to receive IL-6 signals, we co-cultured MCF10A 
cells with (i) primary human MSCs isolated from the bone marrow aspirates of non-metastasized breast 
cancer patients or healthy volunteers, (ii) OBs differentiated from these MSCs or (iii) primary human 
umbilical cord endothelial cells (HUVECs) and genetically manipulated to prolong their life in vitro 
(Ghajar et al., 2013). On day five, flow cytometric analysis revealed cell-surface downregulation of 
gp130 on MCF10A cells co-cultured with MSCs and OBs, but not with HUVECs (Figure 65). 
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Figure 65: Surface gp130 expression of MCF10A analyzed by flow cytometry analysis after 5 days of co-culture with primary 
mesenchymal stem cells (MSCs) from a breast cancer patient, primary osteoblasts (OBs) derived thereof and primary human 
umbilical endothelial cells (HUVECs). MCF10A – cells cultured alone (positive control of gp130 expression). 
The regulation of the gp130 protein expression can be a result of cell-cell contact or contact 
independent. We further investigated the mechanism how MSCs impact expression in mammary cells. 
To examine this we cultivated cells in co-cultures with MSCs and also in a transwell set up, in which 
MCF10A cells are separated from MSCs resulting in an inhibition of the contact, but enabling transfer 
of the secreted soluble factors. Downregulation of the gp130 protein was independent from cell-cell 
contact as it was also detected when MCF10A and MSCs were separated by a transwell membrane 
(Figure 66), indicating that gp130 protein downregulation in mammary cells it occurs via a soluble 
factor secreted by MSCs. 
 
Figure 66: Surface gp130 expression of MCF10A by flow cytometry analysis after 14 hours of co-culture with MSCs from a 
healthy control (HD) or breast cancer patient (MaCa), OBs (co-culture) or MSC-conditioned medium. Grey filled histograms 
indicate MCF10A co-cultures with MSCs, MSC-conditoned medium (CM) or OBs. White filled histograms indicate MCF10A 
cell cultured alone, and dashed histograms isotype control staining for gp130. 
Next, we wanted to examine whether this effect of MSCs on gp130 expression is instant in mammary 
cells or it requires longer stimulation. To answer this question we co-cultured MCF10A cells with MSCs 
and examined expression of gp130 protein in MCF10A cells from these co-cultures after 6, 14, 24, 38 
and 48 hours of cultivation (Figure 67). Downregulation of gp130 from the cell surface was not instantly 
detected, but observed between 6 and 14 hours after initiation of the co-culture with MSCs and remained 
stable until the last analyzed time point. This effect is consistent with constitutive endocytosis of gp130 
that is independent of binding the IL-6/IL-6R ligand complex (Thiel et al., 1998). 
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Figure 67: Surface gp130 expression of MCF 10A after 6, 14, 24, 38 and 48 hours of co-culture with MSCs or MSC-
conditioned medium). Grey filled histograms indicate MCF 10A co-cultures with MSCs or MSC-conditoned medium (CM). 
White filled histograms indicate MCF10A cells cultured alone, and dashed histograms show isotype control staining for gp130. 
To explore whether this MSC-induced phenotype is stable once when achieved, we cultivated the 
MCF10A cells and MSCs in transwell plates, removed MSCs after 5 days and analyzed gp130 
expression on day 6. Persistent downregulation of gp130 after 5 days in the presence of MSCs or CM 
from MSCs (transwell) was rescued by removal of the transwell with the MSCs indicating that gp130 
expression in mammary cells is reversible and dependent on the continuous presence of MSCs as 
removing the MSC-containing transwell restored the gp130 expression level in comparison to MCF10A 
cells co-cultured with MSCs for all 6 days (Figure 68). 
 
Figure 68: gp130 surface expression on MCF10A cells after 5 and 6 days of co-culture with MSCs or MSCs and MCF10A 
separated by a transwell.membrane. Removal of transwell containing inhibiting MSCs retrieves gp130 expression (right panel 
in bottom row). Grey filled histograms indicate MCF 10A co-cultures with MSCs or MSC-conditoned medium (CM). White 
filled histograms indicate MCF10A cells cultured alone, and dashed histograms show isotype control staining for gp130. 
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Finally, we asked whether gp130 cell-surface downregulation had functional consequences and 
therefore tested MCF10A cells pre-treated for 14 hours with conditioned medium (CM) from patient 
derived MSC for their sphere-forming ability in the presence or absence of HIL-6. Compared to control 
cultures, the ones pre-treated with MSC-CM showed an increase in the number of single cells and 
significantly reduced number of spheres, reflecting the impaired IL-6 signaling by endogenously 
produced IL-6/IL-6Ra (Figure 69). Adding HIL-6 restored sphere-numbers only in the range of control-
cultures and failed to reach the level of cultures supplemented only with HIL-6. Taken together, our 
data indicate that the ability of early DCCs to react to IL-6 signaling and trans-signaling is dependent 
on the microenvironment in which they reside, with mesenchymal stem cells and osteoblasts disabling 
IL-6 trans-signaling and consequently also the number of DCCs with a stem-like phenotype and 
function. 
 
Figure 69: MCF10A were pre-treated for 14 hrs with MSC-conditioned medium, washed and then tested for their ability to 
form spheres in the presence or absence of exogenously added H-IL6. A) Quantification of sphere-formation assessed after 7 
days. **** p<0,0001 B) Images of the spheres of the cells treated as described. Arrowheads point to a typical mammospheres 
from given condition. Scale bar 100µm. 
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4 Discussion 
In this study we investigated whether the BM-DCCs originating from breast cancer patients are 
dormant, and consequently in which type of dormancy. Our aims were to i) find the best model(s) of 
mammary cell dormancy, ii) explore mechanisms that regulate dormancy of breast DCCs in the bone 
marrow and apply this knowledge on early DCCs, putative precursors of metastases. Early DCCs 
display significantly fewer chromosomal aberrations than primary tumor cells or DCCs from metastatic 
patients. In that regard, early DCCs are much closer to normal (non-transformed) cells than to advanced 
tumor cells (Schardt et al., 2005; Schmidt-Kittler et al., 2003). Therefore, we chose mammary cells 
isolated from the tissue originating from healthy donors and a non-tumorigenic mammary cell line as a 
model of early DCCs. In search for best model of dormancy we used previously established in vitro 
models and adapted them to our needs Single mammary cells of different proliferation states could be 
isolated from the established models of dormancy and utilized for further analysis. The adapted stem 
cell model enabled isolation and subsequent analysis of the proliferation state of mammary cells and 
was chosen for further analysis. In this model mammary cells were cultured in anchorage independent 
conditions, enabling discrimination of the single quiescent (surviving non-proliferating) cells and 
mammospheres (originating from activated stem-like cells) from which single cells were isolated after 
disaggregation. To determine the proliferation status of isolated cells, we established a PCR-based assay 
which examines the expression of proliferation markers Ki67 and MCM2 in single cells. PKH26-label 
retention assay was combined with PCR analysis to select proliferative and non-proliferative cells for 
gene expression analysis. For analysis of the proliferation markers we isolated (i) sphere-derived LRCs, 
(ii) sphere derived nLRCs and (iii) single cells that had not divided over time and remained single cells 
after one week of sphere culture and therefore were termed quiescent single cells (QSCs). Proliferation 
status of these cells was validated by Ki67 and MCM2 expression giving three groups of cells (sphere-
derived non-proliferating LRCs, sphere derived proliferating nLRCs and non-proliferating QSCs) that 
were subjected to whole gene expression analysis on microarray. K-means clustering following 
microarray analysis divided these three cell phenotypes into 5 groups, with LRCs and QSCs comprising 
two subgroups each. Among several signaling pathways characteristic for stem-like cells (LRC), IL-6-
related signaling events were identified as one of the most prominent. Therefore, we further investigated 
the role of IL-6 signaling in stem cells and DCCs isolated from bone marrow of breast cancer patients. 
Gene expression analysis of human samples using microarray and sequencing, showed that both, 
proliferative and quiescent cells can be found among DCCs in the bone marrow. In further analysis of 
different BM compartments (niches) we learned that mammary cells residing in the mesenchymal or 
osteoblastic niches enter a quiescent state, whereas mammary cells can be activated to enter cell cycle 
if they reside in the vascular niche. 
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In studying dormancy in DCCs derived from breast cancer patients we faced many challenges, among 
which the biggest is lack of the appropriate human DCC-derived models. Therefore we decided to 
employ the Her2-driven mouse model.  
4.1 Balb-NeuT as in vivo model of dormancy  
Balb-NeuT model, in which tumor development closely resembles this process in women (Di Carlo et 
al., 1999) has been intensively used to study breast cancer. Previous findings indicated existence of 
DCCs, which give rise to lung metastases in lung, but do not give rise to metastases in bones. These 
cells are able to proliferate in the BM in the conditions existing upon bone marrow transplantation 
(Husemann et al., 2008). We aimed to isolate these cells from BM and for that purpose engaged different 
labeling methods, such as labeling using cell tracking dye and GFP-genetic labeling. Inability to detect 
any DCC in the bone marrow suspension of recipient mice by any of these approaches prompted us to 
use EpCAM as a selection marker for DCC detection and isolation, which showed us existence of 
EpCAM+ cells both among CD45- and CD45+ (hematopoietic) cells. Although we initially thought 
that inability to detect GFP+ cells was due to immune rejection (Ansari et al., 2016; Gambotto et al., 
2000), experiments with NSG recipient mice and cell labeling using PKH26 pointed to a possibility that 
in these mice dissemination did not occur. EpCAM is regularly used as a marker for DCCs in bone 
marrow. Knowing that EpCAM is also expressed by some of the cells from the erythroid lineage, we 
separated hematopoietic cells (CD45+ cells) from the rest of the BM cells and isolated EpCAM+ cells 
from both fractions. Profiling of these cells will enable discrimination of the true DCCs from the 
confounding population of erythroid cells. 
Having an approach that enables detection of DCCs among bone marrow cells (EpCAM+ cells in 
CD45- fraction) we tested in Balb-NeuT mice the effect of progesterone, steroid hormone that was 
found to affect the migration of Her2+ mammary cells (Hosseini et al., 2016a; Johnson et al., 2010). 
However, we did not detect any change in the number of DCCs in the BM of Balb-NeuT mice, which 
could also be a consequence of an impaired dissemination of mammary cancer cells. Since the number 
of DCCs, we are aiming to isolate, is very low in tested models, we tried to employ the model where 
transplantation of the BM of the young transgenic mice to the wild type recipients resulted in expansion 
of DCCs (Husemann et al., 2008) with 10-30% of DCCs in the whole BM cell population. In the 
experiments of Hüsemann and colleagues, BM transplantation stimulated the outgrowth of DCCs, but 
in our experiments neither recipient mice developed any symptoms of disease nor could we detect DCCs 
in their BM. 
All these results with different models and in different experiments raise the question whether 
dissemination of the mammary cells to BM is impaired. The reason for detected change in dissemination 
in the models can be effect of the environment since the lab was changed in previous years and the 
96 
 
conditions in these laboratories differ. That influences the complete gut microbiota of the laboratory 
animals, which is shown to differ in healthy women from the women with breast cancer (Erdman and 
Poutahidis, 2017; Fernandez et al., 2018; Rea et al., 2018). Therefore, microbiota of the animal model 
in different conditions, as well as its impact on breast cancer development is now intensively studied in 
our laboratory. 
4.2 Establishment of the in vitro models of dormancy 
After failing to establish in vivo model of dormancy, we searched for good in vitro models. Since we 
wanted to study dormancy in early BM-DCCs, which display close-to-normal genomes (Hosseini et al., 
2016a; Schardt et al., 2005) existing cancer cell lines carrying many aberrations were not good as a 
potential model. Therefore, we decided to use mammary epithelial cells ex vivo isolated from reduction 
mammoplasties as a model and MCF10A, immortalized pre-malignant mammary cell line, for 
functional testing. The bone marrow is a very complex organ consisting of hematopoietic cells, 
fibroblasts, macrophages, adipocytes, osteoblasts, osteoclasts and endothelial cells which form 
organized niches with specific roles (Tamma and Ribatti, 2017) among which are endosteal 
(osteoblastic) and vascular (endothelial) are the most important for the function of bone marrow. 
Therefore, we tried to establish these two niches and culture mammary cells in them. The main function 
of the bone marrow is production and lodging of hematopoietic stem cells (HSCs) why we also 
cultivated cells in anchorage independent conditions (mammosphere assay) which favor the growth of 
stem cells. Analysis of the mammary cells cultured in established osteoblastic (Kim et al., 2013a) and 
endothelial (Ghajar et al., 2013) niches showed that they just slow the growth of mammary cells on 
population level, but do not induce dormancy in single cells, which we aimed to study. Contrary, in the 
mammosphere assay we were able to detect and isolate the single cells that did not proliferate for 7-10 
days. Besides that, we could isolated stem-like and proliferating mammary cells. Therefore, we decided 
to proceed with the mammosphere assay as the model for studying dormancy in closest-to-DCCs cells. 
4.3 Studying dormancy and proliferation in BM-DCCs 
To analyze the proliferation status of the DCCs we established assay based on analysis of expression of 
the proliferation markers MKi67 and MCM2 using non-activated and activated CD8+ T-cells. Using 
PKH26 labeling (Cicalese et al., 2009; Pece et al., 2010) and analysis of the expression of proliferation 
markers, we classified mammary cells isolated from human mammary gland and cultured in anchorage 
independent conditions in three groups: (i) non-proliferating quiescent single cells (QSCs), (ii) non-
proliferating stem-like cells (LRCs) and (iii) proliferating progenitor cells (nLRCs). These cells were 
subjected to gene expression analysis using micro arrays and identified “gene signatures” were applied 
to 21 aberrant BM-DCCs (15 M0-DCCs and 6 M1-DCCs), as confirmed by mCGH. This analysis 
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revealed us subgroups in the groups of QSCs and LRCs, pointing to heterogeneity existing both among 
stem and differentiated mammary cells. 
4.3.1 Mammary stem cells 
One of the type of dormancy widely known in literature is dormancy of the stem cells. Cultivation of 
cells in ultra-low attachment conditions in serum free medium results in enrichment of stem and 
progenitor cells (Dontu et al., 2003; Ponti et al., 2005; Rappa et al., 2008; Rybak et al., 2011) which 
correlates to the findings that at least a fraction of DCCs (Bartkowiak et al., 2010) and CTCs express 
stem cell markers, such as CD44, ALDH and Bmi1 (Baccelli et al., 2013; Barriere et al., 2012). 
Additionally, these conditions enable purifying the population of epithelial cells, since fibroblasts 
cannot survive these hostile conditions (Kulkarni and McCulloch, 1994; Wei et al., 2003). Subgrouping 
of the LRCs into two subgroups, was not surprising, since heterogeneity within mammary stem cells 
has already been described, indicating existence of both multipotent basal and luminal MaSCs (Fu et 
al., 2014; Van Keymeulen et al., 2017; Visvader and Stingl, 2014). Whether defined LRC1 and LRC2 
groups fit to this phenotype is to be done. Also, during mammary gland development one can 
discriminate two types of MaSCs, fetal and adult. In adult mammary gland distinct types of stem cells 
exist, long-term and short-term repopulating cells. They are responsible for intensive transient 
alveologenesis during pregnancy, but their self-renewal capacity is lower than of fMaSCs (Asselin-
Labat et al., 2010; Tiede and Kang, 2011). Numerous studies identified different stem cell markers. For 
instance, basal cells display an EpCAMloCD49fhi phenotype (Eirew et al., 2008; Lim et al., 2009; Stingl 
et al., 2001), and express c-Kit (Lim et al., 2009; Stingl et al., 2001). ALDH1 is also often used as 
mammary stem cell marker since ALDH1+ cells show multilineage potential both in vitro and in vivo 
(Ginestier et al., 2007; Liu et al., 2014), but some studies also show its controversial expression and 
demonstrate that these cells are restricted to a luminal subpopulation in in vitro and in vivo experiments 
where they do not provide long-term engraftment (Eirew et al., 2012; Shehata et al., 2012). All these 
methods determine different subpopulations with stem-cell character, but they all emphasize the 
existence of more than one type of stem cell in the mammary gland, going in line with our results where 
we defined different subgroups of stem cells, LRC1 and LRC2. The relevance of our method was 
additionally examined by comparing gene expression profiles of LRCs, nLRCs and QSCs. isolated 
based on label retention, with the gene expression profiles obtained in the study of Lim et al, on stem, 
progenitor and differentiated mammary cells, isolated based on expression of EpCAM and CD49f (Lim 
et al., 2009). Differentiation of cells in our study shows statistically significant correlation to the one in 
above mentioned study with accuracy of 58% - 75%, pointing to a differentiation in a 
LRCnLRCQSC direction. Although the selection based on expression of stem-cell related markers 
was not applied here, we could isolate stem population based on retention of the labeling dye. These 
cells were further analyzed for expression of a distinct set of stem-cell markers using gene expression 
98 
 
microarrays. We found MUC1 to be upregulated in the LRC population correlating with the data of 
other groups where MUC1 was found to be expressed by stem/progenitor MCF-7 cells (Engelmann et 
al., 2008), but also is an oncogene involved in cancer progression (Nath and Mukherjee, 2014) and 
further by stem cells among CTCs of breast cancer patients (Kasimir-Bauer et al., 2012). Also, we 
detected upregulation of CD24 in QSCs compared to sphere-derived LRCs and nLRCs indicating these 
are more differentiated cells (Schabath et al., 2006; Spike et al., 2012). 
4.3.2 Signaling pathways in mammary stem cells 
Analysis of the activated signaling pathways in defined groups of mammary cells (QSCs, LRCs and 
nLRCs) detected that different signaling pathways which were already known to be associated to stem 
cells were also activated in LRCs. Involvement of Wnt (Merrill, 2012; Sokol, 2011; Xu et al., 2016), 
PI3K/AKT (Dubrovska et al., 2009; He et al., 2017; Romorini et al., 2016), MAPK and Notch (Woo et 
al., 2009; Yu et al., 2008) signaling pathways in stem cells is already known. Notch is also involved in 
maintaining the quiescence in adult muscle stem cells and hematopoietic stem cells (Bjornson et al., 
2012; Wang et al., 2015b) while Wnt is also necessary for differentiation of human embryonic stem 
cells, mouse neurons, myocytes and embryonic stem cells, (Atlasi et al., 2013; Davidson et al., 2012; 
Newman et al., 2018; Prakash and Wurst, 2007; Suzuki et al., 2015). Not surprisingly, nLRCs which 
represent actively dividing progenitors mostly overexpress pathways involved in the regulation of the 
cell cycle. The role of IL-6 signaling in mammary gland and breast cancer is not completely elucidated. 
Our data suggest that this pathway is one of the regulators of the stem cell function in mammary cells, 
but its role in stem cells is not yet so intensively studied like the roles of the other pathways which were 
upregulated in stem-like cells. To increase the knowledge of less studied signaling pathway in mammary 
stem cells we further focused on studying IL-6 signaling in the mammary gland. 
4.4 IL-6 signaling in the mammary gland 
IL-6 activates its signaling cascade through binding to its receptor, IL-6R and then the IL-6/IL-6R 
complex induces homodimerization of gp130 which then triggers a downstream activation of Janus 
(JAK) kinases, and the downstream effectors STAT3, SHP-2/Ras, and PI3K/Akt (Kishimoto, 2005; 
Murakami et al., 1993). To investigate the role of IL-6 in normal mammary gland and DCCs from breast 
cancer patients, we started with an analysis of a non-tumorigenic mammary cell line, MCF10A where 
we detected the presence of IL-6R on the surface of cells grown in adherent conditions and cells grown 
as mammospheres. However, we did not detect IL-6R on the surface of patient derived HMECs grown 
as mammospheres. Jiang and colleagues showed that down-regulation of IL-6/IL-6R expression results 
in growth inhibition of MCF-7 cells (Jiang et al., 2011) which is in line with our finding that addition 
of extracellular IL-6 increases the size of the mammospheres, a consequence of increased proliferation 
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of progenitor cells. Besides that, IL-6 induced an increase in the number of mammospheres, stimulating 
stem cell function in mammary cells, as already shown for different cell types, such as hepatic cancer, 
lung and ovarian cancer cells (Ding et al., 2016; Lee et al., 2016; Sansone et al., 2007; Wang et al., 
2016). Lee and colleagues found that in lung cancer this effect is confined to a CD133+ positive 
population (Lee et al., 2016). 
Mammosphere derived patient HMECs do not express IL-6R protein, but still react to IL-6 stimulation. 
An alternative mechanism to activate IL-6 signaling cascade is trans signaling, activated through soluble 
IL-6R that can bind IL-6, bridge binding to the gp130 and activate the signaling cascade, even in cells 
that do not express mIL-6R (Mitsuyama et al., 2006). Soluble IL-6R is in mammary cells mostly 
produced by limited proteolysis of mIL-6R by ADAM proteases (Briso et al., 2008; Holub et al., 1999; 
Horiuchi et al., 1994; Mullberg et al., 1993). Due to the low frequency of cells co-expressing IL-6 and 
IL-6R (membrane or soluble), as detected by transcriptomic analysis, we concluded that IL-6 signaling 
(both classical, conducted via mIL-6R or trans, conducted via sIL-6R) in mammary cells is rather 
maintained in a paracrine than autocrine manner. Different cell types found in mammary gland, such as 
adipocytes (Gyamfi et al., 2018a; Gyamfi et al., 2018b), normal and tumor associated fibroblasts 
(Adams et al., 1991; Subramaniam et al., 2016), but also mesenchymal stem cells (Cortini et al., 2016; 
Ding et al., 2016) secrete IL-6, that fuels the sources of necessary ligand for mammary cells activation. 
The inability to detect IL-6R on the membrane of cells isolated from patient derived mammospheres 
pointed to the trans-signaling as a potential mechanism regulating stem cell function in the mammary 
gland. Therefore, we tested HIL-6, a fusion protein of IL-6 and sIL-6R that directly binds to 
ubiquitously expressed gp130 and activates the signaling cascade (Adam et al., 2009b; Peters et al., 
1998), and found that this triggers trans signaling and confers stem cell features to mammary cells 
(increased number of sphere forming cells, increased CD44+/CD24- fraction), in a significantly higher 
manner than IL-6 alone. Selective inhibition of sIL-6R using sgp130-Fc confirmed that IL-6 trans-
signaling confers stem cell features to mammary cells. This was unknown as trans-signaling was so far 
connected to pathological conditions, such as chronic inflammatory diseases (Scheller et al., 2006) and 
cancers (Becker et al., 2004; Brooks et al., 2016; Matsumoto et al., 2010). Interestingly, progression of 
IL-6 trans-signaling driven colon cancer can be suppressed by TGF- activity (Becker et al., 2004). In 
line with our data are the findings that IL-6 signaling triggers conversion of prostate, breast and lung 
cancer non-stem cells to cancer stem cells (Iliopoulos et al., 2011; Kim et al., 2013b; Rodrigues et al., 
2018). However, in these studies different roles of classical and trans signaling were not examined. 
Although sgp130-Fc inhibits both, classical and trans-signaling at extremely high concentrations 
(Garbers et al., 2011), which cannot be found in physiological conditions, the concentration we used 
(0,1 ng/ml) was very low and selectively affected only the trans-signaling (Jostock et al., 2001; Scheller 
et al., 2005), confirming trans signaling is the responsible factor in maintaining stemness in mammary 
cells. Gene expression analysis of populations in which separate IL-6 signaling pathways were 
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activated/blocked did not indicate different pathways activated by classical or trans-signaling, 
corroborating findings that they share major functions, but the strength of the signal may differ. This 
could also be a consequence of the technical limitation as the stem cell population is quite rare and their 
contribution in whole mRNA samples taken from a bulk of cells might be diluted, and therefore fine 
differences present in that small population are lost. 
The present cell hierarchy we found in the mammary gland raises the question of the population in 
which IL-6 exerts its function. As we found that IL-6R expression is not confined to any of the defined 
subpopulation of HMECs (LRCs, nLRCs or QSCs) we further examined the effect of trans-signaling. 
End point and qPCR analysis confirmed ubiquitous expression of gp130 (Scheller et al., 2014; Xu and 
Neamati, 2013) in patient derived HMECs indicating that IL-6 signaling in these cells depends on the 
presence of mIL-6R or excess of sIL-6R. In our analysis IL-6 signaling, irrespective classical or trans, 
showed the trend to increase the percentage of living cells in MCF10A-spheres, as well as an increase 
in the size of mammospheres as a phenotypic manifestation of increased proliferation. Since the 
percentage of LRCs was unaffected we concluded that the major target population for increased 
proliferation were the progenitor cells. Among the three analyzed subpopulations of cells (QSCs, LRCs, 
and nLRCs), IL-6R was expressed in a similar percentage of cells, with or without sIL-6R. Most of the 
IL-6 expressing cells were found among nLRCs. Although this difference was not statistically 
significant, it confirmed that activation of the endogenous IL-6 signaling could be confined to the 
progenitor cell population enabling them to actively proliferate in mammosphere cultures. 
After we found that the majority of cells isolated from HMEC-spheres (67-83%) express gp130, we 
investigated its expression in DCCs isolated from the bone marrow of breast cancer patients and learned 
that only 48% of aberrant M0-DCCs express this IL-6 signaling transducer, suggesting a gp130 
downregulation upon dissemination to bone marrow. Further we examined the regulation of gp130 
expression in MCF10A cells by the cells comprising the bone marrow microenvironment and found 
that osteoblasts and mesenchymal stromal cells downregulate gp130, opposite to endothelial cells. 
Although this downregulation is contact independent (exists also in the presence of transwell 
membrane), it is also transient, indicating that stimuli dictating downregulation must be constantly 
produced by the environment of the DCCs. Although transient, this downregulation has a long term 
effect since the sphere cultures after 7 days produce significantly lower number of mammospheres, 
reflecting decreased stem cell and proliferating capacity. Proliferation analysis (Ki67 and MCM2 
expression) showed that the number of proliferating cells was significantly higher in group of cells with 
activated IL-6 signaling than in the group where IL-6 signaling was downregulated. Overall, this all 
indicates that IL-6 signaling is at least one of the important pathways that play a role in regulation of 
BM-DCCs quiescence in breast cancer patients. In line with our data, another recent study showed that 
endothelial IL-6 confers tumorigenic (CSC) potential to primary head and neck squamous cell 
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carcinoma cells (Krishnamurthy et al., 2014). Therefore, our findings of IL-6 regulating dormancy of 
BM-DCCs in breast cancer patients is of great importance for further therapeutical approaches. 
4.5 Cancer cell dormancy in the bone marrow niche 
Of advanced breast cancer patients 65-75% develop bone metastases (Langley and Fidler, 2011). In our 
study we aimed to investigate the effect of some of these niches on the proliferation of tumor cells. 
Endosteal (osteoblastic) and vascular niches are the two main types of organized lodges in the bone 
marrow environment (Oh and Kwon, 2010; Tamma and Ribatti, 2017), but very close proximity of 
these niches complicates studying of their role in metastasis. Complex cooperation of these niches with 
mesenchymal stromal cells results in specific stem cell niches as most important functional unit for 
homing of the hematopoietic stem cells (HSC) (Morrison and Scadden, 2014; Yin and Li, 2006). In last 
years it was shown that cancer cells home to the epiphyseal osteoblastic surface of the endosteum 
(Nwajei and Konopleva, 2013) or to metaphysis (Bussard et al., 2008), but they were also found in the 
proximity of blood vessels, with specifically dormant DCCs occupying the regions of stable vasculature 
(Ghajar et al., 2013) or E-selectin- and stromal cell-derived factor 1 (SDF-1)-rich perisinusoidal 
vascular regions (Price et al., 2016). We found that the proliferation rate of mammary cells is decreased 
in co-cultures with osteoblasts, which is in line with earlier findings that the majority of disseminated 
prostate cancer cells in mice occupy the same (osteoblastic) niche as quiescent HSCs (Shiozawa et al., 
2011; Wang et al., 2014) where they reside in a non-proliferative state at least 7 days after injection 
(Wang et al., 2014). A recent study showed that prostate DCCs in the osteoblastic niche take on stem 
cell markers, such as CD133+/CD44+ and increased levels of KLF 4, Bmi-1, and Nanog mRNA, which 
justifies comparison of DCCs with HSCs in this sense (Shiozawa et al., 2016). Osteoblasts have been 
shown to play a role in maintaining HSC quiescence partly through the interactions of CXCR4/CXCL12 
that also regulates homing of tumor cells to the bone (Wang et al., 2014). Quiescence in prostate cancer 
cells is regulated by expression of engaging factors, such as Gas6 and its receptors Axl/Tyro/Mer 
(Shiozawa et al., 2010), whose ratio in disseminated cell determines whether a cell will proliferate or 
be quiescent (Taichman et al., 2013). In lung metastases, activation of the bone morphogenic factor 
(BMP) signaling inhibits colonization, while its inhibitor, Coco, reverses that effect and reactivates cells 
(Gao et al., 2012), as well as expression of VCAM-1. In bones, VCAM-1 promotes osteolytic metastasis 
of breast cancer by activation of α4β1-positive osteoclast progenitors. Interaction of VCAM-1 and α4β1 
integrin activates the PI3K/Akt pathway enabling prolonged survival and potential for metastatic 
outgrowth of the cells (Lu et al., 2011). As HSCs move towards the vasculature and the oxygenated 
endothelial niche, cells acquire a more proliferative phenotype (Ehninger and Trumpp, 2011). In co-
culture of mammary cells with HUVECs we showed that the endothelial niche did not affect the 
proliferation rate of mammary cells. But we must emphasize that our assays were all performed at the 
same oxygen concentration (7% O2). This is in accordance to previously published studies that more 
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oxygenated endothelial niche induces proliferation of the HSCs (Ehninger and Trumpp, 2011). Opposite 
to these findings, a recent study showed that dormant DCCs preferentially reside in E-selectin rich 
vascular niches (Price et al., 2016). A possible explanation of this paradox is existence of distinct 
subniches in the vascular niche and depending whether the cancer cell lodges in the proximity of the 
trunk or the neovascular tip of the endothelial net it will enter a dormant or proliferative state, 
respectively (Ghajar et al., 2013). Endothelial-derived thrombospondin-1 (TSP-1) was defined as a 
mediator of dormancy of breast cancer cells in vascular niches, while periostin (POSTN) and TGF-β1 
were found to activate cell cycle (Ghajar et al., 2013). Leukemia inhibitory factor receptor (LIFR) was 
defined as a factor activating the dormancy program and suppressing metastases in breast cancer (Chen 
et al., 2012; Johnson et al., 2016). LIFR levels are lower in bone metastasis and inversely correlate with 
hypoxia gene activity. Hypoxia reduces the LIFR:STAT3:SOCS3 signaling and enables reactivation of 
the dormant breast cancer cells and bone colonization, suggesting that LIFR:STAT3 signaling confers 
a dormancy phenotype to breast cancer cells disseminated to the bone (Johnson et al., 2016). These 
contradictory results just emphasize the difference in the models, but also points to the involvement of 
these signaling pathways in regulation of dormancy. Therefore, further research in this direction and 
clarification is necessary. 
We identified an activated IL6 pathway in half of the single DCCs and found in mammary 
stem/progenitor cells the pathway being activated via trans signaling. Trans-signaling makes cells 
dependent on the microenvironment, however, bone marrow represents an IL-6 rich environment. In 
the context of breast cancer it is noteworthy that serum levels of IL-6 and sIL-6R and their local 
production in bone marrow by osteoblasts depends on sex-steroids, change with the menstrual cycle, 
are negatively regulated by estrogen and hormone replacement therapy and increase during menopause 
(Abrahamsen et al., 2000; Girasole et al., 1999; Giuliani et al., 2001). Therefore, systemic 
microenvironmental changes may provide a mechanism by which DCCs become activated in post-
menopausal breast cancer patients. Consistently, bone-only metastasis is significantly associated with 
higher age at primary diagnosis in HR-positive breast cancer patients (Diessner et al., 2016). 
4.6 Conclusions 
Among the pre-established in vitro models we identified the adapted stem cell model to be the best 
fitting model in inducing dormancy in single cells. Using this model for further molecular analyses we 
determined pathways involved in the regulation of the state of cellular dormancy and cellular hierarchy 
in the mammary gland. This novel gene expression profile of cellular dormancy was utilized to 
distinguish proliferating and non-proliferating DCCs isolated from breast cancer patients. Pathway 
analysis of the profiles of proliferating and non-proliferating human mammary epithelial cells pointed 
to IL-6 as one of the key players in controlling the differentiation state of the cells in the mammary 
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gland. Therefore, the mechanisms of IL-6 signaling pathway in the human mammary gland were further 
examined. Functional analyses confirmed that the IL-6 signaling plays an important role in stem cell 
function of mammary cells, as well as colonizing behavior of disseminated human breast cancer cells, 
while IL-6 signaling was activated in cells with proliferating phenotype. 
The findings presented in this thesis enabled us to propose the following mechanism depicted in Figure 
70: breast cancer cells that disseminate in the early phases during cancer development reach the bone 
marrow and occupy distinct niches (mesenchymal, endothelial or osteoblastic). Depending on the niche 
that DCC occupies gp130 will be downregulated (osteoblastic or mesenchymal niche) or expressed on 
the membrane (endothelial niche) and cells will acquire a dormant or proliferative phenotype, 
respectively. IL-6 which is enriched in bone marrow environment and binds sIL-6R, which is also 
present in physiological conditions in BM (Cho et al., 2013), triggers proliferation of DCCs which 
regain gp130 expression. Cells downregulating gp130 lose the ability to react to IL-6 stimulation and 
re/-enter a dormant state. 
 
Figure 70: Mechanism of the metastasis outgrowth in bone marrow. Breast cancer cells disseminate form the primary site 
through the vascular net and extravasate to the bone marrow. There they come in contact with MSCs or OBs that induce gp130 
downregulation or with endothelial cells that do not have effect on gp130 expression. Gp130 downregulation leads to cell 
quiescence. 
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5 Summary 
Metastasis is the major cause of death of cancer patients. In breast cancer dissemination from 
the primary site occurs preferentially in early tumor stages, long before the clinical 
manifestation of metastasis, with cases of metastases detected 25 years after removal of the 
primary tumor. Early dissemination and prolonged clinical latency at distant sites raise the 
question about the identity and nature of signals that confer survival, persistence in dormant 
state over extended periods of time and finally, the outgrowth of DCCs. DCCs are extremely 
rare and detected in bone marrow of about 30% of breast cancer patients with no evidence of 
manifest metastasis at very low frequency (1-2 DCCs per 106 BM cells). Genomic studies 
showed that early DCCs often lack critical genetic alterations and need to acquire them at the 
distant site in breast and other cancers. 
Studying dormancy in patient derived DCCs is challenging due to the lack of human DCC-
derived models, as well as spontaneous or transgenic mouse models that generate bone 
metastases. Therefore, to identify signals that support survival or outgrowth of dormant DCCs 
in patients, we profiled ex vivo rare bone marrow-derived DCCs (BM-DCCs) that were isolated 
long before manifestation of metastasis and identified IL-6 signaling as a candidate pathway 
for DCC activation. Since early DCCs often display “close-to-normal” genomes we used 
mammary epithelial cells ex vivo isolated from reduction mammoplasties and available 
immortalized pre-malignant mammary cell lines as a model for in vitro functional testing. We 
identified IL-6 trans-signaling (mediated by sIL-6R), but not the classical IL-6 signaling 
(mediated by mIL-6R), as a pathway to activate stem-like and progenitor traits underlying 
colony formation in anchorage independent conditions. Further we explored that activation of 
this pathway in DCCs depends on a special cell population present within the bone marrow 
niche. Expression of gp130, which is a pre-requisite for IL-6 trans-signaling, was down-
regulated by bone marrow stromal and endosteal, but not vascular niche cells, ensuring that 
only DCCs in vascular niches display a possible responsiveness to IL-6 trans-signaling. The 
bone marrow represents an IL-6 rich environment and data from other studies have also shown 
increased serum levels of sIL-6R in breast cancer patients. Furthermore, serum levels of IL-6 
and sIL-6R and their local production by osteoblasts in the bone marrow depends on sex-
steroids. Expression levels change with the menstrual cycle therefore providing a mechanism 
for activation of DCCs in the bone marrow and outgrowth of metastasis. 
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Our data suggest that the initial steps of metastasis formation depend on microenvironmental 
signals and are not cell-autonomous. They also shed light into early phases of metastasis 
formation and may inform about potential novel adjuvant therapies as a way to delay or prevent 
development of the metachronous metastasis in patients diagnosed only with locally confined 
breast cancer. 
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